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Biologic scaffolds composed of extracellular matrix (ECM) have been used to promote site-
specific, functional remodeling of tissue in both preclinical animal models and human clinical 
applications. Although the mechanisms of action of ECM scaffolds are not completely 
understood, proteolytic degradation of the ECM scaffold and subsequent progenitor cell 
recruitment are thought to be important mediators of the constructive remodeling process. 
 Proteolytic degradation of the ECM scaffolds results in the generation and release of 
cryptic peptides with novel bioactive properties not associated with their parent molecules such 
as angiogenic, antimicrobial, mitogenic, and chemotactic properties. While previous studies have 
suggested that degradation products of ECM scaffolds are chemotactic for progenitor cells in 
vitro, the present thesis expands upon these findings in vivo. 
In a non-regenerating model of mid-second phalanx digit amputation, treatment with 
ECM degradation rpodcuts resulted in the accumulation of a heterogeneous population of cells 
with in vitro differentiation potential along osteogenic, adipogenic, and neuroectodermal 
lineages. Focusing specifically on the Sox2+ population of cells found at the site of injury, work 
in the present thesis showed that Sox2+ cells co-express bone marrow and periosteal stem cell 
markers CD90 and Sca1, but not dermal stem cell marker CD133 or circulating stem cell marker 
c-kit (CD117). Additionally, bone marrow chimeric studies utilizing wild type C57/BL6 and 
Sox2 eGFP/+ mice showed that the Sox2+ cells are not derived from the bone marrow, but more 
likely from a local tissue source such as the periosteum.  
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 Fractionation of the ECM degradation products resulted in the identification of a highly 
conserved cryptic peptide derived from the C-terminal telopeptide of the collagen type IIIα 
molecule with chemotactic activity for multiple progenitor cells in vitro, IAGVGGEKSGGF. 
Administration of the cryptic peptide in a model of digit amputation resulted in the accumulation 
of Sox2+, Sca1+, Lin- cells at the site of amputation. Peptide treatment also resulted in the 
formation of a bone nodule at the site that coincided with the spatial location of Sox2+ cells. In 
vitro, the peptide accelerated osteogenesis of mesenchymal stem cells and increased the 
expression of osteogenic and chondrogenic genes. 
 The result of this body of work shows that degradation products of ECM scaffolds 
contain cryptic peptides with the ability to influence chemotaxis and differentiation of progenitor 
cells in vitro and in vivo. The ability to influence stem cell phenotype and fate may be useful in 
designing new therapies for regenerative medicine approaches to complex, composite tissue 
reconstruction. Additionally, the findings of the present thesis may serve as the basis for future 
studies investigating the importance of ECM degradation in the downstream constructive 
remodeling events at a site of ECM implantation in soft tissue models of injury.  
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1.0  INTRODUCTION 
1.1 BIOLOGIC SCAFFOLDS COMPOSED OF EXTRACELLULAR MATRIX  
The extracellular matrix (ECM) is composed of the secreted products of the resident cells in any 
given tissue, organ, or microenvironment. In addition to serving as a structural scaffold for the 
tissue, ECM is in a constant state of “dynamic equilibrium” with the resident cells of the given 
tissues or organ (Nelson and Bissell 2006). Through a unique composition and structure 
optimized for each tissue, ECM can regulate the phenotype of local cells through modulation of 
various factors including, but not limited to, mechanical forces, biochemical milieu, oxygen 
requirements/concentration, pH, and inherent gene expression. For these reasons, ECM plays a 
central role in mammalian development, normal physiology, and the response to injury (Nelson 
and Bissell 2006).  
This dynamic reciprocity that exists between the cells and ECM of any given tissue also 
makes the ECM from any tissue or organ an ideal substrate for tissue engineering applications. 
Biologic scaffolds composed of allogeneic and xenogeneic ECM have been used in preclinical 
animal studies to facilitate constructive remodeling of a v ariety of muscular tissues including 
esophagus (Badylak, Hoppo et al. ; Badylak, Meurling et al. 2000; Badylak, Vorp et al. 2005; 
Lopes, Cabrita et al. 2006), myocardium (Kochupura, Azeloglu et al. 2005; Robinson, Li et al. 
2005; Badylak, Kochupura et al. 2006; Ota, Gilbert et al. 2007), blood vessels (Badylak, Lantz et 
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al. 1989; Lantz, Badylak et al. 1990; Lantz, Badylak et al. 1992), urinary bladder (Kropp, Eppley 
et al. 1995; Kropp, Rippy et al. 1996; Pope, Davis et al. 1997; Record, Hillegonds et al. 2001), 
and skeletal muscle (Mase, Hsu et al. ; Prevel, Eppley et al. 1995; Clarke, Lantz et al. 1996; 
Badylak, Kokini et al. 2001; Badylak, Kokini et al. 2002). Additionally, commercially produced 
ECM scaffolds (Appendix A) have shown remarkable efficacy in certain human clinical 
applications  (Mase, Hsu et al. 2010; Badylak, Hoppo et al. 2011) and have been implanted 
successfully in over one million patients (Badylak 2007). 
When properly produced, the general host response to ECM scaffolds consists of rapid 
degradation of the scaffold with concomitant replacement by organized, site-appropriate, 
functional host tissue (Allman, McPherson et al. 2001; Record, Hillegonds et al. 2001; Allman, 
McPherson et al. 2002; Gilbert, Stewart-Akers et al. 2007). Within the context of the present 
thesis, this process of site-specific deposition of organized, site-appropriate, functional tissue will 
be referred to as “constructive remodeling.” The otherwise default response to injury at similar 
sites of injury consists of an incomplete regenerative response concomitant with deposition of 
dense, disorganized connective tissue (Turner and Badylak). The mechanisms by which ECM 
scaffolds promote constructive remodeling are still only partially understood, but recent studies 
have begun to identify properties of the ECM scaffold as well components of the host response 
to the scaffold that may be important for constructive remodeling in vivo. 
Some of the first studies to identify potential mechanisms by which ECM scaffolds 
remodel have done so through a time course analysis of remodeling at a site of injury following 
ECM implantation (Valentin, Badylak et al. 2006; Badylak, Valentin et al. 2008). So long as the 
scaffold is properly produced such that immunogenic remnants such as DNA and cellular debris 
are minimized, the remodeling of the ECM scaffold at the site of injury follows a very similar 
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pattern, regardless of the specific site at which the scaffold is implanted. This time course has led 
to the identification of a number of contributing factors that correlate with a r egenerative 
outcome in response to ECM scaffold implantation, as opposed to the default wound healing 
response of scar tissue deposition. In order to understand why these observed factors are thought 
to be important, it is important to understand how and why they represent a deviation from the 
default wound healing response at a site of injury. Thus, the normal phases of the wound healing 
response in adult mammals are briefly discussed to serve as a baseline for understanding the 
importance of the differences observed at a site of injury following implantation of ECM derived 
scaffolds. 
1.2 THE NORMAL PHASES OF WOUND HEALING IN ADULT MAMMALS 
Wound healing in an adult mammal is a well orchestrated integration of multiple systems within 
a host that results in quick closure of the wound so as to maintain the integrity of the barrier 
between the host and outside world (Falanga 2005). The phases of wound healing can be broadly 
be broken into four phases (Figure 1). The coagulation phase is the initial response to injury. 
Immediately after injury, hemostasis occurs via local platelet aggregation, fibrin deposition, and 
activation of the coagulation cascade. The main purpose of this phase is to achieve hemostasis 
and protect against pathogen colonization of the site of injury. This phase culminates in the 
eventual release of inflammatory cytokines and mediators that then recruit innate immune cells 
such as neutrophils and monocytes/macrophages to commence the inflammatory phase of wound 
healing.  Neutrophils and monocytes/macrophages are recruited to the site of injury during the 
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inflammatory phase, and they phagocytose cellular debris at a s ite of injury as well as release 
paracrine factors that then recruit other cell types (Lolmede, Campana et al. 2009).  
This eventually gives rise to the proliferative phase of wound healing in which re-
epithelialization and angiogenesis occurs via migration of epithelial and endothelial cells into the 
site of injury. Over the course of weeks, wound contraction occurs in the remodeling phase and 
the extracellular matrix at the site of injury is eventually replaced by ECM deposited by 
infiltrating fibroblasts and myofibroblasts at the site of injury. In some pathologic cases, 
inflammatory cells such as T cells may be present at later time points after injury. This is 
generally a sign of an ongoing chronic inflammatory response that deviates from the normal 
wound healing response.  
 
Figure 1. A schematic depiction of the phases of normal wound healing in adult mammalian soft tissues (modified 
and adapted from (21)). 
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1.3 MECHANISMS OF REMODELING OF ECM SCAFFOLDS 
While the coagulative phases and inflammatory phases still occur following implantation of an 
ECM scaffold at a site of injury (Wokalek and Ruh 1991; Allman, McPherson et al. 2001), the 
overall time course of remodeling deviates significantly from the default wound healing response 
in the later proliferative and remodeling phases. The specific events that deviate from the normal 
injury response have most extensively been characterized in a rodent model of skeletal muscle 
injury in the abdominal wall (Valentin, Turner et al. ; Valentin, Badylak et al. 2006; Badylak, 
Valentin et al. 2008; Valentin, Stewart-Akers et al. 2009) (Figure 2). Immediately following 
injury and ECM implantation, the initial coagulative phase of wound healing occurs and results 
in the eventual recruitment of neutrophils (Allman, McPherson et al. 2001). As early as 48 hours 
post-ECM implantation, a dense mononuclear infiltrate of cells is observed at the site of injury 
that persists for weeks. At 4 weeks post-injury, the site of ECM scaffold implantation has been 
replaced with dense, connective tissue deposited by host cells. The ECM scaffold is no longer 
present in its intact form. At 16 weeks post-implantation, the site of ECM scaffold implantation 
is populated with multiple vascular structures, small islands of immature muscular tissue, and 
growing nerve fibers that histologically colocalize with the small islands of muscle, i.e. the start 
of constructive remodeling (Valentin, Turner et al. ; Valentin, Badylak et al. 2006; Agrawal, 
Brown et al. 2009; Brown, Valentin et al. 2009). By 26 weeks post-implantation, the site of ECM 
scaffold implantation has been replaced with site appropriate, functional muscular tissue that is 
grossly indistinguishable from the surrounding native muscle (Valentin, Turner et al. ; Valentin, 
Badylak et al. 2006; Badylak, Valentin et al. 2008; Valentin, Stewart-Akers et al. 2009). In this 
time course, the formation of new mature vascular structures and immature, but innervated, 
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muscular tissue (i.e. the events defined as “constructive remodeling”) is consistently observed 
only after the scaffold is no longer histologically present and presumably degraded.  
 
Figure 2. The time course of remodeling at a site of ECM scaffold implantation (adapted from data in (29, 31)). 
 
From this time course analysis and other studies, the immune response, 
mechanotransduction at the site of injury, site directed recruitment of differentiated and 
progenitor cells, and rapid degradation of the ECM scaffold have all been identified as important 
factors that correlate with constructive remodeling in vivo. Although each contributing 
mechanism is discussed below in further detail, the present thesis will focus specifically on two 
of the four mechanisms. Specifically, the work in this thesis will aim to establish a link between 
the release of bioactive peptides from rapid degradation of the ECM scaffold and the site 
directed recruitment of progenitor cells to a site of ECM implantation.  
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1.3.1 The Immune Response to ECM Scaffold Implantation 
Neutrophils, monocytes, macrophages, and T cells are all known to be found at a site of ECM 
implantation in vivo (Wokalek and Ruh 1991; Allman, McPherson et al. 2001; Valentin, Badylak 
et al. 2006; Crisan, Yap et al. 2008; Valentin, Stewart-Akers et al. 2009). However, the 
persistence of mononuclear cells at the site of injury for weeks after ECM implantation markedly 
differs from the time course of normal wound healing at a site of injury. While such a sustained 
mononuclear response may be considered a chronic inflammatory response as seen in pathologic 
conditions, the sustained mononuclear infiltration in response to ECM scaffold implantation 
eventually results in constructive remodeling (Valentin, Badylak et al. 2006), suggesting that 
mononuclear cells may play a role in mediating this process.   
Previous studies have shown that one of the reasons why sustained persistence of 
mononuclear cells at a site of injury may actually be beneficial is the polarization of the immune 
cells towards a m ore anti-inflammatory healing phenotype (Badylak, Valentin et al. 2008), as 
opposed to the classic pro-inflammatory phenotype. Immune cells such as T cells and 
monocytes/macrophages exhibit various phenotypes, or polarizations, that dictate their overall 
function at a site of injury. For example, T cells can broadly be classified into pro-inflammatory 
(Th1), anti-inflammatory (Th2), or regulatory (Treg) T cells (Gatenby, Callard et al. 1984). 
Likewise, macrophages can broadly be classified into pro-inflammatory M1 macrophages or 
anti-inflammatory, pro-wound healing M2 macrophages (Mantovani, Sica et al. 2004). Recently 
a third subgroup of regulatory macrophages has also been reported in the literature (Zorro 
Manrique, Duque Correa et al. ; Mosser and Zhang 2008).  
Properly decellularized and unmodified ECM scaffolds that promote constructive 
remodeling and functional restoration at a site of injury have been showed to elicit a Th2 
8 
restricted T cell response in vivo (Allman, McPherson et al. 2001). Additionally, ECM scaffolds 
induce an early and sustained anti-inflammatory, M2 phenotype in the recruited monocytes and 
macrophages at the site of injury (Valentin, Badylak et al. 2006; Badylak, Valentin et al. 2008). 
Furthermore, removal of the macrophages via depletion of circulating monocytes inhibits the 
constructive remodeling response to ECM scaffolds and results in fibrous encapsulation in vivo 
(Valentin, Stewart-Akers et al. 2009). In each case with a poor remodeling outcome, the 
predominant phenotype of mononuclear phagocytes at the site of ECM implantation is the pro-
inflammatory M1 phenotype (Crisan, Yap et al. 2008; Brown, Valentin et al. 2009).  
Although the role of the immune system in ECM scaffold remodeling is not directly 
addressed in the present thesis, the importance of and the contribution of the immune system 
towards is revisited in the final discussion of the work presented in chapter 5. 
1.3.2 Mechanical Stimulation and Mechanotransduction at the Site of ECM Implantation 
Previous studies have also shown that the microenvironment in which the ECM scaffold is 
placed can influence the overall remodeling outcome. For example, an ECM scaffold derived 
from the porcine urinary bladder can remodel into abdominal wall (Brown, Valentin et al. 2009), 
bladder (Boruch, Nieponice et al. 2010), trachea (Gilbert, Gilbert et al. 2008), or myocardium 
(Kochupura, Azeloglu et al. 2005) depending on the conditions in which it is placed in vivo. One 
component of the microenvironment that is thought to mediate this remodeling response to 
scaffolds is the spatiotemporal pattern of mechanical forces sensed by the ECM scaffold and 
cells at the site of injury. Previous studies shown that mechanical forces can be transduced 
through the scaffold to influence the phenotype and response of local cells in contact with the 
scaffold in vitro (Androjna, Spragg et al. 2007; Gilbert, Stewart-Akers et al. 2007). Other studies 
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have then confirmed that physiologic mechanical load is essential for site appropriate 
constructive remodeling of ECM scaffolds in vivo (Boruch, Nieponice et al. 2010). While local 
mechanical forces within the microenvironment are not further investigated in the present thesis, 
the role of the microenvironment in ECM scaffold remodeling is revisited in the final discussions 
of this thesis in chapter 5.  
1.3.3 Rapid Degradation of the ECM Scaffold and Release of Bioactive Peptides 
One of the hallmarks of unmodified ECM scaffolds is their rapid degradation in vivo within 60-
90 days post-implantation (Record, Hillegonds et al. 2001; Gilbert, Stewart-Akers et al. 2007). 
As discussed in the time course of remodeling, the constructive remodeling response only occurs 
after
One potential mechanism by which rapid degradation of ECM scaffolds results in 
constructive remodeling may be the release of bioactive peptides from degradation of the ECM 
scaffold. In addition to the release of sequestered growth factors and cytokines in the ECM, local 
proteolysis of the ECM scaffolds results in enzymatic digestion of the structural proteins (i.e. 
collagen, fibronectin, laminin) that comprise a majority of the ECM scaffold (Badylak 2002). 
 the scaffold is predominantly degraded. Inhibition of the degradation of the scaffold 
through any of a number of means including chemical cross-linking (Valentin, Badylak et al. 
2006; Valentin, Stewart-Akers et al. 2009), or host depletion of phagocytic cells partially 
responsible for degrading the scaffold (Valentin, Stewart-Akers et al. 2009), results in a poor 
remodeling outcome in vivo.  Based on these observations in the time course of remodeling, 
rapid degradation of ECM scaffolds is an important prerequisite for constructive remodeling at 
the site of injury. In fact, it may be the initiating event for all subsequent events at the site of 
injury that deviate from the normal wound healing response.   
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The resulting degradation products of ECM have been shown to possess novel bioactive 
properties that are not present in the parent ECM structural proteins. These peptides are called 
“matricryptic peptides” (Davis, Bayless et al. 2000; Autelitano, Rajic et al. 2006; Ng and Ilag 
2006; Pimenta and Lebrun 2007; Mukai, Hokari et al. 2008; Mukai, Seki et al. 2009; Davis 
2010). Antimicrobial activity has been attributed to such peptides in the form of defensins (Ganz 
2003), cecropins (Moore, Devine et al. 1994; Moore, Beazley et al. 1996), and magainins 
(Berkowitz, Bevins et al. 1990). Other matricryptic peptides have been shown to be able to 
regulate angiogenesis, with separate peptides possessing angiogenic and anti-angiogenic activity 
(Davis, Bayless et al. 2000; Li, Li et al. 2004). Other cryptic peptides have also been identified 
that modulate the local and systemic immune response by modulating phagocytic activity, gene 
expression, and chemotaxis of various immune cells (Adair-Kirk and Senior 2008). Within the 
context of tissue engineering, cryptic peptides have been identified with mitogenic and 
chemotactic activity for other cell types such as endothelial, Schwann, and smooth muscle cells 
(Davis, Bayless et al. 2000; Li, Li et al. 2004; Agrawal, Brown et al. 2009). The sustained 
generation and release of these matricryptic peptides may be a p otential explanation for how 
ECM scaffolds promote constructive remodeling after their degradation. The work presented in 
the present thesis focuses on a ddressing the contribution of matryptic peptides, subsequently 
referred to as “ECM degradation products,” upon in vivo constructive remodeling. 
1.3.4 Site Directed Recruitment of Progenitor Cells 
Although previous studies have focused on the immune contribution to the cell infiltrate at the 
site of injury (Valentin, Badylak et al. 2006; Badylak, Valentin et al. 2008), circulating bone-
marrow derived cells are known to partially comprise the dense mononuclear infiltrate that 
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populates the site of ECM implantation (Valentin, Badylak et al. 2006; Badylak, Valentin et al. 
2008). Previous studies have further shown that bone marrow derived progenitor cells persist at 
the site of injury and eventually contribute to functionally remodeled tissue (Badylak, Park et al. 
2001; Zantop, Gilbert et al. 2006). Although the mechanisms underlyling the site directed 
accumulation of progenitor-like cells at the site of injury by ECM scaffolds are not well 
understood, it has been previously been hypothesized that ECM scaffold degradation products 
may play a potential role in progenitor cell recruitment. In addition to possessing chemotactic 
properties for site-specific differentiated cells (Li, Li et al. 2004; Agrawal, Brown et al. 2009), 
recent evidence suggests that peptides generated from ex vivo degradation of ECM scaffolds may 
have a net chemotactic effect upon multiple progenitor cell types in vitro. These cells include 
mouse ear blastemal cells (Reing, Zhang et al. 2009) (derived from the regenerating ear of an 
MRL/MpJ mouse (Clark, Clark et al. 1998) ), fetal keratinocyte progenitor cells (Brennan, Tang 
et al. 2008), adult keratinocyte progenitor cells (Brennan, Tang et al. 2008), and human 
mesenchymal perivascular stem cells (Crisan, Yap et al. 2008; Tottey, Corselli et al. 2011). 
However, the in vivo chemotactic properties of these same degradation products have not been 
investigated. 
Thus, as presented in future chapters of the present thesis, a primary goal of the present 
work will be to establish an in vivo link between two major mechanisms by ECM scaffolds 
remodel, namely the generation of bioactive ECM degradation products and the site directed 
recruitment of progenitor cells. If indeed degradation products of ECM scaffolds can promote 
site directed recruitment of progenitor cells in vitro, this approach may be a v iable therapy for 
altering the default wound healing response towards regeneration in more complex models of 
injury that currently cannot be engineered using conventional approaches. Because other species 
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capable of spontaneous regeneration of complex tissues do so via the site directed recruitment of 
multipotent stem cells to a site of injury (Kumar, Godwin et al. 2007; Kragl, Knapp et al. 2009; 
Monaghan, Epp et al. 2009),  a similar type of “endogenous stem cell therapy” in adult mammals 
might be a valuable and new tissue engineering approach for more complex tissue engineering in 
adult mammals (Lee, Cook et al. ; Kim, Xin et al. 2010).  
1.4 CLINICAL SIGNIFICANCE OF LIMB/DIGIT REGROWTH 
Limb and digit amputation is a life altering procedure that is completed secondary to intractable 
malignancy (Steinau, Daigeler et al. 2010), unremitting complications of chronic disease  (Dec 
2006), or acute tramautic injury such as motor vehicle accidents (Barmparas, Inaba et al. 2010) 
or battle related injuries. Amputations can occur to patients of all ages. In addition to potentially 
multiple and irreversible functional deficiencies, amputation can also leave a patient with 
multiple psychological and psychosomatic aberrations such as phantom limb syndrome. Such 
aberrations and deficiencies constitute a decrease in overall quality of life. 
Specifically with respect to acute traumatic injuries, although although medical therapies 
have improved survival rates following, an unfortunate side effect of these advances has been a 
concomitant increase in patients and soldiers living with life-altering limb amputations (Baer, 
Dubick et al. 2009; Ritenour, Blackbourne et al. 2010). Within the US Army from 2002-2010, a 
cumulative total of 791 soldiers have undergone distal extremities amputation following 
traumatic injuries, corresponding to 3.38% of U.S. military patients admitted to a Role III facility 
(e.g. combat support hospital). Stratified by anatomic location of amputation, there have been 
522 finger amputees, 85 toe amputees, and 184 patients who have undergone multiple 
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amputations of fingers and/or toes (unpublished data from David G. Baer, U.S. Military). 
Additionally, over 950 soldiers have undergone more proximal limb amputations following 
combat-related wounds (Stinner, Burns et al. 2010). 
There are currently no effective treatments for restoring function to composite tissues 
such as limbs and digits following extensive injury. Digit replantation has been attempted in the 
past with mixed reported success rates ranging from 59% to 91% success rates following 
replantation. In a meta analysis of published success rates of digit replantation, factors that 
correlated with a poor outcome included type of injury (crushing or avulsion injury as opposed to 
clean cut), location of injury (proximal as opposed to more distal), involved digits (thumbs 
correlate with a worse outcome than pinky finger), involvement of ischemia-prone tissues such 
as muscle, and comorbidities such as smoking (Dec 2006). Notably, a zero percent success rate 
was reported in cases where the patients were diabetic. Even with success of replantation, 
though, motor function of the replanted digit remains suboptimal, possibly secondary to post-
amputation remodeling of central and peripheral neural circuitry (Schieber, Lang et al. 2009).  
1.5 EPIMORPHIC REGENERATION AS A SOLUTION TO POOR COMPOSITE 
TISSUE REGENERATION IN ADULT MAMMALS 
The canonical approach to engineering of new tissue following injury or tissue loss consists of 
utilizing a combination of cells, bioactive factors, and scaffold within a bioreactor system that 
mimics the nutritional and biomechanical environment of the native tissue (Langer and Vacanti 
1993; Nichol and Khademhosseini 2009). Following sufficient maturation, this tissue engineered 
construct is then implanted in vivo at a site of injury to replace the missing tissue. 
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However, the use of bioactive factors, stem cell therapy, or scaffold therapy alone has 
been insufficient for certain applications, specifically tissue engineering of more complex tissues 
such as digits. For example, stem cell therapy and/or addition of exogenous bioactive factors 
have shown some clinical promise in limiting the extent of injury or progression of disease in 
human clinical trials (Brown, Hong et al. 1995; Harada, Friedman et al. 1996; Horwitz, Gordon 
et al. 2002; Okamoto, Yajima et al. 2002; Chen, Fang et al. 2004; Bang, Lee et al. 2005; Jeong, 
Sandhu et al. 2005; Janssens, Dubois et al. 2006; Janssens, Theunissen et al. 2006; Moist, 
Muirhead et al. 2006; Tyndall and Furst 2007; Zadrazil, Horak et al. 2009),  the use of such 
therapies for complex tissue regeneration has been limited both by efficacy and regulatory 
concerns (Bongso, Fong et al. 2008). Scaffolds alone have been used very successfully in tissue 
engineering applications for restoration of tissue. However, most of the successful applications 
utilizing only scaffolds are limited to soft tissues with a repeatable microstructure, innate ability 
to respond favorably to tissue injury, and limited three dimensionality (Kropp, Eppley et al. 
1995; Badylak, Meurling et al. 2000; Robinson, Li et al. 2005; Lopes, Cabrita et al. 2006). Thus, 
these methods alone have not been viable approaches for tissue engineering of more complex 
tissues. 
The problem of complex and composite tissue regeneration in adult mammals is further 
complicated by the limited regenerative capacity of adult mammals. Besides select tissues 
including the bone marrow (Chan and Yoder 2004), intestinal lining (Oates and West 2006), 
superficial layers of the skin (Epstein and Maibach 1965), nailbeds (Lee, Lau et al. 1995), liver 
(Michalopoulos 2007), and deer antler (Li, Yang et al. 2009),  the default response to injury in 
most other tissues involves processes of coagulation, inflammation, migration, and scar tissue 
deposition (Falanga 2005). However, scarless regeneration in the form of epimorphic 
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regeneration occurs following tissue injury in early human fetal development (Metcalfe and 
Ferguson 2005) and in urodeles (e.g. the newt and salamander) of all ages and has been divided 
into two relatively broad categories. The first category of epimorphic regeneration involves the 
formation of a b lastema. A blastema is a pre-programmed accumulation of multipotential cells 
that spontaneously proliferate, migrate, differentiate, and spatially organize in three dimensions 
to form a perfect phenocopy of the missing or injured body part (Morgan 1901). The second 
category of epimorphic regeneration does not involve a blastema and instead utilizes 
mechanisms that include: (a) transdifferentiation of cells to replace the missing tissue; (b) limited 
dedifferentiation and proliferation of cells; and/or (c) proliferation and differentiation of stem 
and progenitor cells in the injured tissue (Sanchez Alvarado 2000). The specific origins of the 
cells, the genetic profile, and the upstream molecular signals that participate in the two categories 
of epimorphic regeneration are only partially known, but the microenviromental cues and cell 
populations required to initiate and sustain the process are gradually and systemically being 
identified (Brockes and Kumar 2005; Kumar, Godwin et al. 2007; Monaghan, Epp et al. 2009).   
The equivalent of a b lastema does not occur in adult mammals, but non-blastemal 
regeneration does occur in certain organs of adult mammals such as the liver (Ito, Hayashi et al. 
1991). In the context of regenerative medicine strategies for adult mammals, including humans, 
non-blastemal approaches may be more plausible for the functional restoration of complex 
tissues and organs. Thus, recruitment of endogenous progenitor cells to a site of injury may alter 
the overall wound healing response from scar tissue deposition towards regeneration. While 
likely insufficient on i ts own, directed recruitment of endogenous progenitor cells would 
conceptually represent an essential component of a non-blastemal based approach to epimorphic 
regeneration of tissues and organs. 
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1.6 CENTRAL HYPOTHESIS 
The work presented in the following chapters broadly aims to investigate whether degradation 
products of ECM scaffolds can promote site-directed recruitment of progenitor cells to a site of 
injury in vivo. A secondary goal of the present work is to utilize this property of ECM 
degradation products as a potential therapeutic approach towards tissue engineering of more 
complex, composite tissues such as digits.  
Thus, the central hypothesis of the present body of work is that degradation 
products of bioscaffolds composed of extracellular matrix recruit progenitor cells to a site 
of injury in an adult murine model of digit amputation.  
1.7 SPECIFIC AIMS 
Specific Aim 1: To determine the effect of treatment with degradation products of ECM 
scaffolds upon recruitment of progenitor cells to a site of amputation in a non-regenerating adult 
mammalian model of digit amputation. 
Corollary Hypothesis for Aim 1: Degradation products of ECM scaffolds promote the 
local accumulation of progenitor cells in a non-regenerating murine adult mammalian model of 
digit amputation.  
 
Specific Aim 2: To determine the chemotactic potential of isolated fractions of degradation 
products of ECM scaffolds in vivo in an adult mammalian model of digit amputation.   
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Corollary Hypothesis for Aim 2: A single, purified chemotactic peptide promotes 
progenitor cell chemotaxis in vitro and the local accumulation of progenitor cells at a site of 
amputation in a murine model of digit amputation.  
 
Specific Aim 3: To determine the effect of treatment with ECM degradation products upon 
tissue reconstruction in an adult mammalian model of digit amputation. 
 Corollary Hypothesis for Aim 3: A purified chemotactic peptide accelerates 
osteogenesis of adult mesenchymal stem cells in vitro and promotes bone formation in vivo in a 
murine model of digit amputation.  
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2.0  RECRUITMENT OF PROGENITOR CELLS BY ECM DEGRADATION 
PRODUCTS IN VIVO 
2.1 INTRODUCTION 
Sections of this chapter have been modified and adapted from (Agrawal, Johnson et al. 2010). 
Biologic scaffolds composed of extracellular matrix (ECM) have been used to promote 
site-specific, functional remodeling of tissue in both preclinical animal models (Badylak, Lantz 
et al. 1989; Lantz, Badylak et al. 1990; Cobb, Badylak et al. 1996; Hodde, Badylak et al. 1997; 
Badylak, Meurling et al. 2000; Caione, Capozza et al. 2006; Zalavras, Gardocki et al. 2006; Ott, 
Matthiesen et al. 2008; Ott, Clippinger et al. 2010; Uygun, Soto-Gutierrez et al. 2010) and 
human clinical applications (Metcalf, Savoie et al. 2002; Witteman, Foxwell et al. 2009; Derwin, 
Badylak et al. 2010; Mase, Hsu et al. 2010). Although the mechanisms of remodeling are not 
completely known, proteolytic degradation of the ECM scaffold and concomitant accumulation 
of progenitor cells at a site of injury are two important mechanisms by which ECM scaffolds 
promote constructive tissue remodeling of the injury site (Badylak, Park et al. 2001; Zantop, 
Gilbert et al. 2006; Valentin, Stewart-Akers et al. 2009). Circulating bone-marrow derived cells 
are known to partially comprise the dense mononuclear infiltrate that populates the site of ECM 
implantation (Valentin, Badylak et al. 2006; Badylak, Valentin et al. 2008), and bone marrow 
derived progenitor cells persist at the site of injury and eventually contribute to functionally 
19 
remodeled tissue (Badylak, Park et al. 2001; Zantop, Gilbert et al. 2006). The degradation of the 
ECM scaffolds results in the release of small cryptic peptides with novel bioactivity not present 
in the parent ECM proteins (Davis, Bayless et al. 2000; Davis 2010).  These cryptic fragments 
have been shown to possess antimicrobial, immunomodulatory, angiogenic and anti-angiogenic, 
mitogenic, and chemotactic properties, among others (Berkowitz, Bevins et al. 1990; Moore, 
Devine et al. 1994; Moore, Beazley et al. 1996; Davis, Bayless et al. 2000; Ganz 2003; Li, Li et 
al. 2004; Adair-Kirk and Senior 2008; Agrawal, Brown et al. 2009). Although full 
characterization of these bioactive peptides has not been completed to date, ex vivo enzymatic, 
chemical, and physical methods (Li, Li et al. 2004; Brennan, Reing et al. 2006; Reing, Zhang et 
al. 2009) have generated a heterogeneous population of ECM peptides (Brennan, Tang et al. 
2008; Freytes, Martin et al. 2008) with both chemotactic and mitogenic properties for a variety 
of  stem and progenitor cells (Zantop, Gilbert et al. 2006; Brennan, Tang et al. 2008; Crisan, Yap 
et al. 2008; Marra, Defail et al. 2008).  
Thus, the work described in the present chapter aims to expand upon previous in vitro 
work and characterize the in vivo chemotactic potential of ECM degradation products in a non-
regenerating model of mid-second-phalanx amputation in adult mice. In the absence of any 
intervention, wound healing is completed by 14 days post-amputation in this model (Schotte and 
Smith 1959; Schotte and Smith 1961). The work in the present chapter shows that treatment with 
ECM degradation products results in a deviation from the default wound healing response from 
scar tissue deposition and instead promotes site directed accumulation of progenitor cells at the 
site of amputation. 
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2.2 METHODS 
2.2.1 Preparation of ECM degradation products: 
Porcine urinary bladders were harvested from euthanized market weight (240-260 lb) pigs. The 
basement membrane and underlying lamina propria were isolated and harvested as previously 
described (Freytes, Badylak et al. 2004). Following peracetic acid, ethanol, deionized H2O, and 
phosphate buffered saline treatment (Reing, Zhang et al. 2009), lyophilized sheets were 
comminuted and digested in pepsin and 0.01 N  HCl for 48 hours prior to neutralization and 
dilution in PBS to yield a 5 mg/ml solution. The soluble protein concentration of ex vivo 
generated ECM degradation products was found to be 1.68 + 0.17 μg/ml, and SDS-PAGE of 
these products in previous studies demonstrated a heterogeneous population of peptides 
(Brennan, Tang et al. 2008; Freytes, Martin et al. 2008).   
2.2.2 Confirmation of Chemoactivity of ECM Degradation Products: 
To confirm the chemotactic activity associated with  ECM degradation products (Reing, Zhang 
et al. 2009), primary human perivascular stem cells (Crisan, Yap et al. 2008) were assayed for a 
chemotactic response in a Boyden chamber. Human perivasular stem cells were a gift from Dr. 
Bruno Peault, and these cells were isolated and prepared as previously described (Crisan, Yap et 
al. 2008). Perivascular stem cells were starved in high glucose Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 0.5% heat inactivated fetal bovine serum (FBS) for 16-18 
hours at 37 0C and 5% CO2 in a humidified incubator. After starvation, cells were resuspended in 
DMEM at a concentration of 6x105 cells/ml for 1 hour. Polycarbonate PFB filters (Neuro Probe, 
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Gaithersburg, MD) with 8 µ m pores were coated with 0.05 m g/ml Collagen Type I (BD 
Biosciences, San Jose, CA). ECM degradation products were placed in the top and bottom 
chambers of Neuro Probe 48-well chemotaxis chambers (Neuro Proe, Gaithersburg, MD) at 
varying concentrations with 3x104 cells in the top chamber, and incubated at 37 0C in 95% O2 / 
5% CO2 for 3 hours. Migrated cells were fixed in methanol, stained with 500 nM DAPI (Sigma, 
D9564), imaged on a Nikon E600 microscope, and counted using ImageJ. 
2.2.3 Flow Cytometry and Immunolabeling of Perivascular Stem Cells 
Cells were detached from culture flasks using pre-warmed 15 mM sodium citrate for 5 minutes, 
centrifuged at 1500rpm for 5 minutes, resuspended, and filtered through a 70 µm filter prior to 
incubation with antibodies, all at a dilution of 1 µl per 1x107 cells/ml, for 1 hr prior to extensive 
washing and resuspension with PBS for flow cytometric analysis. Antibodies included mouse 
monoclonal FITC-CD144 (clone 55-7H1, #560874), APC-CD34 (clone 581, #560940) , PE-
CD146, and V450-CD45 (clone HI30, #560368) (BD Biosciences, San Diego, CA). For 
immunostaining, 1x105 cells were cytospun onto slides and fixed for 30 s econds in ice cold 
methanol. Following permeablization in 0.1% TritonX and 0.1% Tween20 in PBS for 15 
minutes, cells were blocked in 1% BSA diluted with 0.01% TritonX and 0.01% Tween20 in PBS 
for 1 hr. Cells were then stained for 1 hr with CD146 (clone P1H12) (Abcam, Cambridge, MA, 
ab24577), smooth muscle actin (clone 1A4) (Dako, Carpinteria, CA, M0851) or NG2 (Millipore, 
Billercia, MA, AB5320), each diluted 1:200 in blocking solution. Following extensive washing 
in PBS, cells were then incubated with donkey anti-rabbit IgG-Alexa Fluor 546 (Invitrogen, 
A10042) and donkey anti-mouse IgG-Alexa Fluor 488 ( Invitrogen, A21202) diluted 1:400 in 
blocking buffer for 1 hour.  
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2.2.4 Animal Model of Digit Amputation:  
All methods were approved by the Institutional Animal Care and Use Committee at the 
University of Pittsburgh and performed in compliance with NIH Guidelines for the Care and Use 
of Laboratory Animals. Adult female 6-8 week old C57/BL6 mice were obtained from Jackson 
Laboratories (Bar Harbor, ME). Following induction of surgical plane anesthesia with 
isofluorane (1-2%), each mouse was subjected to aseptic mid-second phalanx amputation of the 
third digit of the right hind foot (Figure 3). At 0, 24 and 96 hours post surgery 20 μg of 
chemotactic ECM degradation products were injected at the base of the amputated digit in group 
1 animals via 30 gauge needle. Animals in group 2 were left untreated. Animals were sacrificed 
via cervical dislocation under deep isoflurane anesthesia (5-6%) at various time points following 
surgery. Digits were either fixed and sectioned for histologic analysis and immunolabeling, or 
harvested for cell isolation for subsequent flow cytometric analysis and cytospin. 
 
Figure 3. A schematic diagram overlaying an H&E image of an adult mouse digit. The red, dotted line depicts the 
site of amputation. Figure modified with permission from Scott A. Johnson, MS. 
2.2.5 Fluorescein Labeling of ECM Degradation Products in a Digit Amputation Model 
Degradation products of ECM were labeled with the fluorescein (FITC) fluorophore as per 
manufacturer’s instructions (Thermo PierceNet, Pittsburgh, PA, #53027). Following mid-second 
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phalanx amputation under isoflurane anesthesia, FITC labeled ECM degradation products were 
injected at the base of the amputated digit. Following injection, animals were immediately 
sacrificed, and the entire foot was isolated and fixed in 4% paraformaldehyde prior to serial 
dehydration in 25%, 50%, 75%, 95%, and 100% acetone. Following dehydration, fixed digits 
were then incubated in Dent’s fixative (1:4 DMSO:acetone) for 2 hours. Then, the digits were 
permeablized and bleached overnight in Dent’s bleach (1:4:1 DMSO:acetone:H2O2). Digits were 
then equilibrated to a clearing solution consisting of 1:2 benzyl alcohol (Sigma, 402834) to 
benzyl benzoate (Sigma, B6630) (BABB) by serial 1 hour  incubations in 1:3, 1:1, and 3:1 
solutions of BABB:Dent’s fixative. Afterwards, digits were then kept in 100% BABB until they 
were visibly optically cleared. Optically cleared digits were then imaged using a Nikon E600 
epifluorescent microscope at 100x magnification, and images were taken with a Nuance camera. 
Images were deconvolved with a known FITC and tissue autofluorescence spectra and false 
colored as green and red, respectively.  
2.2.6 Tissue Immunolabeling: 
Harvested mouse digits were fixed in 10% neutral buffered formalin and decalcified for two 
weeks in 5% formic acid prior to being paraffin embedded and sectioned and stained for either 
Sox2, Rex1, or Sca1.  
Sox2 staining utilized a primary antibody from Abcam ab15830 (Abcam, Cambridge, 
MA) or primary antibody from Millipore AB5603 (Millipore, Billerca, CA ). Antigen retrieval 
was in 10 mM Citrate Buffer (Citrate: C1285, Spectrum, New Brunswick, NJ) for 20 minutes at 
96oC. Following antigen retrieval, slides were placed in TBS + 0.05% Tween-20 for five 
minutes, rinsed in PBS for five minutes twice, blocked for 1 hour  in 1.5% BSA / PBS, and 
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incubated overnight with primary antibody diluted in 1.5% BSA / PBS (1:100). Slides were then 
rinsed in PBS, treated with 3% hydrogen peroxide solution in methanol for 30 minutes, rerinsed 
in PBS  and incubated with HRP conjugated secondary antibody for 1 hour (Rabbit anti-rat IgG-
HRP (Dako, Carpinteria, CA, #P0450),  r insed again in  P BS, and developed with 3, 3’  
diaminobenzidine (DAB) (Vector Labs, Burlingame, CA). 
Sca-1 staining utilized the primary antibody ab25196 (Abcam, Cambridge, MA). Antigen 
retrieval was for 10 m inutes at 93oC in R&D Systems Antigen Retrieval Reagent Universal 
(R&D Systems #CTS015, Minneapolis, MN) following manufacturer’s protocol. R&D Systems 
HRP-DAB Cell and Tissue Staining Kit for goat primary IgG antibodies (R&D Systems 
#CTS008, Minneapolis, MN) was used for subsequent staining, following manufacturer’s 
instructions with the following three changes: (1) slides were blocked in 1.5% BSA/PBS, (2) 
primary antibody was diluted 1:1000 in 1.5% BSA/PBS and (3) incubations with biotinylated 
secondary antibody and subsequent washes were deleted since ab25196 is biotin-conjugated. 
Rex1 staining utilized antigen retrieval with Antigen Unmasking Solution (Vector 
Laboratories, Burlingame, CA) by boiling under pressure for 2 min. Slides were then incubated 
in 3% hydrogen peroxide in methanol for 15 min to quench endogenous peroxidase activity. This 
was followed by incubation with the anti-mouse Rex1 primary antibody (affinity-purified, 
polyclonal rabbit antibody, custom-generated and supplied by Alpha Diagnostic, San Antonio, 
TX (project name: ZFP42-17, peptide#13209)) diluted 1:20 in 1.5% goat serum for 1 hour  at 
room temperature. HRP conjugated goat anti-rabbit secondary antibody (Catalog No. 87-9263, 
SuperPicture, Zymed, San Francisco, CA) was added to each tissue section and incubated at 
room temperature for 30 min. Staining of the antigen (brown stain) was accomplished by 
incubation of the tissue sections with DAB chromogen substrate (SuperPicture, Zymed, San 
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Francisco, CA) for 8-10 min at 22°C. The negative control sections were treated identically to 
the adjacent sections except that 1.5% goat serum was used in place of primary Rex1 antibody. 
After staining with DAB, all slides were counter-stained with Harris’ hematoxylin, 
dehydrated, coverslipped with non-aqueous mounting medium, and imaged on a Nikon E600 
microscope, Olympus Provis Microscope, or Olympus Fluoview 1000 Confocal Microscope. 
Images were taken at 40X magnification and 200X magnification. For quantification of the 
number of cells positive for markers, four images were taken in each sample: distal to the 
amputated edge of the second phalanx bone, proximal to the tip of the digit, and lateral to the cut 
edge of the second phalanx bone on either side. The number of positive cells in each image was 
counted by three independent investigators who were blinded to the treatment group. The mean 
number of positive cells was compared between various groups by a two-sided, unpaired 
student’s t-test with unequal variance. Significance was determined at p = 0.05 level (α=0.05, 
β=0.2). 
2.2.7 Cell Isolation 
Following digit amputation and treatment, digits were harvested on day 14 post-amputation and 
placed into cold culture medium consisting of DMEM, 10% fetal bovine serum (Hyclone, 
Pittsburgh, PA), 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen, Carslbad, CA).  
Using a microdissection microscope under aseptic conditions, the epidermis and dermis were 
removed and the tissue distal to the amputated second phalanx bone was harvested into serum 
free DMEM containing 0.2% Collagenase Type II (Gibco Invitrogen, 17101-015) for 30 minutes 
at 37 0C. Cells were then centrifuged and reconstituted into warm culture medium, filtered 
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through a 70 µm filter, and counted on a hemocytometer prior to differentiation assays, cytopsin, 
or further immunolabeling for flow cytometric analysis.  
 
Figure 4. Schematic diagram showing the microdissection procedure by which cells are removed from amputated 
digits. Figure reproduced with permission from Scott A. Johnson, MS. 
2.2.8 Differentiation Assays:  
Mesodermal Differentiation: For adipogenic differentiation, cells were cultured in adipogenic 
differentiation medium (HyClone, Logan, UT, SH30886.02) for 14 days. Cells were then fixed in 
10% neutral buffered formalin (NBF) and incubated in 0.5% Oil Red O (Alfa Aeasar, Ward Hill, 
MA) for 5 m inutes, extensively washed, and imaged for the presence of lipid vacuoles. For 
osteogenic differentiation, cells were cultured in osteogenic differentiation medium (HyClone, 
SH30881.02) for 21 da ys. After fixation in NBF, cells were incubated in 2% Alizarin Red 
solution to investigate for the presence of calcium.  
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Neuroectodermal Differentiation: Cells were cultured in DMEM supplemented with 10% 
FBS and 20 ng/ml bFGF (Sigma, St. Louis, MO, F0291) for 24 hours. Culture medium was then 
replaced with Neurobasal-A medium supplemented with 20 ng/ml bFGF, 20 ng/ml EGF (Sigma, 
E9644), and 2 μM all-trans retinoic acid (Sigma, R2625) for 7 days. After 7 days of culture, cells 
were fixed in 4% paraformaldehyde and prepared for staining. Cells were assessed for the 
presence of neuron and glial cell specific proteins β-tubulin III, NeuN, and glial fibrillary acidic 
protein (GFAP). The primary antibodies used were β-tubulin III ab7751 (Abcam), glial fibrillary 
acidic protein #Z0334 (DakoUSA), and NeuN #MAB377 (Millipore, Billerica, MA). Following 
fixation, slides were then washed, rehydrated in Tris Buffered Saline with 0.05% Tween20 
(TBST), and incubated for 15 m inutes in permeablization buffer (0.1% Triton X in TBST) at 
room temperature. Slides were then incubated in blocking solution (2% w/v bovine serum 
albumin (Sigma, A2153) in TBST) for one hour at room temperature, followed by incubation in 
primary antibody for one hour. All antibodies were used at a concentration of 1:100. After 
extensive washing, slides were then incubated in fluorophore conjugated secondary antibodies 
for 1 hour at room temperature. Secondary antibodies included Alexa Fluor 488 conjugated anti-
rabbit IgG (Invitrogen, A-11008) and Alexa Flour 546 conjugated anti-mouse IgG (Invitrogen, 
A-11001), were used at a concentration of 1:250. Slides were counterstained with DAPI prior to 
mounting in fluorescent mounting medium (DakoUSA).  
2.2.9 Flow Cytometric Analysis of Isolated Cells from Murine Digits 
Following isolation of cells, cells were spun and resuspended in 200 µl in serum free DMEM 
prior to incubation with primary antibodies for 1 hour at 4 0C. Primary antibodies were FITC-
Sca1 (clone D7) (Abcam, ab25031, Cambridge, MA), PE-CD133 (clone 13A4) (eBiosciences, 
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12-1331, San Diego, CA), e450NC-CD90.2 (clone 53-2.1) (eBiosciences, 48-0902), biotin-cKit 
(clone 2B8) (eBiosciences, 13-1171), and SAv-APC-Cy7 (BD Biosciences, 554063, San Diego, 
CA). Primary antibodies were incubated at a dilution of 1:200, and streptavidin conjugates were 
incubated at a dilution of 1:250 after washing away primary antibody. Cells were then fixed and 
labeled for APC-Sox2 by following the manufacturer’s guidelines in the BD Mouse Pluripotent 
Stem Cell Transcription Factor Analysis Kit (BD Biosciences, 560585). Cells were then 
extensively washed, resuspended in PBS, and filtered through 70 µm filter prior to flow 
cytometric analysis.    
2.2.10 Immunolabeling of Cytospins 
Following cytospin of 1x104 isolated cells per slide, each slide was fixed in methanol for 
30 seconds and stored at -20 0C. Prior to staining, slides were rehydrated in PBS for 5 minutes, 
and cells were permeablized in 0.1% TritonX/PBS for 15 minutes. Slides were blocked in 1% 
bovine serum albumin/PBS for 1 hour prior to overnight incubation with rabbit anti-Sox2 (1:100) 
and/or chicken anti-GFP (1:100) (Abcam, ab13970) diluted in blocking solution. Following two 
washes in PBS, slides were incubated for 1 hour  with donkey anti-rabbit IgG-Alexa Fluor 488 
(1:250) (Invitrogen, A21206), donkey anti-rabbit IgG-Alexa Fluor 546 (1:250) (Invitrogen, 
A10040) and/or donkey anti-chicken IgG-Alexa Fluor 488 (1:250) (Invitrogen, A11039) diluted 
in blocking solution. Following two washes in PBS, slides were counterstained with DRAQ5 
(1:500) (Cell Signal, 4084, Danvers, MA) diluted in PBS for 30 seconds prior to three washes in 
PBS and coverslipping with fluorescent mounting medium (Dako, S3023). All images were 
taken at 200X magnification.  
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2.2.11 Nuclei to Collagen Ratio and Histomorphometric Analysis of Trichome Stained 
Sections 
Following mid-second phalanx digit amputation and treatment with either ECM degradation 
products or corresponding control treatment, animals were euthanized at day 14 post-amputation 
and amputated digits were harvested, fixed in 10% neutral buffered formalin, decalcified, and 
sectioned for histologic analysis. Sections were stained with Masson’s Trichrome stain to 
evaluate the ratio of cell to connective tissue at the site of amputation. Three images of the 
Trichrome stained sections were randomly taken at 32x magnification on an inverted microscope 
using AxioVision Rel 4.8 software. The relative cellularity and connective tissue in each image 
was calculated using a custom MATLAB script (version 7.11.0.584 R 2010b, MathWorks, 
Natick, MA). The MATLAB script is available upon request. Nuclei (purple) and connective 
tissue (blue) were isolated by hue histogram filtration and subsequent thresholding. Cellular 
density for each image was calculated as the ratio of the number of brown pixels to the number 
of blue pixels (Figure 5). 
 
Figure 5. An example of the output of separation of nuclei from connective tissue in Trichrome stained samples. 
 
 Analysis of soft tissue area was found using ImageJ 1.44p (National Institutes of Health, 
USA). Blue soft tissue distal to the site of amputation was manually outlined and area of the 
complex object was analyzed (in pixels). Three width measurements (in pixels) of the second 
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phalanx were also taken at distal, mid, and proximal locations on the bone. Tissue growth was 
found as the area of blue soft tissue, as well as area of blue soft tissue normalized to the 
measured bone widths (Figure 6). 
 
Figure 6. Schematic depiction of a Herovici stained digit section showing the measurement of area of soft tissue 
distal to the site of amputation as well as the measurement of bone width. 
 
2.3 RESULTS 
2.3.1 Confirmation of phenotype of human perivascular stem cells 
The phenotype of human perivascular stem cells was confirmed in vitro by flow cytometric 
analysis for cell surface marker expression of perivascular stem cells. Perivascular stem cells 
expressed mesenchymal stem cell markers CD146, but they did not express endothelial cell 
marker CD144 (Figure 7). Additionally, as previously described (Crisan, Yap et al. 2008; Tottey, 
Corselli et al. 2011), perivascular stem cells did not express markers of blood lineage, CD34 and 
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CD45. Perivascular stem cells remained CD146+, CD144-, CD34-, CD45- through culture of 
passages 11-14 in vitro (Figure 7). 
 
 
Figure 7.  Perivascular stem cells express mesenchymal stem cell markers over multiple passages. In order 
to confirm that the perivascular stem cells did not alter phenotype after in vitro culture, cell surface expression of 
various markers was investigated by flow cytometry. Perivascular stem cells expressed mesenchymal stem cell 
marker CD146, sm-actin, and NG2, but they did not express endothelial cell marker CD144 or blood lineage 
markers CD34 and CD45. 
2.3.2 Confirmation of chemotactic activity of ECM degradation products 
Chemotactic activity of ECM degradation products was confirmed in vitro using human 
multipotent perivascular cells (Crisan, Yap et al. 2008) (Figure 8). Chemokinetic and haptotactic 
effects were ruled out by control wells which contained varying concentrations of the same ECM 
degradation products in both the top and bottom chambers. Results showed that cells selectively 
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migrated only when a concentration gradient was present (Figure 8), confirming the chemotactic 
activity of the ECM degradation products. 
 
Figure 8. The in vitro migration of perivascular stem cells from the upper chamber of a Boyden assay to 
the lower chamber only in the presence of an ECM gradient confirms chemotactic and not chemokinetic activity of 
the degradation products. Error bars are S.D. between three wells, with a similar trend seen on three separate 
occasions. 
2.3.3 Mid-second phalanx digit amputation does not regenerate 
In order to confirm previous studies showing a completed wound healing response to murine 
mid-second phalanx digit amputation by day 14 post-amputation (Schotte and Smith 1959; 
Schotte and Smith 1961), a time course analysis of the default response to murine digit 
amputation was completed. At 4 da ys post-amputation, remnants of the immediate clotting 
response as well as local accumulation of inflammatory cells was observed. By day 7 pos t-
amputation, the site of amputation was almost completely re-epithelialized, but the local immune 
response persisted. By day 14 post-amputation, the immune response had largely subsided. The 
site of amputation was replaced with a dense, connective tissue and thick, keratinized epithelium 
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with mature rete pegs, suggestive of a completed wound healing at the site of amputation. As far 
out as day 56 post-amputation, there was no observable growth of soft tissue or bone (Figure 9).  
 
Figure 9. Trichome images of an unampuated digit (left) and amputated digit (right) show that amputation of the 
digit does not result in digit regrowth even as late as 56 days post-amputation, consistent with the overall goal of 
developing a non-regnerating model of composite tissue injury. The yellow line delineates the site of amputation. 
 
2.3.4 Injection at the base of the footpad reaches the site of digit amputation 
ECM degradation products were injected subcutaneously at the base of the amputated digit. 
Subcutaneous injection would theoretically serve as an endogenous repository of the ECM 
degradation products, and it would overcome the logistical limitations of local administration in 
this animal model. In order to confirm that regional administration of ECM treatments at the base 
of the footpad reach the site of amputation, India ink was injected at the base of the digit 
following mid-second phalanx amputation in mice (Figure 10). The injectate preferentially 
diffused along the amputated digit towards the site of amputation. Longitudinal sections of the 
amputated digit and transverse sections of the footpad confirmed anterograde and retrograde 
movement of injectate. A similar trend was observed on three separate occasions.  
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Figure 10. India ink injectate reaches the site of amputation in vivo. To investigate whether injections in the 
footpad reach the site of amputation, female adult C57/BL6 mice were subjected to mid-second phalanx amputation 
of the third digit bilaterally and injection of India ink at the base of the amputated digit. The injectate preferentially 
diffused along the amputated digit towards the site of amputation (A). Longitudinal sections of the amputated digit 
(B) and transverse sections of the footpad (C) confirmed anterograde and retrograde movement of injectate. A 
similar trend was observed on three separate occasions. 
 
In order to directly assess whether ECM degradation products reach the site of 
amputation, a fluorescein (FITC) fluorophore was non-specifically covalently attached to the 
ECM degradation products. While the effect of FITC attachment upon t he bioactivity of the 
ECM degradation products was not known, FITC attachment was still useful for assessing the 
regional distribution of ECM degradation products following administration at the base of the 
footpad. Immediately after injection, FITC labeled ECM degradation products were found at the 
site of injection and tracking along multiple digits, including the amputated digit (Figure 11). 
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Figure 11. Following injection of FITC-conjugated ECM degradation products at base of the amputated 
digit, ECM degradation products were found diffusing along the amputated digit as well as adjacent unamputated 
digits.  
2.3.5 ECM Degradation Products Promote the Accumulation of Mononuclear Cells In 
Vivo 
Following mid-second phalanx amputation in C57/BL6 mice and treatment with ECM 
degradation products, phosphate buffered saline (PBS) carrier control, or no treatment (a clinical 
control), no macroscopic differences were observed between treatment groups prior to 14 days 
post-amputation.  However, Masson’s trichrome stained sections of digits from ECM treated 
mice showed an accumulation of mononuclear cells distal to the site of amputation and a thin, 
keratinized epithelium (Figure 12). The number of accumulated cells varied between animals in 
the ECM-treated group, but the accumulation of cells was consistently limited to the soft tissue 
that began to develop at the cut end of the bone and extended to the digit tip. Mice from the PBS 
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and untreated control groups showed only scar tissue and an overlying thick keratinized 
epithelium at the digit amputation site (Figure 12).  
Quantification of the relative ratio of cellularity to connective tissue on M asson’s 
trichrome stained slides confirmed that treatment with ECM degradation products resulted in a 
more a cellular accumulation at the site of amputation (Figure 13).  Quantification of the area 
over which the accumulated cells were found on the slide showed that there were no significant 
differences in the amount of soft tissue at the site of amputation between treatment groups, 
suggesting that the greater cellularity was due to an increased density of cells as opposed to more 
tissue growth (Figure 13).  
 
Figure 12. Masson’s Trichrome stained slides of histologic sections of amputated digits treated with ECM 
degradation products, PBS control, and no treatment. Images were taken at 40x and 200x in the insets, respectively. 
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Figure 13. At day 14 post-amputation, treatment with ECM degradation products led to the accumulation 
of a heterogeneous population of cells at the site of amputation, whereas no treatment resulted in a less cellular 
accumulation concomitant with scar deposition at the site of amputation, consistent with a completed wound healing 
response to murine digit amputation (A) (Schotte and Smith 1959). Histologic appearance of a more densely cellular 
accumulation following ECM treatment was confirmed by quantification of the relative ratio of cellularity to 
connective tissue on Trichrome slides (B). Quantification of the area of growth distal to the site of amputation 
showed no difference between ECM treatment and no treatment, suggesting that the accumulated cells were more 
densely packed following ECM treatment (C). * p < 0.05. * p < 0.01. Errors bars represent Mean + SEM (n=4). 
 
2.3.6 Accumulated Mononuclear Cells Differentiate Along Neuroectodermal and 
Mesodermal Lineages 
In order to identify the accumulation at the site of amputation, digits were harvested and the 
cellular accumulation was micro-dissected away from the digit. Cells were then plated and 
subjected to conditions of adipogenic, osteogenic, and neuroectodermal differentiation in vitro. 
Following culture in conditions of neuroectodermal differentiation, cells from ECM treated mice 
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showed heterogeneous morphologies including spindle-like cells with long processes that 
expressed β3-tubulin and NeuN, markers of differentiating neurons (Locatelli, Corti et al. 2003), 
and stellate shaped cells that expressed glial fibrillary acidic protein (GFAP), a marker of glial 
cells that is also expressed by some neural stem cells (Eng, Ghirnikar et al. 2000; Zhu and 
Dahlstrom 2007) (Figure 14). Cells from untreated mice cultured in conditions of 
neuroectodermal differentiation showed mainly spindle shaped cells consistent with a fibroblast 
or mesenchymal phenotype, and these cells did not give rise to cells expressing β3-tubulin, 
NeuN, or GFAP (Figure 14). However, when exposed to an adipogenic differentiation 
environment, cells from mice in both groups showed vacuoles that stained positive for Oil Red 
O, a s pecific stain for the presence of lipid accumulations (Figure 14). When subjected to 
conditions of osteogenic differentiation, cells from mice in both groups acquired a round 
morphology and stained positive for Alizarin Red, a stain that confirms the deposition of calcium 
by cells (Figure 14).  
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Figure 14. In vitro lineage differentiation potential of cell isolated distal to the site of amputation in digits 
of mice treated with ECM degradation products and untreated. Neuroectodermal differentiation was confirmed via 
expression for neuroectodermal markers (β-tubulin-III, NeuN, and GFAP). Adipogenic differentiation was 
confirmed via Oil Red O staining for the presence of lipid vacuoles. Osteogenic differentiation was confirmed via 
Alizarin Red staining for calcium deposition. 
2.3.7 ECM Treatment Leads to a Heterogeneous Accumulation of Cells at Site of 
Amputation 
Thus, at least a s ubset of the cells present at the site of amputation were capable of 
neuroectodermal and mesodermal differentiation in vitro, suggesting that a subset of the cells 
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present following digit amputation and treatment with ECM degradation products were 
progenitor cells. Flow cytometric analysis and immunolabeling studies were utilized to identify 
the phenotypes of the cells at the site of amputation, with a specific focus on de termining the 
source of the progenitor cells at the site of amputation. Both local sources (bone marrow, 
periosteum, dermal hair follicles, perivascular) and circulating sources (hematopoietic) were 
considered.  
Upon microdissection and dissociation of accumulated cells from amputated digits, a 
greater number of cells were present in ECM treateg digits as opposed to controls (Figure 15), 
consistent with the qualitative histologic appearance of Trichrome stained sections (Figure 13). 
Following plating and culture of the cells, cells acquired heterogeneous morphologies in vitro 
with separate subsets of cells showing roung, spindle, and triangular morphologies (Figure 15).  
 
Figure 15. To further characterize the accumulation of cells at the site of amputation, the cellular 
accumulation was microdissected and dissociated for flow cytometric anaylsis . More cells were isolated from ECM 
treated digits as opposed to controls (A). Culture of the isolated cells over 2 weeks showed that the cells acquire 
heterogeneous morphologies including round, spindle, and triangular shaped morphologies, suggesting a 
heterogeneous population of cells (B). Flow cytometric analysis of the isolated cells confirmed a heterogeneous 
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accumulation of cells with subsets of cells that express stem cell markers Sca1, Sox2, and CD146 as well as subsets 
that express differentiated markers CD11b, F4/80, and Lineage cocktail (C).  * p < 0.05, ** p < 0.01. Errors 
represent Mean + SEM (n=4). 
  
Flow cytometric analysis of the isolated cells confirmed a heterogeneous accumulation of 
cells with subsets of cells that express stem cell markers Sca1, Sox2, and CD146 as well as 
subsets that express differentiated markers CD11b, F4/80, and Lineage cocktail (Figure 15).  To 
identify the phenotype of the accumulated cells, tissue sections were stained for markers of stem 
and progenitor cells, including Sox2 (Fauquier, Rizzoti et al. 2008), Rex1 (Mongan, Martin et al. 
2006), and Sca1 (van de Rijn, Heimfeld et al. 1989). Mice treated with ECM degradation 
products accumulated a greater number of cells positive for stem cell markers Sox2 and Rex1 
distal to the site of digit amputation compared to untreated mice and compared to normal, 
uninjured mice (Figure 16). 
 
Figure 16. Histologic sections of cell accumulations distal to the site of amputation in mice 14 days post-
amputation and injection of ECM degradation products or no treatment after staining for markers of multipotency. 
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All images were taken at a magnification of 400x. Cell counts are displayed in units of number of cells. * p < 0.05, 
** p < 0.005 (between treatment and no treatment, or treatment and uninjured controls). Error bars represent Mean + 
SEM (n=4). 
2.3.8 ECM Treatment Results in Sox2+ Cell Accumulation at Site of Amputation 
Sox2 is a transcription factor that plays an important role in the self-renewal of embryonic stem 
cells (Avilion, Nicolis et al. 2003) as well as adult progenitor cells including neural stem cells, 
dermal stem cells, neural crest derived stem cells, and osteogenic progenitors (Basu-Roy, 
Ambrosetti et al. ; Mansukhani, Ambrosetti et al. 2005; Biernaskie, Paris et al. 2009; Hutton and 
Pevny 2011). Thus, subsequent work focused on further characterizing the phenotype and source 
of the Sox2+ cells.  
Following treatment with ECM degradation products, a greater number of Sox2+ cells 
were present at the site of amputation at days 10, 14 and 18 post-amputation as compared to PBS 
control (Figure 17). Expression of Sox2+ cells was confirmed by immunolabeling of cytospun 
slides (Figure 17) as well as flow cytometry (Figure 17). Flow cytometric analysis showed that 
the Sox2+ cells did not express dermal stem cell marker, CD133 (Biernaskie, Paris et al. 2009), 
or hematopoietic stem cell marker, c-kit (Spangrude, Heimfeld et al. 1988; Spangrude and 
Scollay 1990). Sox2+ cells did co-express markers Sca1 and CD90, known markers of bone 
marrow and periosteal derived mesenchymal stem cells (Zhang, Xie et al. 2005; De Bari, 
Dell'Accio et al. 2006) (Figure 17).  
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Figure 17. (A) Time course analysis of numbers of Sox2+ cells on histologic sections following digit 
amputation and treatment with either ECM degradation products or PBS control. (B) Confirmation of cytoplasmic 
and nuclear Sox2 expression in isolated cells cytospun to slides. (C) Flow cytometric analysis of Sox2+ cells. * p < 
0.05. Errors bars represent Mean + SEM (n=4). 
 
Immunolabeling of histologic sections of amputated digits showed that the majority of 
Sox2+ cells were found lateral to the amputated bone (Figure 18, 19). Following amputation of 
the proximal interphalangeal joint in which only soft tissue and no bone injury was induced, the 
accumulation of Sox2+ cells was markedly reduced (Figure 18, 19).  
 
Figure 18. Sox2+ cell accumulation requires bone injury and is located lateral to the amputated bone. 
(A) Immunolabeling of histologic sections of amputated digits showed that the majority of Sox2+ cells present at the 
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site of amputation following treatment with ECM degradation products were located lateral to the amputated P2 
bone, consistent with a periosteal location. (B) Following digit amputation proximal to P2 bone at the joint such that 
no bone injury was induced, the accumulation of Sox2+ cells at the site of amputation following ECM degradation 
products was decreased. * p < 0.05. ** p < 0.01. Error bars are Mean + SEM. 
 
 
Figure 19.  Representative images of immunohistochemical staining for the marker, Sox2. Unstained 
sections adjacent to Trichome stained sections (A) were stained with an antibody to the Sox2 antigen, and then 
counterstained with hematoxylin (B). Dermal stem cell staining at the base of hair follicles was used as a positive 
control (Avilion, Nicolis et al. 2003) (C). Sox2+ cells were found within and lateral to the amputated P2 bone of the 
digit. The cells showed predominantly cytoplasmic staining for Sox2 (D).  
2.3.9 Sox2+ Cells are not Derived from Bone Marrow or Circulation 
To distinguish between the bone marrow and the periosteum as the source of the Sox2+ cells, 
transgenic Sox2 eGFP/+ and wild type C57/BL6 mice transplanted with Sox2 eGFP/+ bone 
marrow were both subjected to mid-second phalanx amputation and treatment with ECM 
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degradation products. Bone marrow chimeric mice all displayed stable engraftment 4 weeks 
post-transplant with >80% of the blood expressing the Sox2-eGFP transgene. Expression of GFP 
in Sox2+ cells was confirmed in primary isolated subependymal neural stem cells from the mice 
(Figure 20). Cells were microdissected and isolated from digits of Sox2 eGFP/+ transgenic mice 
as well as bone marrow chimeric mice at day 14 post-amputation. Flow cytometric analysis 
confirmed GFP+ cells at the site of amputation in transgenic mice, but no GFP+ cells from 
amputated digits of bone marrow chimeric mice (Figure 21). GFP+ and GFP- populations were 
sorted by flow cytometry, cytospun, and immunolabeled for Sox2. All GFP+ cells co-expressed 
Sox2, whereas GFP- cells did not express Sox2 (Figure 21). GFP+ cells from β-actin-GFP/+ 
mice were used as a positive control. 
 
Figure 20. Sox2 eGFP/+ supendymal neural stem cells and bone marrow stromal cells were isolated from 
mice to serve as positive and negative controls, respectively, for eGFP expression. GFP expression was confirmed in 
subependymal neural stem cells, and the absence of GFP expression was confirmed in bone marrow stromal cells. 
These controls were used to gate for GFP+ expression in cells isolated from amputated digits (Figure 21). 
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Figure 21. Sox2+ cells at the site of digit amputation are not derived from the bone marrow or 
circulation. Sox2 eGFP/+ transgenic mice and wild type C57/BL6 transplanted with Sox2 eGFP/+ bone marrow 
were subjected to mid-second phalanx digit amputation and treatment with ECM degradation products. At day 14 
post-amputation, cells at the site of amputation were micro-dissected and dissociated for flow cytometric analysis 
for GFP expression. (A)  GFP+ cells were found in cells isolated from Sox2 eGFP/+ transgenic mice. (B) A GFP+ 
population of cells was not found in cells isolated from bone marrow chimeric wild type mice. (C) Cells isolated 
from Sox2 eGFP/+ mice showed a population of cells by flow cytometric analysis that was not present in bone 
marrow chimeric wild type mice. (D) After sorting and cytospinning GFP+ and GFP- cell populations, 
immunolabeling confirmed that the GFP+ cells expressed Sox2 and GFP, whereas GFP- cells did not express Sox2 
or GFP.  
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2.4 DISCUSSION 
The findings of this chapter showed that degradation products of ECM promote the accumulation 
of a heterogeneous population of cells at a site of injury, a subset of which have the capacity to 
differentiate into ectodermal and mesodermal phenotypes in vitro. Additionally, a subset of the 
accumulated cells express Sca1, Sox2, and Rex1, all markers that have been associated with 
multipotential progenitor cells (van de Rijn, Heimfeld et al. 1989; Abdallah, Jensen et al. 2004; 
Mongan, Martin et al. 2006; Ceder, Jansson et al. 2008; Fauquier, Rizzoti et al. 2008). Further 
characterization of the Sox2+ subset of cells present at the site of amputation showed that the 
Sox2+ cells co-expressed surface antigens Sca1 and CD90, consistent with bone marrow 
mesenchymal stem cells. The periosteal location of Sox2+ cells, as well as the lack of bone 
marrow derived Sox2+ cells, suggest that the periosteum may be a source of the Sox2+ cells at 
the site of amputation.  
2.4.1 ECM degradation products, matricryptic peptides, and progenitor cell recruitment 
The generation of matricryptic peptides with biologic activity from ECM is not novel.  
Antimicrobial activity has been attributed to such peptides in the form of defensins (Ganz 2003), 
cecropins (Moore, Devine et al. 1994; Moore, Beazley et al. 1996), and magainins (Berkowitz, 
Bevins et al. 1990). Angiogenic and anti-angiogenic activity has been shown to be caused by 
maticryptic peptides derived from a variety of collagen molecules (Davis, Bayless et al. 2000; Li, 
Li et al. 2004). Peptides derived from extracellular matrix molecules have also been shown to 
modulate inflammation (Adair-Kirk and Senior 2008).  
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The mechanisms by which matricryptic peptides recruit stem cells in vivo are as of yet 
unknown. Additionally, the extent to which matricryptic peptides remain active in vivo is not 
known. Since ECM scaffolds consist of various molecules such as collagen and fibronectin, 
proteoglycans, glycoproteins, growth factors, and cytokines (Chun, Lim et al. 2007), degradation 
of these ECM scaffolds releases a heterogeneous set of molecules (Brennan, Tang et al. 2008; 
Freytes, Martin et al. 2008), each with varying biologic properties in vivo. Subsets of these 
peptides have been found to have different bioactive properties in vitro (Davis, Bayless et al. 
2000; Sarikaya, Record et al. 2002; Brennan, Reing et al. 2006; Beattie, Gilbert et al. 2008; 
Brennan, Tang et al. 2008; Reing, Zhang et al. 2009). While a subset of generated peptides is 
clearly chemotactic for progenitor cells, the overall contribution of these peptides to progenitor 
cell recruitment in vivo is as of yet unknown. The contribution of otherwise inert proteins in this 
mixture to the chemotactic process is also not known with certainty, but further degradation of 
these inert molecules by local proteases at the site of injury may produce new, active matrcryptic 
residues (Lackie, Wilkinson et al. 1981; Davis, Bayless et al. 2000).  
 The present study focused upon the use of ECM degradation products generated ex vivo 
using a non-physiologic method of enzymatic digestion using the pepsin enzyme (Brennan, Tang 
et al. 2008; Freytes, Martin et al. 2008). However, other methods of degradation have also been 
utilized, including non-physiologic degradation via papain digestion (Reing, Zhang et al. 2009) 
and non-enzymatic degradation via acid digestion (Li, Li et al. 2004; Brennan, Reing et al. 
2006). Pepsin was chosen as the singular method by which to degrade due to previous studies 
identifying chemotactic properties of the resulting ECM degradation products for progenitor 
cells (Brennan, Tang et al. 2008; Reing, Zhang et al. 2009). No published methods exist for 
robustly degrading ECM scaffolds ex vivo using physiologically relevant methods (e.g. 
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macrophage mediated degradation, MMP mediated degradation), and previous studies aiming to 
identifying the chemoattractive properties of endogenously created matricryptic peptides were 
not conclusive and open to multiple interpretations (Beattie, Gilbert et al. 2009). However, future 
studies may further investigate the chemoattractive properties of ECM degradation products 
resulting from more physiologic methods of degradation. 
 The present study focused only on the use of ECM derived from porcine urinary bladder. 
The ECM of porcine urinary bladder is a s ource of commercially available, FDA approved 
biologic scaffolds for tissue engineering applications. It has been widely studied for tissue 
engineering applications in a variety of soft tissues (Badylak, Vorp et al. 2005; Kochupura, 
Azeloglu et al. 2005; Nieponice, Gilbert et al. 2006; Gilbert, Gilbert et al. 2008; Kelly, Rosen et 
al. 2009; Nieponice, McGrath et al. 2009; Parekh, Mantle et al. 2009; Boruch, Nieponice et al. 
2010; Medberry, Tottey et al. 2010; Davis, Callanan et al. 2011). In addition to studies 
investigating the surface ultrastructure (Brown, Lindberg et al. 2006; Brown, Barnes et al. 2010; 
Barnes, Brison et al. 2011) and composition (Chun, Lim et al. 2007) of urinary bladder matrix, 
the mechanisms of tissue remodeling by urinary bladder matrix have also been widely studied 
(Record, Hillegonds et al. 2001; Gilbert, Sacks et al. 2006; Valentin, Badylak et al. 2006; 
Gilbert, Stewart-Akers et al. 2007; Gilbert, Stewart-Akers et al. 2007; Gilbert, Stewart-Akers et 
al. 2007; Valentin, Stewart-Akers et al. 2009). While the ECM in scaffolds can be derived from 
multiple species and organs, it is unclear how much the source of the ECM affects the overall 
properties of the resulting ECM scaffold. Studies have shown in vitro that cells preferentially 
adhere, proliferate, and survive on E CM derived from the same organ as the cells (Petersen, 
Calle et al. ; Petersen, Calle et al. ; Sellaro, Ravindra et al. 2007). However, constructive 
remodeling has been observed following implantation of different sources of ECM in vivo in 
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certain injury models such as the rodent abdominal wall injury model (Valentin, Turner et al. ; 
Valentin, Badylak et al. 2006; Badylak, Valentin et al. 2008; Brown, Valentin et al. 2009; 
Valentin, Stewart-Akers et al. 2009). Additionally, in vitro studies with ECM degradation 
products have also shown that the post-natal age of the tissue from which the ECM is derived 
correlates more significantly with the chemoattractive properties of the resulting ECM 
degradation products (Brennan, Tang et al. 2008; Tottey, Johnson et al. 2010) than the actual 
tissue or organ source. Regardless, differences in the compositions between various sources of 
ECM (Brennan, Tang et al. 2008) may alter the in vivo effect of ECM degradation products upon 
progenitor cell accumulation. Future studies may directly compare ECM degradation products 
from different sources of ECM.   
2.4.2 The Mid-second Phalanx Digit Amputation Model: Advantages, Disadvantages, and 
Implications  
The present chapter utilized a mid-second phalanx amputation model to investigate the effect of 
ECM degradation products upon pr ogenitor cell recruitment in vivo. This model was chosen 
because the default response to injury in this model consists of tissue granulation, wound 
contraction, and complete re-epithelialization by 14 days post-amputation (Schotte and Smith 
1959; Schotte and Smith 1961). Thus, as confirmed in the present chapter, mid-second phalanx 
amputation does not spontaneously result in tissue regeneration. This model differs from the 
more commonly studied model of distal phalanx amputation in neonatal (Fernando, Leininger et 
al. ; Yu, Han et al. ; Reginelli, Wang et al. 1995; Han, Yang et al. 2003; Han, Yang et al. 2008) 
and young mice (Borgens 1982; Neufeld and Zhao 1993; Neufeld and Zhao 1995; Mohammad 
and Neufeld 2000; Neufeld and Mohammad 2000). Because distal phalanx amputation results in 
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spontaneous regrowth of bone and soft tissue by 128 days post-amputation (Fernando, Leininger 
et al.), it is a useful model for understanding the basic mechanisms by which murine digits 
regrow functional tissue following distal amputation. In fact, bone morphogenic proteins (Yu, 
Han et al. ; Han, Yang et al. 2003), the Msx1 transcription factor (Reginelli, Wang et al. 1995; 
Han, Yang et al. 2003), and soluble factors released by the nearby nerves (Mohammad and 
Neufeld 2000) have all been identified as factors important for spontaneous distal phalanx 
regrowth following amputation. 
However, the limitation of the model of distal phalanx amputation is that it is impossible 
to distinguish between whether a treatment fundamentally alters the default wound healing 
response or simply impedes/accelerates the host’s natural ability to regenerate. Because adult 
mammals are not capable of regeneration of more proximal injuries, a treatment that simply only 
accelerates or decelerate’s the host’s natural regenerative response is not likely to be a v iable 
therapeutic option for digit regeneration. However, the model of mid-second phalanx amputation 
utilized in the present chapter addresses this limitation, and the findings of the present study 
show that treatment with ECM degradation products results in a deviation from the default 
wound healing response of scar tissue deposition and instead causes a greater accumulation of 
cells that express markers of progenitor cells and show neuroectodermal and mesodermal 
differentiation potential in vitro. As discussed below, this response could be considered the 
initial phase of a non-blastemal epimorphic regenerative response to digit amputation.  
2.4.3 Site Directed Accumulation of Progenitor Cells and Epimorphic Regeneration 
The accumulation of cells expressing progenitor cell markers peaks at days 14 and 18 pos t-
amputation, after which the number of cells progressively decreases. Since it is obvious that the 
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cells recruited to the site of injury following treatment with ECM degradation products do not 
spontaneously regenerate the missing body part, these cells do not fit the classic definition of a 
blastema. The response observed in the present study would be most consistent with the initial 
phase of a non-blastemal, epimorphic regenerative response (Morgan 1901; Sanchez Alvarado 
2000). This type of regeneration is characterized by cell proliferation and subsequent 
regeneration of site appropriate tissue, the classic example of which in mammals is liver 
regeneration following acute liver injury (Ito, Hayashi et al. 1991; Michalopoulos 2007). 
Considered in this light, it is  plausible that the recruitment of endogenous stem and progenitor 
cells to a site of injury that would not normally be populated by such cells, at least in such great 
numbers, could constitute the initial phase of a regenerative response.  
Establishment of an optimal microenvironmental niche is critical for appropriate 
differentiation of multipotential cells. If the microenvironment could be controlled sufficiently 
by factors such as pH, state of hydration, electric field potential, and nutrient and growth factor 
availability among others, it may be possible to promote the development of site appropriate 
tissues in adult mammals. Thus, the logical next step is to identify strategies that can promote 
site appropriate differentiation, spatial organization, and patterning of these cells. In species such 
as the newt and salamander, the recruitment of multipotent stem cells to the site of amputation is 
only the first step of epimorphic regeneration (Kumar, Godwin et al. 2007). It is possible, and in 
fact likely, that the progenitor cells found at the site of amputation in our model are not pre-
programmed to proliferate and differentiate into functional tissue. One possible explanation for 
this difference is that the recruited progenitor cells do not have the proper microenvironmental 
cues necessary to appropriately direct their proliferation, differentiation, and eventual patterning 
into functional tissue. If the concentrations and gradients of factors necessary to direct the cells 
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are known, then this may be possible by very precisely controlling the microenvironment at the 
site of amputation using a microfluidic device to cover the site of amputation (Hechavarria, 
Dewilde et al.) (see section 5.6.1) 
2.4.4 Regional vs Local Treatment at the Site of Amputation 
The work in the present study focused on using a regional subcutaneous injection as the primary 
method by which to provide a treatment at the site of amputation. While subcutaneous injection 
has logistical advantages with respect to animal compliance in an animal study, the critical 
limitation of such a method is the variable bioavailability and pharmacokinetics from treatment 
to treatment in this model. While fluorophore-labeled ECM degradation products were used to 
show that ECM degradation products can reach the site of amputation following treatment, the 
exact percentage of treatment or spatiotemporal distribution of ECM degradation products 
cannot be determined. As a result, it is not possible to distinguish between a regional effect and a 
local effect of ECM degradation product upon the outcome of progenitor cell accumulation. 
ECM degradation products are known to contain self-assembling peptides derived from 
structural ECM proteins that become highly viscous at physiologic pH and temperature (Freytes, 
Martin et al. 2008). Thus, the physical properties of the ECM degradation products likely affect 
the overall bioavailability and pharmacokinetics of the treatment in vivo.  
An alternative method of treatment has been proposed in previous studies (Hechavarria, 
Dewilde et al.). Utilizing a microfluidic device at the site of amputation, it is possible to 
precisely control the localization and concentration of any given treatment option (section 5.6.1). 
Utilizing this device, known as the BIODOME (Biomechanical Interface for Optimized Delivery 
of MEMS Orchestrated Mammalian Epimorphosis), a previous study has shown that local 
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treatment with ECM degradation products in a similar proximal phalanx digit amputation model 
results in a similar heterogeneous accumulation of cells at the site of amputation (Hechavarria, 
Dewilde et al.), confirming that the ECM degradation products at least exert a local effect upon 
progenitor cell accumulation.  
2.4.5 The importance of injury in ECM mediated progenitor cell recruitment 
A surprising finding of the work in the present chapter was the dependency of progenitor cell 
accumulation upon the presence of injury. In the absence of a digit amputation, injection of ECM 
degradation products resulted in no c hange in number of progenitor cells as compared to 
untreated controls. Furthermore, additional work to identify the source of Sox2+ cells showed 
that bone injury was important for the accumulation of cells. Thus, some component of injury is 
important for the effect of ECM degradation products upon progenitor cell accumulation in vivo.  
There is abundant evidence suggesting the importance of the innate immune response in 
overall remodeling of the ECM scaffold and subsequent constructive remodeling (Friedenstein, 
Piatetzky et al. 1966; Allman, McPherson et al. 2001; Badylak, Valentin et al. 2008; Brown, 
Valentin et al. 2009; Valentin, Stewart-Akers et al. 2009). Previous studies investigating the 
effect of the innate immune response upon progenitor cell recruitment have shown that polarized 
macrophages, both pro- and anti-inflammatory phenotypes, secrete paracrine factors that are 
chemotactic for adult progenitor cells (Lolmede, Campana et al. 2009). Consistent with this 
finding, the present study observed that injury alone increased the number of cells expressing 
markers of progenitor cells at the site of amputation in vivo. It is possible that ECM degradation 
products exert their effect upon progenitor cell recruitment by directly inducing paracrine release 
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of chemotactic factors from immune cells. It is also possible that ECM degradation products 
require a co-factor produced by immune cells in order to promote progenitor cell recruitment.  
The time course of progenitor cell accumulation following digit amputation and treatment 
is consistent with this possibility that ECM degradation products act synergistically or 
secondarily through immune cells. While treatment with ECM degradation products is complete 
by day 4 pos t-amputation, peak accumulation of progenitor cells is not observed until days 14 
and 18 pos t-amputation. While the present work cannot determine how long the ECM 
degradation products stay at the site of amputation, degradation products would still be present at 
the site of amputation within the first 4 days post-amputation during which the neutrophils and 
macrophages would be active at the site of amputation (i.e. the inflammatory phase of wound 
healing). Future studies are underway to address the effect of ECM degradation products upon 
macrophages in vitro, and this is discussed in greater detail in final discussions of the thesis in 
chapter 5. P reliminary work suggests that ECM degradation products potentiate the release of 
HMGB1 from macrophages, a known chemoattractant for progenitor cells (Porto, Palumbo et al. 
2006; De Mori, Straino et al. 2007; Campana, Bosurgi et al. 2008; Lolmede, Campana et al. 
2009; Ranzato, Patrone et al. 2009). 
2.4.6 Site Directed Progenitor Cell Accumulation: Sources and Mechanisms 
Recruitment and activation of a resident population of progenitor cells may be advantageous to 
the overall remodeling response. The use of bioactive factors for the site directed recruitment of 
progenitor cells can be thought of as a form of “endogenous stem cell therapy” (Kim, Xin et al. 
2010; Lee, Cook et al. 2010).  S tem cell therapy is a promising therapeutic approach to 
regenerative medicine, and numerous studies have shown efficacy following exogenous 
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introduction of stem cells at a site of injury (Horwitz, Gordon et al. 2002; Okamoto, Yajima et al. 
2002; Chen, Fang et al. 2004; Bang, Lee et al. 2005; Janssens, Dubois et al. 2006; Janssens, 
Theunissen et al. 2006; Tyndall and Furst 2007). However, clinical translation of exogenous 
stem cell therapy has partially been limited by risks of immunorejection, infection, potential 
tumorigenesis, and difficulties in regulatory approval of exogenous stem cell therapy (Bongso, 
Fong et al. 2008). In vivo recruitment and differentiation of endogenous stem cells to a site of 
injury is an attractive alternative that may mitigate these risks. The present study further 
characterized ECM degradation products as a f easible therapy for promoting site directed 
recruitment of endogenous tissue progenitor cells in vivo. 
 However, previous studies have also shown that the mechanism of injury can directly 
dictate the relative contribution of various subsets of progenitor cells to the injury response 
(Majka, Jackson et al. 2003; Kienstra, Jackson et al. 2008). In addition to disrupting the stem cell 
niche of resident progenitor cells, the mechanism of injury can also affect the overall spatial and 
temporal composition of bioactive factors and cells within the injury microenvironment. Thus, 
understanding the phenotype and sources of the progenitor cells recruited following treatment 
with ECM degradation products is paramount to further directing these cells to proliferate and 
differentiate to recapitulate the missing digit.  
Potential sources that contribute to the accumulation of progenitor cells at the site of 
amputation could include bone marrow derived cells, periosteal cells, perivascular cells, dermal 
stem cells, and circulating progenitor cells should all be considered (Friedenstein, Piatetzky et al. 
1966; Friedenstein, Petrakova et al. 1968; Owen 1988; Crisan, Yap et al. 2008).  Previous studies 
have shown that marrow derived cells participate in the constructive remodeling of tendon tissue 
(Zantop, Gilbert et al. 2006). However, the number of marrow derived cells in the reconstructed 
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tendon was relatively low compared to the number of cells observed at the amputation site in the 
present study.  T ransdifferentation or dedifferentiation are also plausible explanations for the 
presence of the multipotent cells, but these phenomena have not been shown to occur in large 
numbers in vivo in mammalian tissue (Shen, Slack et al. 2000; Frid, Kale et al. 2002; McKinney-
Freeman, Jackson et al. 2002; Camargo, Green et al. 2003). The possibility that the observed 
multipotent cells were generated in situ following lineage reprogramming cannot be ruled out. 
However, few studies have demonstrated such a phenomenon in vivo and the mechanisms 
underlying such processes are not well understood (Zhou and Melton 2008). 
In order to partially address potential mechanisms and sources of progenitor 
accumulation in this model of digit amputation, the work in the present chapter focused on 
further characterizing the Sox2+ cell population. The identification of a periosteal Sox2+ cell 
population at a site of injury following treatment with ECM degradation products that does not 
express markers of known Sox2+ adult progenitor cells (Biernaskie, Paris et al. 2009; Hutton and 
Pevny 2011) was an unexpected finding that warrants further study. Sox2 is a transcription factor 
that plays an important role in the maintenance of pluripotency (Avilion, Nicolis et al. 2003), and 
it has also been found to be expressed in a restricted set of adult progenitor cells such as neural 
stem cells, dermal stem cells, and neural crest derived stem cells (Biernaskie, Paris et al. 2009; 
Hutton and Pevny 2011). Recently, other studies have suggested that the Sox2 transcription 
factor plays a role in self-renewal of osteogenic progenitor cells (Basu-Roy, Ambrosetti et al. ; 
Mansukhani, Ambrosetti et al. 2005). The presence of periosteal Sox2+ cells in the present study 
is most consistent with activated osteogenic progenitors at the site of bone injury, but future 
studies are necessary to directly address this question.  
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Although Sox2 is most well studied as a nuclear transcription factor that mediates self-
renewal of cells, the present study found Sox2 expression was not restricted to the nucleus but 
also found in the cytoplasm. Although the significance of cytoplasmic localization of Sox2 is not 
known with certainty, previous studies have shown that Sox2 activity can be regulated by 
shuttling of the Sox2 transcription factor in and out of the nucleus (Baltus, Kowalski et al. 2009). 
Export of Sox2 outside of the nucleus has been postulated to be an indicator of cell 
differentiation in Sox2+ progenitor cells (Li, Pan et al. 2007). Therefore, the cytoplasmic 
localization of Sox2 in cells may be a sign of these cells undergoing differentiation. Previous 
studies have also found that only a subset of Sox2+ cells at a site of amputation undergo mitosis, 
consistent with the hypothesis that heterogeneity amongst Sox2+ cells may be due to asymmetric 
division and differentiation. However, the present study did not directly determine the lineage 
differentiation potential of Sox2+ cells in vitro or in vivo, and future studies will investigate the 
phenotype and function of this Sox2+ population at the site of digit amputation.  
Utilizing bone marrow chimeric mice, previous studies have shown that circulating 
progenitor cells contribute to remodeled tissue at the site of injury following implantation of an 
ECM scaffold (Badylak, Park et al. 2001; Zantop, Gilbert et al. 2006). In contrast, the present 
study shows for the first time that a subset of the progenitor cells recruited to a site of injury may 
not be derived from the bone marrow or circulation, but rather from resident progenitor cell 
populations near the site of injury (Zhang, Xie et al. 2005; De Bari, Dell'Accio et al. 2006). 
However, the present study does not rule out the possibility that circulating progenitor cells 
contribute to other subsets of Sca1+ and CD146+ progenitor cells also found at the site of 
amputation. In a complex injury microenvironment, certain types of progenitor cells such as 
lineage-restricted resident tissue progenitors may have a phenotype more optimal for survival, 
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proliferation, and eventually site specific differentiation into functional tissue at the site of 
injury.  Thus, activation and recruitment of tissue resident progenitor cells may be advantageous 
for promoting the most optimal regenerative or constructive remodeling response to injury.  
However, the present study did not directly determine the lineage differentiation potential 
of Sox2+ cells in vitro or in vivo, and future studies will investigate the phenotype and function 
of this Sox2+ population at the site of digit amputation. This is most convincingly done utilizing 
transgenic mice in which the Sox2+ cells can be tracked long-term in vitro and in vivo (Basu-
Roy, Ambrosetti et al.).  
2.4.7 Conclusions 
Although questions remain that may serve as the basis for future studies, the work presented 
herein is the first set of studies to directly use ECM degradation products in vivo as a potential 
therapeutic option for tissue engineering of tissues. Not only has this body of work laid the 
foundations for future studies to address the importance of ECM degradation in a more 
controlled fashion (discussed in more detail in chapter 5), but it has also provided further insight 
into the mechanisms by which ECM scaffolds remodel. In addition to showing the degradation 
products of ECM scaffolds are biologically active at a site of injury in vivo, the findings of this 
chapter show for the first time that non-circulating progenitor cells also contribute to the cells 
that populate a site of injury and ECM implantation.  
Even though the findings of this chapter did not result in constructive remodeling of the 
digit following amputation and treatment with ECM degradation products, the model is still very 
useful as a first-pass in vivo model for investigating bioactive properties of cryptic peptides. As 
discussed in future chapters, this model of digit amputation will be used to partially validate in 
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vivo the ability of a specific cryptic peptide to influence progenitor cell chemotaxis and 
differentiation in vitro. 
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3.0  CHARACTERIZATION OF A SINGLE CRYPTIC PEPTIDE WITH 
CHEMOTACTIC PROPERTIES 
3.1 INTRODUCTION 
Sections of this chapter have been modified and adapted from (Agrawal, Tottey et al. 2011). 
Biologic scaffolds composed of extracellular matrix (ECM) have been used successfully 
to promote site-specific, functional remodeling of soft tissue in both preclinical animal models 
(Badylak, Lantz et al. 1989; Lantz, Badylak et al. 1990; Cobb, Badylak et al. 1996; Hodde, 
Badylak et al. 1997; Badylak, Meurling et al. 2000; Caione, Capozza et al. 2006; Zalavras, 
Gardocki et al. 2006; Ott, Matthiesen et al. 2008; Ott, Clippinger et al. 2010; Uygun, Soto-
Gutierrez et al. 2010) and human clinical applications (Metcalf, Savoie et al. 2002; Witteman, 
Foxwell et al. 2009; Derwin, Badylak et al. 2010; Mase, Hsu et al. 2010). Secreted by the cells of 
each tissue, ECM is highly conserved amongst many species and consists of molecules such as 
collagen, fibronectin, laminin, vitronectin, glycosaminoglycans, and growth factors oriented in a 
specific three dimensional structure and composition optimized for each tissue of origin 
(Badylak 2002; Sellaro, Ravindra et al. 2007). Although the mechanisms of ECM scaffold 
mediated constructive remodeling are not fully  understood, stem cell recruitment (Badylak, Park 
et al. 2001; Zantop, Gilbert et al. 2006) and the release of bioactive peptides by protease 
mediated ECM degradation are thought to play a role in the constructive remodeling process 
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(Valentin, Badylak et al. 2006; Valentin, Stewart-Akers et al. 2009; Melman, Jenkins et al. 
2011). In addition to possessing antimicrobial properties (Berkowitz, Bevins et al. 1990; Moore, 
Devine et al. 1994; Moore, Beazley et al. 1996; Ganz 2003), cryptic bioactive peptides derived 
from degradation of ECM components have been shown to be capable of initiating and 
potentiating constructive remodeling pathways such as angiogenesis, mitogenesis, and 
chemotaxis of site specific cells (Davis, Bayless et al. 2000; Li, Li et al. 2004; Agrawal, Brown 
et al. 2009). A number of specific fragments of ECM peptides have been identified, and these 
peptides are reviewed elsewhere (Davis, Bayless et al. 2000).  
 Work in the previous chapter focused on de termining the overall net effect of ex vivo 
generated ECM degradation products upon the site directed accumulation of progenitor cells at a 
site of injury in a murine model of mid-second phaland digit amputation. The findings suggested 
that degradation products of ECM may be a therapeutic option for promoting site directed 
recruitment of endogenous tissue progenitor cells for constructive remodeling of tissue following 
injury. However, to date, the specific peptides within the mix of ECM degradation products 
responsible for their net chemotactic effect have not been identified.  
The objective of the work in the present chapter is to outline the prospective 
identification of a single cryptic peptide with chemotactic properties for adult stem cells of 
mesenchymal origin. Specifically, a single cryptic peptide derived from protease mediated 
degradation of an ECM bioscaffold derived from porcine urinary bladder was isolated that 
promotes in vitro migration of multiple cell types. Furthermore, the work in the present chapter 
shows that the isolated peptide was capable of promoting localized accumulation of progenitor 
populations to a site of injury in vivo, many of which express markers of multipotency.  
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3.2 MATERIALS AND METHODS 
3.2.1 Overview of Experimental Design 
The experimental methods were designed to systematically isolate a single matricryptic peptide 
that exhibits chemotactic potential for a well characterized population of human perivascular 
stem cells (Crisan, Yap et al. 2008) previously shown to migrate towards degradation products of 
ECM in low and high oxygen conditions (Tottey, Corselli et al. 2011). Matricryptic peptides 
were prepared by enzymatic degradation of biologic scaffolds derived from urinary bladder 
extracellular matrix, and subsequent serial fractionation of the resulting degradation products by 
ionic charge, size, and hydrophobicity. At each step, a transwell assay was utilized to determine 
the chemotactic potential of each eluted fraction for these stem cells. After isolation of a single 
cryptic peptide, the peptide was then synthesized and its chemotactic potential was evaluated for 
multiple types of progenitor cells and differentiated cells. Finally, an established model of adult 
murine digit amputation (Agrawal, Brown et al. 2009) was utilized to evaluate the ability of the 
cryptic peptide to promote the site-specific accumulation of progenitor cells in vivo. In all cases, 
statistical significance was determined by two-tailed student’s t-test with α=0.05 and β=0.2.  
3.2.2 Decellularization of Tissue and Preparation of ECM Degradation Products: 
Porcine urinary bladders were harvested from euthanized market weight (240-260 lb) pigs. The 
basement membrane and underlying lamina propria were isolated and harvested as previously 
described (Freytes, Badylak et al. 2004). Following peracetic acid, ethanol, deionized H2O, and 
phosphate buffered saline treatment, lyophilized sheets were comminuted and digested in 0.1 
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mg/ml pepsin and 0.01 N HCl for 48 hours prior to neutralization and dilution in PBS to yield a 5 
mg/ml solution (Reing, Zhang et al. 2009).  
3.2.3 Isolation of Chemotactic Peptide: 
Peptides of pepsin-digested UBM were fractionated via ammonium sulfate precipitation. 
Fractions were analyzed for protein content via BCA assay (Thermo) and chemotactic ability (as 
described below). Molecules in the 0-20% fraction of ammonium sulfate precipitation were 
discarded to remove the most gelatinous fractions and leave a solution suitable for subsequent 
chromatographic separation. The remaining 20-80% ammonium sulfate precipitant was isolated, 
dialyzed into PBS and concentrated using Amicon Ultra-4 (Millipore, MA, USA) devices. 
Concentrated protein was fractionated via two G3000SWXL HPLC size exclusion columns 
(Tosoh, Tokyo, Japan) in series at 0.5 ml/min in 10mM Tris, pH 7.4, 50 mM NaCl. Each fraction 
was analyzed for protein content and chemotactic ability.   
Larger post size exclusion chromatography chemotactic fractions were pooled and 
adjusted to pH 8.8 in 50 mM Tris buffer and loaded onto a 1ml HiTrap Q ion exchange column 
at 0.5ml/min. Bound peptides were washed in buffer (50 mM Tris, pH 8.8) before fractionation 
using 0.2, 0.4, 0.5, 0.6, 0.7, 0.8, and 1.0 M salt concentrations in the same buffer. Fractions were 
dialyzed into PBS, and analyzed for protein concentration and chemotactic properties.  Fractions 
showing chemotactic ability were concentrated via centrifugal filtration and injected onto an 
Octadecyl 4PW reverse phase column (Tosoh) and eluted over a 0-80% gradient of methanol in 
10mM ammonium carbonate buffer at 0.5 ml/min. Fractions were concentrated via centrifugal 
evaporation, resuspended in H2O, and analyzed for protein abundance and chemotactic 
properties.  T he peptide that revealed maximal chemotactic ability per mg of chemoattractant 
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was further characterized by mass spectrometry (NextGenSciences, Ann Arbor, MI) and then 
chemically synthesized (GenScript, Piscataway, NJ). A BLAST search 
(http://blast.ncbi.nlm.nih.gov/) for sequence homology was conducted using the non-redundant 
protein sequences (nr) database and Blastp algorithm. Parameters of the search were as follows: 
[1] max target sequences=100, [2] expect threshold=200000, [3] word size=2, [4] 
Matrix=PAM30, [5] gap cost existence=9 and extension=1, [6] no compositional adjustments.  
3.2.4 Source of Cells and Culture Conditions  
Human perivasular stem cells were a gift from Dr. Bruno Peault, and these cells were isolated 
and prepared as previously described (Crisan, Yap et al. 2008). Perivascular stem cells were 
cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM, Invitrogen) containing 
20% fetal bovine serum (FBS; Thermo), 100 U/mL penicillin, and 100 μg/ml streptomycin 
(Sigma) at 37°C in 5% CO2. Human cortical neuroepithelium stem (CTX) cells were a gift from 
ReNeuronTM. CTX cells were cultured in DMEM:F12 supplemented with 0.03% Human 
albumin solution, 100µg/ml human Apo-Transferrin, 16.2µg/ml Putrescine DiHCl, 5µg/ml 
Insulin, 60ng/ml Progesterone, 2mM L-Glutamine, 40ng/ml Sodium Selinite, 10ng/ml human  
bFGF, 20ng/ml human Epidermal growth factor, and 100nM 4-Hydroxytestosterone. Human 
adipose stem cells were isolated as previously described (Aksu, Rubin et al. 2008), and cultured 
in DMEM/F12 supplemented with 10% heat inactivated fetal bovine serum, 100 U/ml penicillin, 
and 100 µ g/ml streptomycin. C2C12 muscle myoblast cells, IEC-6 intestinal epithelial cells, 
RT4-D6P2T rat Schwann cells, and HMEC human microvascular endothelial cells were obtained 
from ATCC and cultured following ATCC guidelines. 
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3.2.5 Transwell Cell Migration Assays 
Chemotaxis assays were conducted in a transwell as described previously (Reing, Zhang et al. 
2009).  Perivascular stem cells were grown in culture medium to 80% confluence and starved 
overnight in DMEM containing 0.5% heat inactivated serum. After starvation, cells were 
resuspended in DMEM at a concentration of 6x105 cells/ml for 1 hour. Polycarbonate PFB filters 
(Neuro Probe, Gaithersburg, MD) with 8 µm pores were coated with 0.05 mg/ml Collagen Type 
I (BD Biosciences, San Jose, CA). The number of cells that migrated toward the lower chamber 
through 8 µm pore polycarbonate PFB filters (Neuro Probe, Gaithersburg, MD) was determined 
after 5h. The lower wells contained different amounts of the ECM peptide fraction of interest.  
Migrated cells were stained by 4′,6 -diamidino-2-phenylindole and quantified with ImageJ (NIH). 
All of the data are reported as the mean value of triplicate determinations with standard 
deviations. The assay was performed on three separate occasions. C2C12, IEC-6, RT4-D6P2T, 
and HMEC cells were grown to 80% confluence, and starved in serum free media overnight prior 
to placement in the transwell assay. CTX cells were grown to ~80% confluence were unstarved 
prior to resuspension and placement in the transwell assay.  All other methods were identical for 
each cell type.  
3.2.6 Animal Model of Digit Amputation:  
All methods were approved by the Institutional Animal Care and Use Committee at the 
University of Pittsburgh and performed in compliance with NIH Guidelines for the Care and Use 
of Laboratory Animals. Mid-second phalanx digit amputation of the third digit on each hindfoot 
in adult 6-8 week old C57/BL6 mice (Jackson Laboratories, Bar Harbor, ME) was completed as 
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previously described (chapter 2). Following amputation, digits were either treated with a 
subcutaneous injection of 15 µ L of 10 m M peptide, or the same volume of PBS as a carrier 
control (n=4 for each group). Treatments were administered at 0, 24 and 96 hours post surgery. 
Animals were sacrificed via cervical dislocation under deep isoflurane anesthesia (5-6%) at day 
7 post-surgery. Digits were either fixed and sectioned for histologic analysis and 
immunolabeling (described below), or harvested for cell isolation for subsequent FACS analysis, 
cytospin, or immunolabeling (described below). 
 
3.2.7 Tissue Immunolabeling 
Harvested mouse digits were fixed in 10% neutral buffered formalin and decalcified for two 
weeks in 5% formic acid prior to being paraffin embedded, sectioned, and stained for Sox2 
(Millipore, AB5603, Billerica, MA), Sca1 (Abcam, ab25196, Cambridge, MA) , o r Ki67 
(Abcam, ab15580). Following deparaffinization, antigen retrieval in 10 mM citrate buffer 
(citrate: C1285, Spectrum, New Brunswick, NJ) was performed for 25 minutes at 950C. Slides 
were blocked for 1 hour at room temperature in 1% bovine serum albumin (BSA) in phosphate 
buffered saline (PBS), and then incubated with primary antibody overnight at 40C. Slides were 
then rinsed in PBS, treated with 3% hydrogen peroxide solution in PBS for 30 minutes, washed, 
and incubated for 1 hour with HRP conjugated anti-rat IgG (P0450, Dako, Carpinteria, CA) or 
anti-rabbit IgG (P0448, Dako) antibodies, washed, and developed with 3, 3’ diaminobenzidine 
(DAB) (Vector Labs, Burlingame, CA). All primary antibodies were diluted 1:100 in blocking 
solution, and all secondary antibodies were diluted 1:200 in blocking solution. 
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After staining with DAB, all slides were counter-stained with Harris’ hematoxylin, 
dehydrated, coverslipped with non-aqueous mounting medium, and imaged. Images were taken 
at 40X magnification and 200X magnification. For quantification of the number of cells positive 
for markers, three images were taken for each sample: distal to the amputated edge of the bone, 
and lateral to the cut edge of the bone on either side. The number of positive cells in each image 
was counted by three independent investigators who were blinded to the treatment group. The 
mean number of positive cells was compared between various groups by a two-sided, unpaired 
student’s t-test with unequal variance. Significance was determined at p = 0.05 level (α=0.05, 
β=0.2).   
3.2.8 Flow Cytometric Analysis: 
Amputated digits were harvested and placed into cold culture medium consisting of DMEM, 
10% mesenchymal stem cell grade fetal bovine serum (Invitrogen, Carlsbad, CA), 100 U/ml 
penicillin, 100 μg/ml streptomycin,  and 0.1 mg/ml ciprofloxacin (USP, Rockville MD, 
1134313).  Using a microdissection microscope and aseptic technique, the epidermis and dermis 
were removed and the soft tissue distal to the amputated second phalanx bone was harvested into 
serum free DMEM containing 2% Collagenase Type II (Gibco Invitrogen, 17101-015) for 30 
minutes at 370C, filtered through a 70 µ m filter, counted, and prepared for flow cytometric 
analysis expression of Sca1 (Abcam, ab25031, Cambridge, MA) or markers of differentiated 
blood derived cells (Lineage cocktail, 559971, BD Biosciences, San Diego, CA). Cells were 
filtered through a 70 µm filter and incubated in primary antibody for 1 hour, washed, and then 
incubated in a streptavidin APC-Cy7 conjugated secondary antibody (554063, BD Biosciences) 
for 1 hour prior to  washing and flow cytometric analysis.  
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3.2.9 Cytospin and Cell Immunolabeling 
Following cytospin of 1x104 cells per slide, each slide was fixed in methanol for 30 seconds and 
stored at -20 0C. Prior to staining, slides were rehydrated in PBS for 5 minutes, and cells were 
permeablized in 0.1% TritonX/PBS for 15 m inutes. Slides were blocked in 1% bovine serum 
albumin/PBS for 1 hour prior to overnight incubation with goat anti-Sox2 (1:50) (SantaCruz, Y-
17, sc17320, Santa Cruz, CA), rabbit anti-Sox2 (1:100) (Millipore, AB5623), rat anti-Sca1-FITC 
(1:50) (Abcam, ab25031), or rabbit anti-phospho-Histone-H3 (1:100) (Abcam, ab32107) primary 
antibody diluted in blocking solution. Following two washes in PBS, slides were incubated for 1 
hour with donkey anti-goat IgG-Alexa Fluor 350 (1:100) (Invitrogen, A21081, Carlsbad, CA) 
and/or donkey anti-rabbit IgG-Alexa Fluor 546 (1:250) (Invitrogen, A10040) diluted in blocking 
solution. Following two washes in PBS, slides were counterstained with DRAQ5 (1:500) (Cell 
Signal, 4084, Danvers, MA) diluted in PBS for 30 s econds prior to three washes in PBS and 
coverslipping with fluorescent mounting medium (Dako, S3023). All images were taken at 200X 
magnification.  
3.2.10 Cell Adhesion Assays 
The cell adhesion assay was completed as previously described (Humphries 2009). Briefly, wells 
were either left uncoated or coated with 10% fetal bovine serum, collagen type I (a known pro-
adhesive substrate), or the isolated cryptic peptide. Non-specific binding was blocked with heat 
denatured 10% bovine serum albumin. Five thousand human perivascular stem cells were seeded 
into each well and allowed to attach for 20 m inutes. After 20 m inutes, unattached cells and 
media were removed from each well. The attached cells were fixed in 10% neutral buffered 
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formalin overnight, and then stained in 0.05% w/v crystal violet solution for 10 m inutes and 
destained until optimal staining had occurred. Each well was then destained with 10% (v/v) 
acetic acid, and absorbance was measured at 570 nm on a spectrophotometer as a surrogate for 
cell number. 
3.3 RESULTS 
3.3.1 Isolation, Identification and Synthesis of Chemotactic Cryptic Peptide 
The various protein fractions following ammonium sulfate precipitation were dialized against 
phosphate buffered saline (PBS) and all fractions showed chemotactic activity (migration of the 
perivascular stem cells to the bottom well of the transwell chambers) compared to the PBS 
control (Figure 22 a,b).   The fractions were pooled, concentrated and further fractionated via 
size exclusion chromatography (Figure 22c). Protein quantification showed that the peptide 
fragments distributed into two peaks, with a long tail of small size molecules. Analysis of each 
fraction showed that the chemotactic effect was also distributed into two peaks. However, these 
chemotactic peaks were not aligned with the protein peaks. Chemotactic activity of each fraction 
did not correlate with the total amount of protein, but rather was a net effect of the distribution of 
specific molecules with the UBM peptide mix.  
Analysis of the second chemotactic peak showed these molecules to be too small to bind 
to ion exchange beads carrying either a positive or negative charge resulted in very little capture. 
Thus, the most chemotactic fractions from the first size exclusion peak were pooled and 
refractionated via ion exchange chromatography (Figure 22d). After adjustment to pH 8.8, the 
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remaining peptides were bound to a HiTrap Q ion exchange column, washed in salt free buffer 
and eluted over a series of increasing concentrations of salt. The fractions were adjusted to a 
biological buffering condition and analyzed for chemotactic activity (Figure 22e). The fraction 
with the greatest chemoactivity per mg/ml of protein was chosen for further study.   The fraction 
with the greatest chemotactic activity per mg/ml of protein was the 0.6 M fraction. The 0.6 M 
fraction was further fractionated by reverse phase chromatography (Figure 22f). Unbound 
peptides (peak 1) and bound peptides were eluted over a 0-80% methanol gradient and analyzed 
for protein concentration. Protein peaks were then evaluated for chemotactic activity (Figure 
22g). Fractions 2 a nd 4 showed the greatest amount of chemotactic activity, and lesser 
chemotactic activity was also shown in the unbound fraction. Because Fraction 2 s howed the 
greatest chemoactivity per mg of protein, this fraction was isolated for sequence analysis by 
mass spectrometry. Analysis showed that the fraction consisted predominantly of a single 
peptide with the amino acid sequence of IAGVGGEKSGGF, a sequence identical to a string of 
amino acids from the C-terminal telopeptide of collagen IIIα. The peptide was chemically 
synthesized and evaluated in the same transwell chemotactic assay over a range of 
concentrations (Figure 22h, 23).  Chemokinetic activity as a cause of the cell migration was ruled 
out by varying the relative concentrations of the peptide in the upper and lower wells of the 
transwell chambers (Figure 22h). A BLAST search of the isolated peptide sequence showed that 
the peptide sequence was highly conserved in collagen IIIα amongst eight mammalian species 
including human (Figure 22i). A hydropathy plot showed that the IAGVGGEKSGGF sequence 
was derived from the most hydrophobic region of the collagen type IIIα C-terminal telopeptide 
(Figure 24). 
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Figure 22. Identification of chemotactic peptide. UBM digest was fractionated and chemotactic ability 
quantified against perivascular stem cells by ammonium sulfate (a, b), size exclusion (c), ion exchange (d, e), and 
reverse phase (f, g) chromatography.  Peptide was identified via mass spectroscopy and synthesized to assay for 
chemotactic potential for human perivascular stem cells (h). A BLAST search for the isolated peptide sequence 
showed over 75% homology with the Collagen IIIα molecule over eight separate species. Error bars are Mean + SD. 
* p < 0.05 as compared to negative control. 
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Figure 23.. A schematic diagram of the collagen type IIIα molecule and the region that the isolated cryptic 
peptide is derived from.  
 
Figure 24. A hydropathy plot showed that the isolated cryptic peptide (red box) was derived from the most 
hydrophobic region of the collagen type IIIα C-terminal telopeptide. Hydropathy plot was completed at 
http://expasy.org/cgi-bin/protscale.pl using the Kyte & Dolittle scale.  
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3.3.2 Cryptic Peptide Shows In-vitro Chemotactic Activity Toward Several Cell Types 
In order to test whether the isolated cryptic peptide affected migration of other cell types, the 
migration of various cell types was assessed in response to the isolated cryptic peptide. The 
synthesized peptide showed positive chemotactic activity toward human neuroepithelial cells 
(Figure 25a), human adipose stem cells (Figure 25b), C2C12 mouse myoblast cells (Figure 25c), 
the RT4-D6P2T rat Schwann cell line (Figure 25d), and human microvascular endothelial cells 
(HMEC) (Figure 25e). The rat intestinal cell IEC-6 line (Figure 25f) was unresponsive to the 
peptide. 
 
Figure 25. Peptide promotes migration of multiple cell types in vitro. The chemotactic ability of the 
peptide was tested over six orders of magnitude concentration against human neuroepithelial cortical (CTX) stem 
cells (a), human adipose stem cells (b), mouse myoblast (C2C12) cells (c), rat Schwann (RT4-D6P2T) cells (d), 
human microvascular endothelial (HMEC) cells (e), and rat intestinal epithelial (IEC6) cells (f). Error bars are Mean 
+ SD. * p < 0.05 as compared to negative control.  
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3.3.3 Cryptic Peptide Shows In vivo Recruitment of Sox2+, Sca1+, Lin- cells 
Histologic examination of peptide treated digits at day 7 pos t-amputation showed a dense, 
cellular infiltrate both lateral and distal to the site of amputation, concomitant with an 
invaginating epithelium and incomplete basement membrane (Figure 26a). The PBS treated 
digits showed a less dense cellular infiltrate concomitant with scar tissue deposition and a mature 
epithelium consistent with a typical wound healing response in the murine digit (Figure 26b) 
(Schotte and Smith 1959). Immunolabeling studies showed a 6.6 fold increase in Sox2+ cells and 
a 1.6 f old increase in Sca1+ cells at the site of amputation following peptide treatment as 
compared to PBS treatment (Figure 26c). FACS analysis of the Sca1+ cells showed that the 
Sca1+ cells did not co-express markers of differentiated blood lineage (Figure 26d). Isolated 
cells that were co-immunolabeled for both Sox2+ and Sca1+ confirmed co-expression of Sca1 
and Sox2 in a subset of cells (Figure 26e).  
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Figure 26. Peptide results in greater numbers of progenitor cells in vivo.  Adult mouse hind foot digits 
were amputated at the mid-second phalanx and treated with 15µL of either PBS or peptide. Histologic examination 
by hematoxylin and eosin staining showed a thinner, invaginating epithelium concomitant with a denser cellular 
response following peptide treatment (a) as compared to PBS carrier control treatment (b). Histologic sections 
showed that peptide treatment led a greater number of Sox2, Sca1, and Ki67 positive cells at the site of amputation 
(c). Flow cytometric analysis confirmed that Sca1+ cells did not express markers of differentiated blood lineage (d). 
Co-expression of Sca1 and Sox2 was observed in subsets of cells following cytospin and co-immunolabeling 
(arrow) (e). Images were taken at 40x magnification (a, b), 630x magnification (a,b), or 400x magnification (c,e). 
Error bars are Mean + SD. * p < 0.05. ** p < 0.01. 
 
Histologic sections from peptide treated and PBS treated digits were also stained for Ki67 
to evaluate cell proliferation. At day 7 post-amputation, peptide treatment led to a 1.9 f old 
increase in Ki67+ cells at the site of amputation (Figure 26c). Cells were located both lateral and 
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distal to the plane of amputation. To confirm that Sox2+ and Sca1+ cells were undergoing 
mitosis, accumulated cells were isolated and co-immunolabeled for phosphorylated Histone H3 
(Hans and Dimitrov 2001) and either Sox2 or Sca1. Subsets of both Sox2+ cells and Sca1+ cells 
also showed pan-nuclear expression of phosphorylated Histone H3 (Figure 27), consistent with 
ongoing mitosis (Hans and Dimitrov 2001). 
 
Figure 27. A subset of Sox2 and Sca1+ cells are mitotic. To confirm that Sca1+ and Sox2+ cells were 
actively proliferating, isolated cells were cytospun and co-immunolabeled for either Sca1 or Sox2 and a marker of 
cells in the M phase of the cell cycle, phosphorylated Histone H3 (Hans and Dimitrov 2001). Subsets of Sca1+ and 
Sox2+ co-expressed nuclear Histone H3 (arrows). Images were taken at 400x magnification.  
 
3.3.4 Chemotactic Activity of Peptide is Specific to the Peptide Composition, but not the  
sequence 
The work thus far in the present chapter outlined the chemotactic activity of the peptide to a 
carrier control for multiple cell types in vitro, and it showed the ability of the peptide to cause the 
site-directed accumulation of Sox2+, Sca1+, Lin- cells at a site of digit amputation. However, the 
relative chemoattractive properties as compared to a known chemoattractant was not been 
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investigated thus far. Thus, in vitro migration assays were completed with human perivascular 
stem cells to compare the chemotactic potential of the isolated cryptic peptide to the chemotactic 
potential of unfractionated ECM degradation products and fetal bovine serum, both known 
chemoattractants in vitro. At each concentration in vitro, unfractionated ECM degradation 
products resulted in more migration of human perivascular stem cells compared to the single 
cryptic peptide. The only exception was at the highest concentration of 1 mg/ml, which is likely 
due to the spontaneous gelation of the ECM degradation at such high concentrations (Freytes, 
Martin et al. 2008) (Figure 28). 
 
Figure 28. Migration of human perivascular cells towards the isolated cryptic peptide, IAGVGGEKSGGF, 
compared to the unfractionated ECM degradation products showed that the isolated cryptic peptide showed 50-75% 
of the activity that the unfractionated ECM degradation products showed. PBS and 10% FBS were used as negative 
and positive controls. 
 
In order to investigate the importance of the peptide sequence for its chemotactic activity, 
a scrambled peptide, GIAEGVGKGFGS, was created (Table 1). The scrambled peptide was 
designed to scramble the non-polar amino acids in the cryptic peptide. It was theorized that any 
receptor interacting with the peptide would do s o via hydrogen bonding between non-polar 
amino acids in the peptide and the receptor. Although variation in the migration of human 
perivascular stem cells towards the scrambled peptide was greater, there was no significant 
79 
difference between the effect of the original and scrambled cryptic peptides in vitro (Figure 29). 
This suggests that perhaps the sequence of the peptide itself is not the primary determinant of the 
peptide’s chemoattractive effect. 
Table 1. Sequences of peptides utilized for migration assay studies. 
Peptide 
Cryptic Peptide 
Sequence 
IAGVGGEKGSGGF 
Scrambled Peptide GIAEGVGKGFGS 
Hydrophobic Peptide CCGGGAAAIAGV 
Hydrophilic Peptide RGAPGPQGPRGD 
 
 
Figure 29. Migration of human perivascular stem cells towards the isolated cryptic peptide, 
IAGVGGEKSGGF, or a scrambled peptide, GIAEGVGKGFGS, showed that there was no significant difference in 
migration towards the unscrambled or scrambled peptide. PBS and 10% FBS were used as negative and positive 
controls. 
 
Because the peptide was derived from one of the most hydrophobic regions of the 
collagen type IIIα molecule, it was possible that the chemotactic effect of the cryptic peptide was 
due to a physical propery of the peptide such as hydrophobicity. To test this possibility, the 
chemotactic activity of the peptide was compared to the most hydrophobic 12 amino-acid 
sequence in collagen type III, CCGGGAAAIAGV, as well the most hydrophilic region of 
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collagen type III, RGAPGPQGPRGD (Table 1). The more hydrophobic peptide showed no 
chemotactic effects at any concentration tested when compared to a n egative control, but the 
hydrophilic peptide caused a greater amount of migration at every concentration tested when 
compared to the cryptic peptide (Figure 30). Thus, the physical property of hydrophobicity did 
not correlate directly with chemotactic potential. 
 
Figure 30. Migration of human perivascular stem cells towards the isolated cryptic peptide, 
IAGVGGEKSGGF, a more hydrophobic peptide, CCGGGAAAIAGV, or a more hydrophilic peptide, 
RGAPGPQGPRGD, showed that peptide hydrophobicity did not correlate with perivascular stem cell migration.  
3.3.5 Effect of Peptide upon Adhesion of Human Perivascular Stem Cells 
Because the peptide was derived from collagen type III, and because integrin receptors are 
abundant on mesenchymal stem cells such as the human perivascular stem cell, integrins were 
suggested as a potential target receptor of the peptide. A hallmark of integrin receptors is that 
their ligands, when immobilized or adsorbed to a surface, cause a dose dependent increase in cell 
adhesion (Humphries 2009). Thus, the adhesion of human perivascular stem cells to surfaces 
coated with the cryptic peptide was tested. The peptide caused increased cell adhesion compared 
to uncoated controls. Compared to a known adhesion protein, collagen type I, the peptide caused 
less cell adhesion (Figure 31). 
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Figure 31. A cell adhesion assay for human perivascular stem cells showed that the isolated cryptic can increase cell 
adhesion, but less so than known positive controls Collagen type I and 10% FBS. 
3.4 DISCUSSION 
The present chapter identifies a novel matricryptic peptide with in vitro chemotactic activity for 
several types of progenitor cells and differentiated cells.  This peptide is also associated with the 
increased presence of Sox2+ and Sca1+,Lin- cells at the site of experimentally induced injury in 
a mouse model. As a short twelve amino acid oligopeptide derived from the C-terminal 
telopeptide region of the collagen IIIα molecule, the sequence of this molecule is highly 
conserved amongst at least eight mammalian species. 
3.4.1 The chemotactic cryptic peptide 
The cryptic peptide identified in the present study was derived from the C-terminal telopeptide 
region of the collagen type IIIα molecule. The C-terminal telopeptide region of fibrillar collagen 
is known to be a site of interchain cross-linking of cysteine residues that ultimately stabilize the 
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triple helix structure of collagen (Barth, Kyrieleis et al. 2003). Thus, in the absence of injury and 
protease mediated degradation, it is unlikely that such a sequence would actively interact with 
cells due to extensive cross-linking. However, protease mediated matrix degradation at a site of 
injury would not only destabilize and release peptides from the triple helical domain of collagen, 
but also expose and cleave the telopeptide regions of collagen to release cryptic peptides similar 
in sequence to the isolated peptide in the present study. Previous studies have shown that 
telopeptide sequences can be isolated in the circulating blood following turnover of collagen and 
soft tissue remodeling in a clinical setting (Kitahara, Takeishi et al. 2007; Banfi, Lombardi et al. 
2010; Kanoupakis, Manios et al. 2010). Thus, while the cryptic peptide in the present study was 
isolated by non-physiologic methods of degradation, it is likely that a similar peptide can and 
would be released in vivo at a site of injury.  
The present chapter identified a single peptide derived from a mixture of matricryptic 
peptides that can recruit stem, progenitor, and differentiated cells in vitro and is associated with 
an increased accumulation of such cells at sites of injury in vivo. However, the findings of the 
present study do not  preclude the existence of other pro- and anti-chemotactic matricryptic 
peptides. It is likely that degradation of ECM leads to release of a large mixture of anti- and pro-
chemotactic peptides that yields an overall net effect in vivo. Indeed, certain fractions of the 
ammonium sulfate precipitated peptides in the present study showed inhibited migration of 
progenitor cells; a finding that suggests degradation products of ECM contain chemotactically 
positive, negative, and likely also neutral peptides. Isolation of these peptides was not pursued. 
Although an active peptide described in the present study was isolated from a mix of mammalian 
matricryptic peptides, the naturally occurring contribution of this particular peptide to the host 
response to injury was not determined. The present study also showed the efficacy of the isolated 
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oligopeptide in an adult mammalian model of digit amputation via local accumulation of 
progenitor cells at the site of injury. While the present study cannot determine whether the 
efficacy of the isolated peptide is dependent on the type of injury, future studies will further 
investigate the potential role of the peptide in progenitor cell recruitment in various other types 
of injury.  
Additionally, the present chapter focused on identifying a bioactive cryptic fragment of 
one source of extracellular matrix. Extracellular matrix derived from the porcine urinary bladder 
has been used in multiple pre-clinical applications for site-specific remodeling of a variety of soft 
tissues (Badylak, Vorp et al. 2005; Kochupura, Azeloglu et al. 2005; Nieponice, Gilbert et al. 
2006; Gilbert, Gilbert et al. 2008; Kelly, Rosen et al. 2009; Nieponice, McGrath et al. 2009; 
Parekh, Mantle et al. 2009; Boruch, Nieponice et al. 2010; Medberry, Tottey et al. 2010; Davis, 
Callanan et al. 2011). However, commercially available biologic scaffolds composed of 
extracellular matrix are derived from a number of species and organs (Crapo, Gilbert et al. 2011).  
It is possible that a similar cryptic peptide would be found in ECMs from other sources. Collagen 
III is a common constituent of many soft tissues from which ECM scaffolds are made, and its 
sequence is highly conserved from species to species. The present study found that the isolated 
cryptic peptide’s sequence is also highly conserved amongst over eight species, many of which 
are already used as sources of ECM for commercial applications. Thus, it is likely and expected 
that the isolated cryptic peptide, or a similar derivative of such a peptide, would qualitatively 
possess the same bioactive properties in multiple mammalian species and commercially available 
extracellular matrix scaffolds.  
The work presented in the present chapter focused on unde rstanding the single cryptic 
peptide. Thus, there is no data that evaluates the overall contribution of this peptide to the net 
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chemotactic properties of the unfractionated ECM degradation products from which the peptide 
was isolated. Ideally, this would be measurable by supplementation of the peptide to degradation 
products mix as well as depletion of the peptide from the ECM degradation products, 
presumably by an antibody or column-mediated depletion method. While supplementation of 
ECM degradation products in vitro and in vivo is possible for future studies, depletion may be 
logistically difficult. The short length of the peptide and its similarity in sequence to other 
structural protein components within the degradation products does not allow for specific 
depletion (i.e. antibody mediated) of the cryptic peptide from the unfractionated ECM 
degradation products. The work presented herein will serve as the future basis for studies to more 
directly address the contribution of the cryptic peptide towards the net chemotactic properties of 
ECM degradation products. 
3.4.2 Mechanisms of action of the chemotactic cryptic peptide 
The findings of the present chapter show that the identified cryptic is most active at 
concentrations of 0.1mM and 1 mM in vitro. By pharmacological standards, these concentrations 
are fairly high, especially considering the possibility of a single ligand, receptor interaction. Most 
chemotactic peptides that act via a known ligand/receptor interaction are active in the nanomolar 
and picomolar concentrations, approximately 106 fold more potent than the peptide identified in 
the present study. 
 However, the findings of the present chapter also suggest that there is something specific 
about the cryptic peptide that contributes to its chemotactic effect, however weak the effect may 
be when normalized to concentration. Although a randomly scrambled peptide showed 
approximately the same chemotactic effect in vitro, a similar 12 amino acid peptide derived from 
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the collagen type IIIα C-terminal telopeptide (CCGGGAAAIAGV) showed no chemoactivity at 
the same concentrations. This confirms that the effect of the isolated cryptic peptide is not purely 
due to the presence of a high concentration of protein or peptide. 
 The finding that a scrambled peptide showed effectively the same chemotactic effect that  
the cryptic peptide showed in vitro was a surprising finding with multiple potential explanations. 
Scrambling of the peptide is meant to disrupt any specific combination of amino acids in the 
peptide that may bind to a specific receptor on a  cell, for example. Because scrambling of the 
peptide did not affect overall migration of perivascular stem cells, one potential explanation for 
the findings is that the mechanism of action of the cryptic peptide is not via a direct 
receptor/ligand interaction. However, it is possible that the scrambled peptide and cryptic peptide 
both promote migration via separate mechanisms. Ideally, multiple scrambled sequences would 
be used to address this question fully.  
 The derivation of the cryptic peptide from one of the most hydrophobic regions of 
collagen type III suggests that potentially a biophysical property of the peptide is the primary 
determinant of its chemotactic properties. The most logical biophysical property would be 
hydrophobicity. However, the more hydrophobic 12 a mino acid peptide also derived from the 
telopeptide region of collagen type III showed very little activity. 
It is possible that the effect of the peptide is actually a h ybrid of a receptor/ligand 
interaction and a biophysical property. The biophysical properties of the peptide would allow for 
it to non-specifically bind receptors or other proteins on a cell surface. If the concentration of the 
non-specifically bound peptides on the cell surface is high enough, it is possible that the peptides 
may then  actually induce signaling through the receptors that are bound. Although the present 
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study does not address this potential mechanism directly, it is possible to do so through a number 
of focused experiments. 
Labeling of the peptide either a fluorophore or a radiolabel would allow for the tracking 
of the peptide when supplemented into a culture flask containing cells. Following fixation of the 
cells, it would be possible to localize the peptides to either on the cell surface or within the cell 
itself. A cell surface localization would support the theory of a hybrid mechanism of action of 
the peptide. If the peptide could then be attached to biotin, it would be possible to either use 
immunoprecipitation or use a column in order to find and identify proteins that attach to the 
peptide. While this approach does not require a priori identification of candidate proteins that 
bind the peptide, it may not be a feasible approach given the low affinity of the peptide for any 
receptor that would exist. The last potential approach is a hypothesis driven approach in which 
specific signaling pathways would be targeted systematically in order to identify which pathways 
are important for exerting the peptide’s effect in vitro and in vivo.  
An attractive target of action of the cryptic peptide is via modulation of integrin signaling 
pathways (Agrez, Bates et al. 1991; Horton, Spragg et al. 1994; Xia and Zhu 2010). Integrins are 
important in stem cell chemotaxis (Chavakis, Aicher et al. 2005), and the cryptic peptide 
identified in the present chapter is derived from the collagen type III molecule, a protein known 
to bind to integrins (Humphries, Byron et al. 2006). Although the sequence of the cryptic peptide 
does not contain any known integrin binding motifs (Humphries, Byron et al. 2006), it is  still 
possible that non-specific binding of integrins by the peptide may promote signaling through the 
integrin receptors. Future studies may investigate integrin mediated pathways. 
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3.4.3 In vivo Progenitor Cell Recruitment by the Cryptic Peptide 
The recruitment of various cell types such as stem and progenitor cells, endothelial cells, and 
muscle precursor cells to sites of tissue injury represents a plausible host response to support 
tissue reconstruction. The mechanisms underlying such a recruitment process are largely 
unknown, but it is feasible that cryptic peptide-mediated recruitment represents one such 
strategy. The manner in which the oligopeptide described herein was generated was non-
physiologic but a previous study has shown naturally occurring degradation products following 
ECM mediated tissue reconstruction have similar properties (Beattie, Gilbert et al. 2009). In fact, 
degradation products of ECM have been shown to regulate the site directed recruitment of 
differentiated (Davis, Bayless et al. 2000; Li, Li et al. 2004; Agrawal, Brown et al. 2009) and 
progenitor cells (Brennan, Tang et al. 2008; Reing, Zhang et al. 2009) in vivo. 
 However, the work in the present chapter focused upon a  single cryptic peptide that is 
derived from a mixture of ECM degradation products. Both the single cryptic peptide and the 
mixture of ECM degradation products show chemotactic activity in vitro, and the work in the 
present chapter utilized a murine model of digit amputation to assess the in vivo ability of the 
peptide promote the site directed accumulation of progenitor cells. Although the outcomes in the 
present chapter focused only identification of progenitor cells by their expression of transcription 
factors and cell surface antigens associated with multipotent stem cells, work in chapter 2 
showed that a subset of cells found at the site of amputation are capable of mesodermal and 
neuroectodermal differentiation in vitro. The work in the present chapter expanded upon t he 
previous characterization of the Sca1+ population of cells by confirming that they did not 
express markers of differentiated cells found within the blood. Additionally, the work in the 
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present chapter confirmed that a subset of Sca1+ cells also co-expressed the progenitor cell 
marker Sox2, consistent with flow cytometric findings in the previous chapter. 
 Although treatment with the single cryptic resulted in the accumulation of the same 
population of Sca1+, Sox2+, Lin- cells that were found following treatment with unfrractionated 
ECM degradation products, there was a marked difference in the time course of accumulation of 
these cells following peptide treatment. A peak in Sca1+ and Sox2+ cells was observed at day 14 
post-amputation following treatment with unfractionated ECM degradation products, whereas 
the peak of accumulation of cells following treatment with the single cryptic peptide occurred at 
day 7 pos t-amputation. This difference is not due just to differences in the potency of the 
treatments because the peak numbers of Sox2+ and Sca1+ cells found at the site of amputation 
did not differ between the two treatments. As discussed in chapter 2, a critical difference 
between these two treatments may be their physical properties. Due to the presence of self-
assembling collagen derived peptides in the unfractionated mixture, physiologic pH and 
temperature induced geleation of the ECM degradation products. However, the single purified 
cryptic peptide diluted to same protein concentration in vitro remained completely aqueous at 
physiologic pH and temperature. This differing physical property between the two treatments 
would likely result in a difference in bioavailability in vivo. 
 As discussed in chapter 2, a critical limitation of the digit amputation model of injury 
utilized is the method of treatment. Limited by a regional administration of treatment by 
subcutaneous injection at the base of amputated digit, a true assessment of the spatiotemporal 
concentration of any treatment has not been feasible. Thus, differing physical properties such as 
viscosity could affect both the spatial and temporal bioavailability of any treatment without any 
way of actually monitoring it. For example, an aqueous solution such as the single cryptic 
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peptide would likely diffuse faster as well as be excreted from the system quicker. Thus, any 
bioactive effect such as site directed accumulation of progenitor cells may occur earlier post-
treatment, and the effect of peptide treatment would also be diminished that much more quickly. 
This is consistent with the findings of the present chapter.  
 Future studies will aim to mitigate this confounding factor by utilizing the BIODOME 
device discussed in Chapter whereby any treatment’s spatiotemporal concentration can locally be 
controlled at the site of amputation.   
3.4.4 Clinical Relevance of a Purified Chemotactic Peptide  
Site specific recruitment of multipotent progenitor cells in response to limb amputation is a 
prerequisite for blastemal based epimorphic regeneration in species such as newts and axolotls 
(Kragl, Knapp et al. 2009).  Soluble factors are present that can recruit selected cell types and 
selected genetic programs are activated to participate in the regeneration process that results in a 
perfect phenocopy of the missing tissue structure (Kumar, Godwin et al. 2007; Kragl, Knapp et 
al. 2009; Monaghan, Epp et al. 2009). While blastema formation does not occur following injury 
in adult mammalian species, recruitment to and/or directed differentiation of tissue specific 
progenitor cells at the site of injury has the potential to alter the default scar tissue wound healing 
response toward a more constructive tissue remodeling response (Lee, Cook et al. ; Kim, Xin et 
al. 2010). In organs such as the liver, bone marrow, and intestinal lining that are capable of 
mounting a regenerative response to injury, activation and recruitment of progenitor cell 
compartments is an important prerequisite to site appropriate tissue regeneration (Lewis and 
Trobaugh 1964; Lagasse, Connors et al. 2000; Barker, van Es et al. 2007). Thus, recruitment of 
multipotent progenitor cells to a site of injury in response to placement of a chemotactic peptide 
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may be considered as a form of endogenous stem or progenitor cell therapy. The clinical efficacy 
of such therapies, however, remains to be determined. However, while the previous chapter 
focused on using a less characterized mixture of peptides for treatment in vitro and in vivo, the 
present chapter’s work focused on a single peptide. The potential for further characterization and 
understanding of the mechanisms of a single purified peptide subsequently also increases the 
translational potential of such a therapy.   
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4.0  ACCELERATION OF OSTEOGENESIS BY AN ISOLATED CRYPTIC PEPTIDE 
IN VITRO AND IN VIVO 
4.1 INTRODUCTION 
Sections of this chapter have been modified and adapted from (Agrawal, Kelly et al. 2011) 
Biologic scaffolds composed of extracellular matrix (ECM) have been used to promote 
site-specific, functional remodeling of tissue in both preclinical animal models (Badylak, Lantz 
et al. 1989; Lantz, Badylak et al. 1990; Cobb, Badylak et al. 1996; Hodde, Badylak et al. 1997; 
Badylak, Meurling et al. 2000; Caione, Capozza et al. 2006; Zalavras, Gardocki et al. 2006; Ott, 
Matthiesen et al. 2008; Ott, Clippinger et al. 2010; Uygun, Soto-Gutierrez et al. 2010) and 
human clinical applications (Metcalf, Savoie et al. 2002; Witteman, Foxwell et al. 2009; Derwin, 
Badylak et al. 2010; Mase, Hsu et al. 2010). Following implantation of a non-crosslinked ECM 
scaffold at a site of injury, a dense mononuclear infiltrate (Valentin, Badylak et al. 2006; 
Badylak, Valentin et al. 2008) degrades the scaffold over the course of 60-90 days (Record, 
Hillegonds et al. 2001; Gilbert, Stewart-Akers et al. 2007). The degradation of the ECM 
scaffolds results in the release of small cryptic peptides with novel bioactivity not present in the 
parent ECM proteins (Davis, Bayless et al. 2000; Davis 2010).  These cryptic fragments have 
been shown to possess antimicrobial, immunomodulatory, angiogenic and anti-angiogenic, 
mitogenic, and chemotactic properties, among others (Berkowitz, Bevins et al. 1990; Moore, 
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Devine et al. 1994; Moore, Beazley et al. 1996; Davis, Bayless et al. 2000; Ganz 2003; Li, Li et 
al. 2004; Adair-Kirk and Senior 2008; Agrawal, Brown et al. 2009). Additionally, cryptic 
fragments of ECM proteins have also been shown to be able to regulate the chemotaxis of a 
variety of progenitor cell populations in vitro and in vivo (Brennan, Tang et al. 2008; Crisan, Yap 
et al. 2008; Reing, Zhang et al. 2009; Tottey, Corselli et al. 2011).  
 To date, no studies have investigated the differentiation potential of cryptic peptides 
derived from degradation of ECM proteins. Findings of the previous chapter characterized a 
single cryptic peptide derived from the C-terminal telopeptide region of the collagen IIIα 
subunit, IAGVGGEKSGGF. Specifically, the work showed that the peptide had in vitro and in 
vivo chemotactic activity for multiple progenitor cells including human perivascular stem cells. 
An unexpected finding of the previous chapter was that the same peptide then repeatedly caused 
a bone nodule formation at the site of amputation. Although this was not discussed in the 
previous chapter, this finding is the subject of the present chapter. Specifically, the present 
chapter will show data that this cryptic peptide accelerates osteogenesis of mesenchymal stem 
cells in vitro and promotes the formation of a bone nodule at a site of digit amputation consistent 
with the presence of Sox2+, Sca1+, Lin- mesodermal progenitor cells identified in the previous 
chapters.  
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4.2 MATERIALS AND METHODS 
4.2.1 Overview of Experimental Design 
The experimental methods were designed to address the hypothesis that an isolated cryptic 
peptide, IAGVGGEKSGGF, alters osteogenesis in vitro and in vivo. Osteogenesis in vitro was 
assessed by measuring calcium deposition, alkaline phosphatase activity, and mRNA expression 
of osteogenic markers via quantitative RT-PCR. Osteogenesis was investigated in vivo in an 
established adult mammalian model of digit amputation (Schotte and Smith 1959; Schotte and 
Smith 1961). The deposition of calcium was determined by histologic examination as well as by 
injection of calcium dyes.  
4.2.2 Peptide Synthesis 
The cryptic peptide, IAGVGGEKSGGF, was chemically synthesized (GenScript, Piscataway, 
NJ). The peptide was reconstituted at a s tock concentration concentration of 10 mM in sterile 
filtered calcium and magnesium free phosphate buffered saline. 
4.2.3 Source of Cells and Culture Conditions  
Human perivasular stem (PSC) cells, a perivascular progenitor cell population (Crisan, Yap et al. 
2008), were isolated and prepared as previously described (Tottey, Corselli et al. ; Crisan, Yap et 
al. 2008). PSCs were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM, 
Invitrogen, Carlsbad, CA) containing 20% fetal bovine serum (FBS; Thermo, Pittsburgh, PA), 
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100 U/mL penicillin, and 100 μg/ml streptomycin (Invitrogen) at 37°C in 5% CO2. PSCs were 
characterized by immunolabeling and flow cytometry. Human cortical neuroepithelium stem 
(CTX) cells and human spinal cord neural stem (SPC) cells were a gift from ReNeuronTM. CTX 
cells were cultured in DMEM:F12 supplemented with 0.03% human albumin solution, 100µg/ml 
human apo-transferrin, 16.2µg/ml putrescine DiHCl, 5µg/ml insulin, 60ng/ml progesterone, 
2mM L-glutamine, 40ng/ml sodium selinite, 10ng/ml human  bFGF, 20ng/ml human epidermal 
growth factor, and 100nM 4-hydroxytestosterone. 
4.2.4 In vitro osteogenic differentiation and Alizarin red stain 
PSC, CTX, or SPC cells were seeded at a density of 2x104 cells/well in 24 well plates. Following 
attachment, cells were cultured in either normal culture medium or osteogenic differentiation 
medium, consisting of DMEM containing 10% FBS, 100 U /ml penicillin, 100 µ g/ml 
streptomycin, 10 mM β-glycerophosphate (Sigma, St. Louis, MO, G9422), and 50 µ g/ml 
ascorbic acid (Sigma, A4544). Wells were supplemented to a final concentration of 0, 1, 10, or  
100 µM of the cryptic peptide. At days 4, 7, 14, and 21, wells were fixed in 10% neutral buffered 
formalin and stained with 40 m M Alizarin red at pH 4.1 ( Sigma, A5533). Semi-quantitative 
analysis of alizarin red staining was completed as previously described (Gregory, Gunn et al. 
2004). Briefly, wells were stained for 20 minutes with 40 mM alizarin red and then washed twice 
with distilled H2O. Following washing, wells were incubated in 400 µl of 10% acetic acid until 
complete destaining was achieved. Each well was then neutralized with 160 µ l of 10% 
ammonium hydroxide. The optical density of each sample to 405 nm wavelength light was then 
read measured on a spectrophotometer. 
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4.2.5 Alkaline Phosphatase staining 
PSCs were seeded at a density of 2x104 cells/well in 24 well plates. At day 7 post-culture in 
either normal growth medium or osteogenic differentiation medium supplemented with 0, 1, 10,  
or 100 µM of peptide, cells were fixed for 2 minutes in 10% neutral buffered formalin. A subset 
of wells were stained with alkaline phosphatase substrate (Vector Labs, Burlingame, CA, SK-
5100) and imaged. Semi-quantitative analysis of alkaline phosphatase activity was completed by 
incubating the second subset of wells in 0.5 mg/ml p-Nitrophenyl Phosphate (Thermo, 
Pittsburgh, PA, #37620) for 30 m inutes at 37 0C in the dark prior to measuring the optical 
density of each sample to 405 nm light using a spectrophotometer. 
4.2.6 Adipogenic Differentiation 
PSCs were seeded in wells at a d ensity of 2x104 cells/well in 24 well plates. Following cell 
attachment, cells were cultured in normal culture medium or adipogenic differentiation medium 
(Hyclone, Pittsburgh, PA, SH30886.02). Cells were fixed at days 7 a nd 14 i n 10% neutral 
buffered formalin prior to staining with 0.5% Oil Red O solution (Alfa Aeasar, Ward Hill, MA) 
in 3:2 isopropanol:distilled H2O for 30 minutes. Following washing twice with distilled H2O. 
Semi-quantitative analysis of Oil Red O staining was completed as previously described 
(Trouba, Wauson et al. 2000). Briefly, wells were destained in 100% isopropanol for 30 minutes. 
Aliquots of each well were then read on a s pectrophotometer for absorbance at 490 nm  
wavelength.  
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4.2.7 PCR studies 
Following culture of PSCs in culture medium or osteogenic medium supplemented with either 0 
or 100 µM peptide, cells were cultured for 4, 7, or  14 days. Cells were then incubated in Trizol 
solution (Invitrogen, 11596-018) for 15 minutes at room temperature. RNA was extracted from 
Trizol solutions using phenol-chloroform extraction, and RNA was converted to cDNA using 
DNA Superscript Assay (Invitrogen, 18080). Real time quantitative PCR was then carried out 
using SYBR green dye (Applied Biosystems, Carlsbad, CA, 4385614) on a BioRad iCycler iQ5 
PCR machine. After initial denaturation at 95 0C for 3 minutes, PCR was run for 45 cycles, with 
each cycle consisting of: (1) melting at 95 0C for 10 seconds, (2) annealing for 30 seconds, and 
(3) extension at 72 0C for 30 s econds.  PCR was carried out for osteogenic, chondrogenic, 
adipogenic, and housekeeping genes (Table 2). The annealing temperature for Col1, SPP1, LPL, 
and 1HAT was 60 0C, and the annealing temperature for ABCB1 and Runx2 was 62 0C. A 
housekeeping gene control, 23s, was run simultaneously for each gene marker at each annealing 
temperature. 
 
Table 2. A list of primers used in the present chapter along with Accession Number and predicted product size. 
Marker Forward (5’-3’) Reverse (5’-3’) 
Accession 
Number 
Size 
(bp) 
SPP1 CTCCATTGACTCGAACGACTC CAGGTCTGCGAAACTTCTTAGAT NM_000582 230 
Col1 ATGGATTCCAGTTCGAGTATGGC CATCGACAGTGACGCTGTAGG NM_000088 246 
1HAT AACTGCTTTTGGTTACAAGGGT GAAGTAAGGTTCCGAATGGCTT NM_003642 239 
ABCB1 GGGAGCTTAACACCCGACTTA GCCAAAATCACAAGGGTTAGCTT NM_000927 154 
Runx2 AGATGATGACACTGCCACCTCTG GGGATGAAATGCTTGGGAACTGC NM_001024630 125 
LPL AGGAGCATTACCCAGTGTCC GGCTGTATCCCAAGAGATGGA NM_000237 126 
23s GCACAGCCCTAAAGGCCAACCC TCACCAACAGCATGACCTTTGCG NM_001025 243 
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4.2.8 Animal Model of Digit Amputation 
All methods were approved by the Institutional Animal Care and Use Committee at the 
University of Pittsburgh and performed in compliance with NIH Guidelines for the Care and Use 
of Laboratory Animals. Mid-second phalanx digit amputation of the third digit on each hindfoot 
in adult 6-8 week old C57/BL6 mice (Jackson Laboratories, Bar Harbor, ME) was completed as 
previously described (chapter 2). Following amputation, digits were either treated with a 
subcutaneous injection of 15 µ L of 10 m M peptide, or the same volume of PBS as a carrier 
control (n=4 for each group). Treatments were administered at 0, 24 and 96 hours post surgery. 
Animals were sacrificed via cervical dislocation under deep isoflurane anesthesia (5-6%) at day 
7, 14, 18, or 28 post-surgery. Digits were fixed in 10% neutral buffered formalin, decalcified for 
2 weeks in 10% formic acid, and then sectioned at 5 µ m thickness on to slides for further 
staining. Slides were either stained with Masson’s trichrome stain or Alcian blue stain.  
4.2.9 Calcium Dye Studies and Optical Clearance of Tissue 
Analysis of in vivo calcium deposition was adapted from previous studies (Neufeld and Zhao 
1995; Zhao and Neufeld 1995). Three days prior to digit amputation, mice were injected IP with 
3.5 mg/kg green calcein dye (Invitrogen, C481). Mice then were subjected to digit amputation 
and treatment. One day prior to harvest, mice were injected IP with 50 mg/kg alizarin red 
calcium dye (Sigma, A5533). Animals were sacrificed on da y 14 pos t-amputation via cervical 
dislocation under deep isoflurane anesthesia (5-6%). Isolated digits were then fixed in 4% 
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paraformaldehyde prior to serial dehydration in 25%, 50%, 75%, 95%, and 100% acetone. 
Following dehydration, fixed digits were then incubated in Dent’s fixative (1:4 DMSO:acetone) 
for 2 hours. Then, the digits were permeablized and bleached overnight in Dent’s bleach (1:4:1 
DMSO:acetone:H2O2). Digits were then equilibrated to a clearing solution consisting of 1:2 
benzyl alcohol (Sigma, 402834) to benzyl benzoate (Sigma, B6630) (BABB) by serial 1 hour  
incubations in 1:3, 1:1, and 3:1 solutions of BABB:Dent’s fixative. Afterwards, digits were then 
kept in 100% BABB until they were visibly optically cleared. Optically cleared digits were then 
imaged using a Nikon E600 epifluorescent microscope at 100x magnification, and images were 
taken with a Nuance camera. Images were deconvolved with known spectra for alizarin red and 
calcein dye to identify new versus old depositions of calcium. 
4.3 RESULTS 
4.3.1 Peptide promotes bone formation in vivo. 
Work in the previous chapter had shown that treatment with the single cryptic peptide in an 
established model of murine digit amputation (Schotte and Smith 1959; Schotte and Smith 1961) 
resulted in the accumulation of Sox2+, Sca1+, Lin- cells at day 7 post-amputation. An 
unexpected finding of the work was that a bone nodule was observed at the site of amputation at 
day 14 post-amputation that was not present in PBS or untreated amputated digits (Figure 32a). 
Differential calcium dye stains were to determine whether there was new calcium deposition at 
the site of amputation utilized (Neufeld and Zhao 1995; Zhao and Neufeld 1995) following 
peptide treatment. Following initial injection with a green calcein dye to label all bones green, 
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mice were subjected to mid-second phalanx amputation and treatment. On day 14 pos t-
amputation, mice were injected with a second dye, Alizarin red, to label all new deposited 
calcium red. Following peptide treatment, more new calcium deposition was noted in the 
amputated P2 bone (Figure 32a). Additionally, Alcian blue and Trichrome staining showed that 
the bone-like nodule progressed from a glycosaminoglycan-rich structure with at day 14 pos t-
amputation towards a collagenous nodule devoid of glycosaminoglycans at day 28 post-
amputation, suggesting endochondral ossification as the primary mechanism of osteogenesis in 
in vivo (Figure 32b).  
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Figure 32. Cryptic peptide promotes bone deposition in an adult mammalian model of digit 
amputation. To determine whether the isolated cryptic peptide promotes osteogenesis in vivo, adult C57/BL6 mice 
were subjected to mid-second phalanx amputation and either left untreated, treated with PBS carrier control, or 
treated with the isolated cryptic peptide.  (A) At day 14 post-amputation, histologic analysis revealed a bone-like 
nodule present at the site of amputation in the peptide treated group. Differential calcium dye injections showed that 
peptide treatment increases calcium deposition at the site of amputation. (B) Alcian blue stain showed that the bone 
nodule stained positive for glycosaminoglycans at early time points, suggesting that the nodule underwent 
endochrondral ossification. Images are representative of n=4 animals in each treatment group. 
 
Work in the previous chapter had determined that the cellular accumulation seen at the 
site of amputation lateral to the amputated expressed Sox2 and Sca1, both markers of multipotent 
progenitor cells. The same site where these cells were found on d ay 7 post-amputation 
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histologically showed a bone nodule at day 14 post-amputation (Figure 33). Additionally, a time 
course analysis of Sox2+ cell expression and histomorphometric analysis of bone nodule growth 
showed that the growth of the bone nodule coincided with a decrease in Sox2+ cells (Figure 34). 
Thus, while not conclusively the only mechanism by which the bone nodule may form, one 
plausible hypothesis was that the mesodermal progenitor cells present lateral to the site of 
amputation eventually underwent osteogenic differentiation to give rise to the bone nodule. Thus, 
the remainder of the in vitro work aimed to determine the in vitro effect of peptide treatment 
upon osteogenic differentiation of a model mesenchymal stem cell, the human perivascular stem 
cell (Crisan, Yap et al. 2008).  
 
 
Figure 33. Cellular accumulation correlates with bone nodule formation. Representative Trichrome 
images from day 7 post-amputation and day 14 post-amputation digits treated with the isolated cryptic peptide show 
that the accumulation of cells at the site of amputation spatially correlates with the bone nodule formation. 
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Figure 34. Immunohistochemical staining of Sox2 staining as well as histomorphometric analysis of bone 
growth showed that the increase in bone growth coincided with a decrease in Sox2+ cells, suggesting that Sox2+ 
cells may play a role in osteogenesis.  
 
4.3.2 Peptide accelerates osteogenesis in vitro. 
Following culture of human perivascular stem (PSC) cells in either normal growth medium or 
osteogenic differentiation medium supplemented with 0, 1, 10,  or 100 µ M peptide, calcium 
deposition by the cells was measured by Alizarin red staining. There was a dose-dependent 
increase in Alizarin red staining at days 7 and 14 post-treatment (Figure 35). By day 21 post-
treatment, no significant difference in Alizarin red staining was noted between treatment groups. 
Culture of PSCs in normal growth medium supplemented with 0, 1, 10, o r 100 µM peptide did 
not result in any changes in Alizarin red staining at any time point (Figure 35), suggesting that 
the isolated cryptic peptide accelerates osteogenesis only in conditions of osteogenic 
differentiation. Concomitant with increased calcium deposition, a dose dependent increase in 
alkaline phosphatase activity was observed on day 7 post-treatment with peptide in conditions of 
osteogenic differentiation (Figure 36). 
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Figure 35. Cryptic peptide accelerates osteogenesis of perivascular stem cells. Human perivascular 
stem cells were cultured in either culture medium or osteogenic differentiation medium. Following supplementation 
of medium with 0, 1, 10, 100 µM of the isolated cryptic peptide,  osteogenic differentiation was determined by 
Alizarin red stain of the cells. At 7 and 14 days post-differentiation, the isolated cryptic peptide accelerated 
osteogenesis of perivascular stem cells. *p < 0.05, ** p <0.01 as compared to the 0 µM osteogenic differentiation 
group. Error bars represent Mean + SEM of experiments in triplicate (n=3). 
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Figure 36. Cryptic peptide increases alkaline phosphatase activity. Human perivascular stem cells were 
cultured in either culture medium or osteogenic differentiation medium. Following supplementation of medium with 
0, 1, 10, 100 µM of the isolated cryptic peptide,  alkaline phosphatase activity was measured by PNPP substrate 
reaction and staining. At 7 days post-differentiation and treatment, the isolated cryptic peptide resulted in increased 
alkaline phosphatase activity. *p < 0.05, ** p <0.01 as compared to the 0 µM osteogenic differentiation group. Error 
bars represent Mean + SEM of experiments in triplicate (n=3). 
 
To determine whether the peptide promotes osteogenesis in stem cells not known to show 
osteogenic differentiation potential, human cortical neuroepithelial stem cells (CTX) and spinal 
cord neural stem cells (SPC) were cultured in normal growth medium or osteogenic 
differentiation medium supplemented with 0, 1 , 10, or  100 µM peptide. PSCs cultured in 
osteogenic differentiation medium with no supplement was used as a positive control. At day 7 
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post-treatment, peptide treatment in normal growth medium or osteogenic differentiation 
medium did not result in calcium deposition and Alizarin red staining of CTX and SPC cells 
(Figure 37). 
 
Figure 37. To determine whether the isolated cryptic peptide promotes osteogenic differentiation of non-
mesenchymal stem cells, human cortical neuroepithelial stem cells and human spinal cord neural stem cells were 
cultured in normal culture medium or osteogenic differentiation medium in the presence of 0, 1, 10, or 100 µM of 
the isolated cryptic peptide. The isolated peptide did not promote osteogenic differentiation of the neural stem cells. 
Error bars represent Mean + SEM of experiments in triplicate (n=3). 
 
To confirm that the observed in vitro calcium deposition was due to true osteogenesis and 
not secondary to necrotic ossification from overgrowth of cells, the ability of the peptide to 
induce proliferation in human perivascular stem cells was assessed. Although unfractionated 
ECM degradation products induced mitogenesis of PSCs, consistent with previous studies 
(Tottey, Corselli et al. 2011), no c hange in PSC proliferation was observed in response to 
treatment with the cryptic peptide (Figure 38). Because no differences were noted in cell number 
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between peptide treated groups and negative controls, the calcium deposition observed in 
response to peptide treatment cannot be secondary to selective overgrowth in peptide treated 
groups.   
 
Figure 38. Cryptic peptide does not alter proliferation of perivascular stem cells. To determine 
whether the peptide induced osteogenesis by increasing proliferation of cells, perivascular stem cells were 
supplemented in normal growth medium supplemented with 0, 1, 10, or 100 µM peptide, or 100 µg/ml of 
unfractionated cryptic peptides as a positive control (Tottey, Corselli et al. 2011). Over the course of 12 days, no 
change in cell number was observed following culture in any concentration of cryptic peptide. *p < 0.05 as 
compared to normal growth medium at each time point. Error bars represent Mean + SEM of experiments in 
triplicate (n=3). 
4.3.3 Peptide does not alter adipogenesis in vitro. 
To determine whether the peptide alters the differentiation of PSCs along other mesenchymal 
lineages in addition to osteogenesis, PSCs were cultured in normal growth medium or adipogenic 
differentiation medium supplemented with 0, 1, 10, or 100 µM peptide. Although an increase in 
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Oil Red O staining was noted in conditions of adipogenic differentiation at days 7 and 14 post-
treatment, peptide treatment did not alter the rate of adipogenesis (Figure 39). 
 
Figure 39. Cryptic peptide does not alter adipogenesis of perivascular stem cells. Human perivascular 
stem cells were cultured in either culture medium or adipogenic differentiation medium. Following supplementation 
of medium with 0, 1, 10, 100 µM of the isolated cryptic peptide, differentiation was determined by Oil Red O stain. 
No differences were noted between treatment groups at any time point. Error bars represent Mean + SEM of 
experiments in triplicate (n=3). 
4.3.4 Peptide promotes expression of osteogenic and chondrogenic markers in human 
perivascular stem cells. 
To determine whether the cryptic peptide accelerates osteogenesis by increasing mRNA 
expression of osteogenic genes, PSCs were cultured in either normal growth medium, growth 
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medium supplemented with 100 µM cryptic peptide, osteogenic differentiation medium alone, or 
osteogenic medium supplemented with 100 µM cryptic peptide. At 4 days post-culture, peptide 
treatment did not significantly change the expression of osteogenesis-related genes Collagen I, 
Runx2, or Osteopontin (SPP1). However, supplementation of the peptide in osteogenic medium 
resulted in a significant increase in Collagen I and Osteopontin expression in PSCs (Figure 40). 
Peptide treatment alone also resulted in a significant increase in the expression of the 
chondrogenic gene, ABCB1, and peptide supplementation of osteogenic medium resulted in a 
significant increase in expression of both chondrogenic genes, ABCB1 and 1HAT (Figure 40). 
No mRNA expression of lipoprotein lipase, a marker of adipogenesis, was observed through 45 
cycles of qRT-PCR.  
 
Figure 40. Cryptic peptide increases expression of osteogenic and chondrogenic genes in vitro. To 
determine whether the cryptic peptide accelerates osteogenesis by increasing mRNA expression of osteogenic genes, 
perivascular stem cells were cultured for 4 days in normal growth medium or osteogenic medium unsupplemented 
or supplemented with 100 µM cryptic peptide. Osteogenic medium supplemented with peptide resulted in a 
significant increase in Collagen I, Osteopontin (SPP1), 1HAT, and ABCB1 expression. No expression of LPL was 
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observed over 45 cycles of RT-qPCR. * p < 0.05 as compared to normal growth medium for each gene. Error bars 
represent Mean + SEM of six experiments (n=6). 
 
4.4 DISCUSSION 
4.4.1 Osteogenic Activity of Cryptic Peptides 
The work of the present chapter identified a novel property of a cryptic peptide previously shown 
to possess chemotactic activity in chapter 3. The cryptic peptide accelerated osteogenic 
differentiation of human perivascular stem cells (PSC), and treatment with the cryptic peptide at 
a site of digit amputation in vivo resulted in formation of calcified bone at the site of amputation. 
An increasing body of literature has begun to recognize the importance of cryptic fragments of 
proteins that contain novel activity not associated with their parent molecules. Collectively 
referred to as the “cryptome” (Davis, Bayless et al. 2000; Autelitano, Rajic et al. 2006; Ng and 
Ilag 2006; Pimenta and Lebrun 2007; Mukai, Hokari et al. 2008; Mukai, Seki et al. 2009; Davis 
2010), various peptides have been identified to show bioactive properties including 
antimicrobial, pro- and anti-angiogenic, chemotactic, and mitogenic activity (Berkowitz, Bevins 
et al. 1990; Moore, Devine et al. 1994; Moore, Beazley et al. 1996; Davis, Bayless et al. 2000; 
Ganz 2003; Li, Li et al. 2004; Adair-Kirk and Senior 2008; Agrawal, Brown et al. 2009). The 
present study shows that such cryptic peptides may also be able to affect the differentiation of 
stem cells. Since stem cell are known to home to sites of inflammation and participate in the 
injury response, the release of cryptic peptides with the ability to alter stem cell differentiation at 
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the site of injury may be a conserved, desirable response to promote tissue reconstruction 
following injury.  
The cryptic peptide used in the present study is derived from the C-terminal telopeptide 
of collagen III, a region known to be enzymatically cleaved and released into the circulation 
following soft tissue injury (Kitahara, Takeishi et al. 2007; Banfi, Lombardi et al. 2010; 
Kanoupakis, Manios et al. 2010). However, most trauma does not lead to spontaneous bone 
formation at the site of injury secondary to the release of cryptic peptides such as the one 
identified in the present study. Following an injury, there are likely thousands of peptides 
released from wound sites, and the cryptic peptide in the present study would only be one of 
many peptides that exert an overall net effect upon differentiation of local stem cells. It is likely 
that cryptic peptides exist which can not only promote differentiation of stem cells, as shown in 
the present study, but also can inhibit differentiation. The present study investigated the activity 
of a single cryptic peptide by injecting supra-physiologic concentrations in vivo, many orders of 
magnitude greater than the concentrations of other cryptic peptides that would be expected to be 
released from a site of digit amputation. 
4.4.2 Injury Dependence of Peptide’s Osteogenic Activity: Implications and Clinical 
Relevance 
The findings of the present chapter show that the cryptic peptide depends on a n osteogenic 
microenvironment in order to promote osteogenesis in vitro and in vivo. The dependence of the 
cryptic peptide’s osteogenic activity upon the microenvironment is an interesting property with 
potential therapeutic implications. There are many well known osteogenic growth factors such as 
bone morphogenic protein that have been used with varying degrees of success to induce and/or 
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promote bone growth in vivo (Dickinson, Ashley et al. 2008; Rogozinski, Rogozinski et al. 
2009). However, in many cases, these growth factors also promote heterotopic ossification at 
sites where osteogenesis is not desired, in addition to other side effects (Mannion, Nowitzke et 
al. 2010). The cryptic peptide in the present study only enhanced osteogenesis of perivascular 
stem cells in vitro when cultured in the presence of osteogenic differentiation medium. 
Additionally, peptide treatment only resulted in the formation of a bone nodule lateral to the 
amputated bone at the site of amputation, i.e. an active site of periosteal injury/inflammation. 
Bone injury in vivo locally activates pathways of bone deposition and osteogenesis (Ai-Aql, 
Alagl et al. 2008). Furthermore, injury to the periosteum that surrounds the bone activates latent 
PSCs within the periosteum (De Bari, Dell'Accio et al. 2006) to promote osteogenesis (Zhang, 
Xie et al. 2005). The present study found bone nodule formation in vivo only lateral to the bone, 
consistent with a l ocation where activated periosteal mesenchymal stem cells (MSC) would 
likely promote osteogenesis.   
The microenvironmental niche at a site of injury is a complex, important determinant of a 
host response to injury (Lutton and Goss 2008). Previous studies have extensively examined the 
role of the microenvironmental niche in controlling stem cell adhesion, migration, and 
differentiation (Watt and Hogan 2000). In addition to cues from nearby cells (Chow, Lucas et al. 
2011) and biophysical cues from the environment (Keung, Kumar et al. 2010), extracellular cues 
are thought to regulate stem cell behavior in an injury microenvironment  (Jackson, Majka et al. 
2001; Majka, Jackson et al. 2003; Kienstra, Jackson et al. 2008; Discher, Mooney et al. 2009). 
While the present study shows a novel property of cryptic peptides that may contribute to the 
regulation of stem cell behavior at a site of injury, it also shows that the microenvironment itself 
plays a reciprocal role in altering the activity of cryptic peptides. In the absence of osteogenic 
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differentiation conditions, the cryptic peptide utilized in the present study shows no osteogenic 
activity. Additionally, the peptide only induces bone formation at a site of amputation in vivo. It 
is possible that a co-stimulatory growth factor or molecule is present in an osteogenic 
microenvironment that is necessary for the peptide’s mode of action. It is also possible that the 
cryptic peptide activates a signaling pathway that acts in synergy with existing activated 
osteogenic signaling pathways to enhance osteogenesis. An attractive target of action of the 
cryptic peptide in the present study is via modulation of integrin signaling pathways (Agrez, 
Bates et al. 1991; Horton, Spragg et al. 1994; Xia and Zhu 2010). Integrins are important in both 
osteogenesis (Shih, Tseng et al. 2011) and stem cell chemotaxis (Chavakis, Aicher et al. 2005), 
both properties of the cryptic peptide in the present study. Future studies will further investigate 
these mechanisms. 
4.4.3 Future Studies 
In addition to studies investigating the mechanism by which the peptide accelerates osteogenesis 
of mesenchymal stem cells in vitro (potential approaches to elucidating a mechanism were 
discussed in Chapter 3), a number of future studies can further investigate the osteogenic activity 
of the single cryptic peptide. 
 The present study only administered peptide at a site of injury where a basal amount of 
ostoegenesis would be expected following bone injury. Although in vitro studies suggest that the 
the effect of the peptide is specific to osteogenesis and requires an osteogenic microenvironment 
to be effective, this could be tested in vivo by administrering the same peptide in a non-
osteogenic environment. For example, the peptide could be injected subcutaneously in an injured 
muscle as well at a site of muscle injury to determine the injury-dependent and injury-
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independent osteogenic properties of the cryptic peptide. The effect of peptide treatment in these 
cases may not only confirm the in vitro findings of the present chapter, but also may offer more 
clues as to the mechanisms by which the peptide exerts its effect. 
In summary, the present study identified a novel property of a cryptic peptide derived 
from C-terminal telopeptide region of the collagen IIIα molecule. The cryptic peptide selectively 
enhanced osteogenesis in vitro, and treatment with the peptide resulted in the formation of a bone 
nodule lateral to the amputated bone in a mouse model of digit amputation. While further work is 
necessary to identify the mechanisms of action of the cryptic peptide, the identification of cryptic 
peptides capable of altering stem cell differentiation is a novel property not previously attributed 
to cryptic peptides. In addition to potential therapeutic implications for the treatment of bone 
injuries and chronic diseases, cryptic peptides with the ability to alter stem cell recruitment and 
differentiation at a site of injury may serve as powerful new tools for influencing stem cell fate in 
the local microenvironmental niche. 
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5.0  DISSERTATION SYNOPSIS, GENERAL DISCUSSIONS, AND FUTURE 
DIRECTIONS 
The findings of the present thesis aimed to establish a l ink between the in vitro and in vivo 
chemoattractive properties of degradation products of ECM scaffolds for progenitor cells, with a 
long term goal of using ECM degradation products as a potential therapy for site directed 
recruitment of progenitor cells and constructive remodeling of more complex tissues such as 
limbs and digits. Because species capable of limb regeneration do s o via local recruitment of 
multipotent stem cells (Kragl, Knapp et al. 2009), the use of ECM degradation products in adult 
mammals following digit amputation might serve as a form of “endogenous stem cell therapy” to 
alter the default wound healing response of scar tissue deposition at a site of amputation.  
In order to understand the in vivo bioactive properties of ECM degradation products, the 
work in the present thesis specifically addressed three aims. It showed that ex vivo generated 
ECM degradation products were chemotactic for progenitor cells in vitro and promoted the site 
directed recruitment of progenitor cells in vivo. Additionally, a single cryptic peptide was 
isolated from the mixture of ECM degradation products with similar in vitro and in vivo 
properties for progenitor cells. Although the contribution of this single peptide to the net 
chemotactic effects of ECM degradation products was not elucidated and the mechanisms by 
which the single cryptic peptide exerts its effect were not determined, the identification of a 
single ECM cryptic peptide with chemotactic potential for progenitor cells is the first to be 
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reported in the literature. Finally, the work in the present thesis also identified a new property of 
ECM cryptic peptides by showing that a single cryptic peptide had the potential to alter 
progenitor cell differentiation in vitro and in vivo, specifically along an osteogenic lineage.  
Nevertheless, the results of the present thesis identified a number of questions that 
remain. As such, these are potential future avenues of investigation that will not only serve to 
further confirm the findings of the present thesis, but also give new insight into the biological 
basis for ECM scaffold mediated constructive remodeling at a site of injury. Additionally, these 
future avenues of investigation may identify new therapeutic strategies as well as molecular 
targets by which to further influence a site of injury and alter the default wound healing response 
from scar tissue deposition towards more of a regenerative response. 
One of the predominant themes in the discussion that follows is the establishment of links 
between the various known mechanisms by which ECM scaffolds remodel. As discussed in the 
introduction of the present thesis, the mechanisms by which ECM scaffolds exert their 
constructive remodeling effect in vivo are only partially understood. However, based on previous 
studies, four potential mechanisms have been identified: [1] rapid degradation of the ECM 
scaffold, [2] site directed recruitment of differentiated and progenitor cells, [3] 
mechanotransduction through the implanted scaffold, and [4] polarization of the local immune 
cells at the site of scaffold implantation. Although previous have studies have focused on 
understanding these phenomena separately, the present thesis attempted to establish a link 
between two of these mechanisms. Specifically, the present thesis showed that ECM degradation 
products may be responsible for site directed recruitment of progenitor cell recruitment to a site 
of ECM scaffold implantation that has previously been observed.  
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Previous studies have unequivocally showed that rapid degradation of ECM is an 
essential prerequisite for constructive remodeling of tissue to occur at a site of ECM implantation 
(Valentin, Stewart-Akers et al. 2009). Thus, the proceeding discussion focuses on future studies 
that either directly or indirectly addresses a global hypothesis that the existence of ECM 
degradation products and cryptic peptides may be the precipitating factor for other downstream 
events of constructive remodeling: immune cell polarization, rapid angiogenesis, and site 
directed recruitment of differentiated and progenitor cells.  
The findings of the present thesis showed that the existence of injury was an essential 
prerequisite to accumulation of progenitor cells, potentially suggesting that ECM degradation 
products may interact with the immune system. While mechanotransduction itself was not 
investigated in the present thesis, the findings of the present thesis highlight the importance of 
the local injury microenvironment in dictating the response to injury.  Finally, if in fact ECM 
degradation products are the unifying link between all of the proposed mechanisms by which 
ECM scaffolds exert their constructive remodeling effect, then molecular signaling pathways that 
are common to all mechanisms discussed may be responsible for mediating the effect of ECM 
degradation products upon cells.  
5.1 DIRECT ASSESSMENT OF THE ROLE OF ECM DEGRADATION IN 
CONSTRUCTIVE REMODELING AFTER SCAFOLD IMPLANTATION 
Although the present attempted to establish a l ink between bioactive cryptic peptide released 
from ECM degradation and the subsequent site-directed accumulation of progenitor cells that has 
been observed in previous studies (Badylak, Park et al. 2001; Zantop, Gilbert et al. 2006), the 
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work of the present thesis did not directly address the necessity of ECM degradation for 
subsequent progenitor cell recruitment. Two critical limitations of the digit amputation model 
utilized in the present work were the type of treatment used and the lack of regeneration 
following treatment. Previous studies that have shown that ECM scaffolds promote constructive 
remodeling generally utilized a sheet or compacted form of ECM scaffolds (Badylak, Hoppo et 
al. ; Mase, Hsu et al. ; Badylak, Lantz et al. 1989; Lantz, Badylak et al. 1990; Lantz, Badylak et 
al. 1992; Kropp, Eppley et al. 1995; Prevel, Eppley et al. 1995; Clarke, Lantz et al. 1996; Kropp, 
Rippy et al. 1996; Pope, Davis et al. 1997; Badylak, Meurling et al. 2000; Badylak, Kokini et al. 
2001; Record, Hillegonds et al. 2001; Badylak, Kokini et al. 2002; Badylak, Vorp et al. 2005; 
Kochupura, Azeloglu et al. 2005; Robinson, Li et al. 2005; Badylak, Kochupura et al. 2006; 
Lopes, Cabrita et al. 2006; Ota, Gilbert et al. 2007). While other studies have also shown that 
inhibition of ECM degradation (Valentin, Stewart-Akers et al. 2009), studies thus far have not 
directly investigated the importance of degradation of the scaffold upon subsequent progenitor 
cell recruitment. In the studies that have tried to alter scaffold degradation, the methods used to 
inhibit degradation (cross-linking and macrophage depletion) may have other confounding 
effects in vivo besides inhibition of ECM degradation. Cross-linking not only alters the 
degradation of the scaffold, but also then affects surface topology and macromolecular 
composition of the scaffold. Macrophage depletion not only inhibits phagocyte mediated 
degradation of the scaffold, but also eliminates the contribution of the innate immune response to 
injury and remodeling (both positive and negative contributions).  
Thus, it is necessary to utilize a more versatile model of injury where ECM implantation 
results in the formation of functionally appropriate tissue and no t reatment results in a poor 
outcome. To partially address these questions, preliminary work in the laboratory has resulted in 
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the development of a murine model of volumetric muscle injury (section 5.6.3). In such a model, 
it is possible to fill the defect with a powdered ECM construct that then facilitates constructive 
remodeling of the muscle tissue. The advantage of such a model, though, is that the volumetric 
defect can be filled with any of a number of scaffolds. To directly address the importance of 
ECM degradation upon subsequent constructive remodeling, the defect could be filled with: [1] 
ECM degradation products, [2] a normal ECM construct, [3] a cross-linked ECM construct, [4] 
normal ECM construct with macrophage depletion, and [5] a normal ECM construct with 
protease inhibitors within the scaffold. The use of these four treatments groups spans the 
spectrum of ECM degradation by using a treatment method where ECM is completely degraded 
as well as three separate methods where ECM degradation is inhibited. The volumetric construct 
allows for the inclusion of protease inhibitors in the three dimensional ECM construct, and this 
treatment option theoretically accounts for many of the confounding factors in previously 
utilized methods of inhibiting ECM degradation (Valentin, Stewart-Akers et al. 2009). It is 
possible that the protease inhibitors themselves may interact with the innate host response to 
injury and/or have other undesirable side effects, but this would be addressable with control 
untreated mice that are only locally administered protease inhibitors.   
Such a model would be very powerful for addressing the effect of ECM degradation 
and/or subsequent cryptic peptide release upon any of the mechanisms by which ECM scaffolds 
remodel. It would be possible to determine a correlation between ECM scaffold degradation and 
immune cell polarization, rapid angiogenesis, mechanotransduction, or progenitor cell 
recruitment. More importantly, any alterations could then be causally linked to overall 
constructive remodeling and restoration of functional muscular tissue. Future studies may 
investigate this.   
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5.2 THE IMPORTANCE OF INJURY IN ECM-MEDIATED RECRUITMENT OF 
PROGENITOR CELLS IN VIVO: PARACRINE EFFECTS OF IMMUNE CELLS 
A key finding of the present thesis that was not further discussed was the importance of the 
injury in ECM degradation product mediated progenitor cell recruitment in vivo. In the absence 
of any injury, and specifically in the absence of a bone type of injury, there was a severe 
reduction in the number of cells expressing markers of progenitor cells at a s ite of digit 
amputation. These findings suggest that some component of the injury is critical for ECM-
mediated recruitment of progenitor cells. 
As discussed in chapter 1, one possible explanation for this dependence on injury is that 
the effect of ECM degradation products upon pr ogenitor cell recruitment occurs through a 
immune system derived secondary mediator. Given the peak accumulation of progenitor cells at 
14 days post-amputation, even though treatment with ECM degradation products ceased after 4 
days post-amputation, it is likely that the direct of ECM degradation products is on another cell 
present at the site of injury at the time. Within the context of the time course of immune cell 
infiltration at a wound site, macrophages would be abundant at the site of injury when ECM 
degradation products were locally administered. Furthermore, given the abundant evidence 
showing the importance of macrophages in tissue regeneration (Valentin, Stewart-Akers et al. 
2009), and specifically given the importance of local macrophages in ECM scaffold mediated 
constructive remodeling at a site of injury,. (Friedenstein, Piatetzky et al. 1966; Allman, 
McPherson et al. 2001; Badylak, Valentin et al. 2008; Brown, Valentin et al. 2009; Valentin, 
Stewart-Akers et al. 2009), it is plausible that macrophages may be the secondary mediator by 
which ECM degradation exert their effect upon progenitor cells in vivo. 
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Although the present thesis did not directly address this question, preliminary evidence 
suggests that macrophages may, in fact, play a role in promoting progenitor cell recruitment 
(section 5.6.2). Expanding upon previous studies showing that activated macrophages can have a 
paracrine effect upon progenitor cell migration in vitro (Lolmede, Campana et al. 2009), 
preliminary studies conducted in vitro with a human monocyte/macrophage THP-1 cell line 
suggest that paracrine factors released by macrophages in response to ECM degradation products 
may be chemotactic for multiple progenitor cell populations (section 5.6.2). In fact, one of the 
potential molecules released by the macrophages has been identified as HMGB1, a high mobility 
group protein that plays reciprocal roles in both tissue regeneration and septic shock (Bianchi 
2007; Campana, Bosurgi et al. 2008). In fact, in regenerative conditions, HMGB1 is known to 
possess chemotactic properties for multiple differentiated and progenitor cell types (Porto, 
Palumbo et al. 2006; De Mori, Straino et al. 2007; Lolmede, Campana et al. 2009; Ranzato, 
Patrone et al. 2009).  
Although it ma y seem surprising that HMGB1 may play a role in ECM mediated 
progenitor cell recruitment, there are many reasons that ECM scaffolds may exert their effect at 
least partially through molecules such as HMGB1. HMGB1 has increasingly been recognized as 
a part of a family of proteins known as damage associated molecular patterns (DAMPs), proteins 
that are released systemically following injury to cells to signal that damage has occurred 
(Bianchi 2007). Because the methods  u tilized to create ECM scaffold require mechanical, 
chemical, and enzymatic methods of removal of cellular components (Crapo, Gilbert et al. 2011), 
clearly many components of cell debris may be left over in the resulting scaffold (Gilbert, Freund 
et al. 2009)  which could exhibit properties of DAMPs. Unpublished data from our laboratory 
suggests that HMGB1 is one of these DAMPs that can be found in scaffolds even after 
121 
decellularization has been completed to meet well accepted standards (Crapo, Gilbert et al. 
2011). 
Thus, the role of DAMPs within the scaffold as well as other DAMPs known to be 
released by local inflammatory cells at a site of injury may be an important mechanism by which 
ECM scaffolds exert their constructive remodeling effect in vivo. As such, the role of DAMPs in 
the host response to biomaterials, and the subsequent effect of this interaction upon the overall 
remodeling response, is an area of research that requires further study.  
5.3 THE BIODOME AND THE ABILITY TO CONTROL THE 
MICROENVIRONMENT OF THE SITE OF AMPUTATION 
As discussed throughout the thesis, one of the main limitations of the approach undertaken in the 
present thesis to recruit multipotent stem cells to a site of injury was the lack of constructive 
remodeling in the digit following amputation, treatment, and progenitor cell recruitment. As 
such, the findings of the present thesis are most consistent with the initial phase of non-blastemal 
epimorphic regeneration. The next step in non-blastemal epimorphic regeneration is 
spatiotemporally appropriate proliferation, self-renewal, and differentiation of the recruited 
multipotent progenitor cells, a process that is dependent on the microenvironment of the injury 
(Watt and Hogan 2000; Kumar, Godwin et al. 2007; Lutton and Goss 2008; Kragl, Knapp et al. 
2009; Monaghan, Epp et al. 2009; Keung, Kumar et al. 2010; Tottey, Corselli et al. 2011). 
Thus, progress in tissue engineering of more complex and composite tissues may require 
a more precise ability to control the microenvironment of the site of injury. As discussed in 
previous chapters, one approach to more precisely controlling the injury microenvironment may 
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be through the use of a microfluidic device that covering the site of amputation and is capable of 
controlling various properties of the injury microenvironment including hydration, pH, 
temperature, electrical potential, and concentrations of bioactive factors (Hechavarria, Dewilde 
et al.). In collaboration with the Automation & Robotics Research Institute (ARRI) at the 
University of Texas Arlington, a prototype device designated as the BIODOME (Biomechanical 
Interface for Optimized Delivery of MEMS Orchestrated Mammalian Epimorphosis) has been 
developed for an adult mouse model of digit amputation (section 5.6.1). Preliminary evidence 
suggests that treatment with the isolated cryptic peptide used in the present thesis results in a 
similar accumulation of heterogeneous cells at the site of amputation, but the cells are only 
capable of osteogenic differentiation potential (section 5.6.1). This finding is consistent with the 
unexpected finding that the peptide altered osteogenesis of progenitor cells in vitro.  
Future studies will further investigate the use of the BIODOME for both therapeutic 
purposes as well as a scientific tool to better understand the role of various components of the 
injury microenvironment in constructive remodeling.  
5.4 ECM DEGRADATION AND THE IDENTIFICATION OF OTHER CRYPTIC 
PEPTIDES 
In the present thesis, ECM degradation products were created ex vivo utilizing pepsin mediated 
digestion of ECM scaffolds. The resulting soluble solution was considered a model of ECM 
degradation products. While not similar to the type of ECM degradation that would be expected 
at a site of injury following implantation of an ECM scaffold, previous studies have shown that 
the peptide mixture of pepsin-digested ECM scaffolds does show repeatable bioactivity for 
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multiple cells in vitro (Brennan, Reing et al. 2006; Crisan, Yap et al. 2008; Agrawal, Brown et 
al. 2009; Reing, Zhang et al. 2009; Tottey, Johnson et al. 2010). The work in the present thesis 
focused specifically on its net chemotactic effect upon multiple progenitor cells in vitro 
(Brennan, Tang et al. 2008; Crisan, Yap et al. 2008; Reing, Zhang et al. 2009; Tottey, Johnson et 
al. 2010; Tottey, Corselli et al. 2011). The work in the present thesis identified a specific cryptic 
peptide from this mixture that can partially recapitulate the net effect of the unfractionated ECM 
degradation products. 
Given the framework provided in the present thesis for isolation of a specific peptide 
from a mixture of peptides with a net bioactive effect, a very tangible future direction is the 
further identification of peptides from the pepsin-digested ECM degradation products. Because 
the effect of the mixture is a net effect, it is likely that both pro- and anti-chemotactic peptides 
exist within the mixture of ECM degradation products.  Given the low potency of the isolated 
cryptic peptide in the present thesis, it is likely that there are many other peptides that exist 
within the ECM degradation product mixture that contribute to the net chemotactic effect that is 
seen in vitro and in vivo. Identification of these peptides could result in the creation of an optimal 
mixture of specific peptides that is chemotactic for progenitor cells in vitro and in vivo. 
Additionally, utilizing the same methods for fractionation and isolation of a peptide, 
future studies can purify a peptide with other bioactive properties. Previous studies have shown 
that degradation products of ECM have both mitogenic (Reing, Zhang et al. 2009) and 
antibacterial properties (Brennan, Reing et al. 2006)  i n addition to the chemotactic properties 
that were the focus of the present thesis. The present thesis also showed that at least a subset of 
the ECM degradation products is able to alter the rate of progenitor cell differentiation in vitro. 
Fractionation of the ECM degradation products and further fractionation based on an assay other 
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than a B oyden chamber migration assay might allow for the purification and identification of 
other bioactive peptides with these properties.  
Of specific interest to the work in the present thesis is the identification of peptides and 
treatments that can influence the differentiation of progenitor cells. Serendipitously, the cryptic 
peptide isolated in the present thesis altered the rate of osteogenic differentiation of human 
perivascular stem cells in vitro. However, because the fractionation scheme was meant to purify 
a peptide based on hum an perivascular stem cell chemotaxis and not based on os teogenic 
differentiation, it is not known whether other peptides exists that would more potently promote 
osteogenic differentiation. Additionally, it is possible that peptides also exist that would inhibit 
osteogenic differentiation. Finally, cryptic peptides may exist that might accelerate or decelerate 
the rate of differentiation of stem cells along other lineages such as chondrogenesis, 
adipogenesis, and myogenesis. Identification of such peptides would result in a library of 
peptides that could be utilized to influence and/or control the differentiation of progenitor cells in 
vitro or in vivo at a site of injury.  
5.5 DIFFERENTIAL SIGNALING THROUGH INTEGRINS: A POTENTIAL 
STRATEGY FOR CONTROLLING STEM CELL FATE IN VITRO AND IN VIVO 
The findings of the present thesis suggest that ECM degradation products may play an important 
role in the ECM mediated constructive remodeling response. While multiple ECM cryptic 
peptides have been identified with novel abilities to modulate and initiate pathways such as 
angiogenesis, mitogenesis, and chemotaxis that are not associated with the parent ECM 
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molecules from which the peptides are derived, the mechanisms underlying these novel bioactive 
properties are not well understood (Davis, Bayless et al. 2000; Hocking and Kowalski 2002).  
Most of the literature investigating the biology of degradation products of ECM focuses 
on the new epitopes that are exposed following enzymatic digestion of fibrillar, structural ECM 
proteins (Davis, Bayless et al. 2000). The ECM of any given tissue has a highly ordered 
structure. Because the fibrillar proteins formed tightly packed structures in which many motifs 
are not generally available to bind to cells, degradation of the structural proteins of ECM may 
uncover hidden epitopes within the structural proteins that can influence cell behavior and 
phenotype. However, relatively fewer studies have investigated whether the existing integrin-
binding epitopes also still play a role within the ECM degradation products.  
In cells interacting with an ECM scaffold, the cell is polarized with respect to integrin 
signaling because only one side of the cell actually interacts with the scaffold itself [citation]. 
During ECM degradation, the highly ordered structure of the ECM scaffold is lost. Thus, while 
the cell cannot bind to the highly ordered ECM scaffold in a tightly coordinated fashion, it may 
still be able to the bind the soluble integrin-binding ligands (i.e. ECM degradation products) that 
are released from the degrading ECM scaffold. The spatial distribution of integrin signaling 
within a cell may potentially contribute to differences in cell phenotype or function, and these 
differences may be one explanation as to why degradation products of ECM scaffolds exhibit 
novel bioactive properties such as osteogenic differentiation.  
Integrins have been shown to play important roles in stem cell biology. Not only have 
integrins been found to be reliable and specific cell surface markers for multiple adult tissue stem 
cells (Zheng and Taniguchi 2003; Tsuchiya, Heike et al. 2007; Kamiya, Kakinuma et al. 2009), 
but other studies have also shown that integrin signaling can influence various responses of stem 
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cells. For example, previous studies have shown that ECM proteins partially regulate embryonic 
stem cell fate (Suzuki, Iwama et al. 2003; Flaim, Chien et al. 2005). Additionally, integrins are 
thought to regulate proliferation, migration, and differentiation of adult neural stem cells 
(Weaver, Yoshida et al. 1995; Anton, Kreidberg et al. 1999; Vogelezang, Liu et al. 2001; 
Nakamoto, Kain et al. 2004; Leone, Relvas et al. 2005). In multiple other adult stem cell 
populations including hematopoietic, mammary, crypt, satellite, and spermatogonial stem cells, 
expression of specific subsets of integrin receptors has been shown to regulate their localization 
to and function within their respective stem cell niches (reviewed in (Ellis and Tanentzapf) and 
(Raymond, Deugnier et al. 2009) ). A recent study has also shown that integrin receptor 
expression on stem cells is predictive of their ability to home to various sites within the body 
(Kanatsu-Shinohara, Takehashi et al. 2008). 
A recent study has also shown that differential signaling through integrin receptors may 
be a useful approach for directing the differentiation of stem cells for tissue engineering 
applications (Lee, Yun et al. 2011). By utilizing a combination of ligands for various integrin 
receptors, Lee et al showed that they can not only maintain the pluripotency of embryonic stem 
cells but also control the lineage along which the embryonic stem cells differentiate depending 
on the exact combination of integrin ligands utilized (Lee, Yun et al. 2011). While the referenced 
study focused on in vitro manipulation of embryonic stem cells, the findings of the present thesis 
suggest that ECM degradation products may be identified that could recapitulate this process for 
adult stem cells in vitro and in vivo. 
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5.6 FUTURE DIRECTIONS 
5.6.1 Control of the digit amputation microenvironment with a BIODOME 
In collaboration with the Automation & Robotics Research Institute (ARRI) at the University of 
Texas Arlington, a prototype device designated as the BIODOME (Biomechanical Interface for 
Optimized Delivery of MEMS Orchestrated Mammalian Epimorphosis) has been developed for 
an adult mouse model of digit amputation (Figure 41). Consisting of a septum and two one-way 
valves for easy access to the fluid reservoir, testing of this device is currently under way in the 
Badylak laboratory. 
 
Figure 41. Prototype of a microfluidic device capable of controlling the microenvironment of the site of 
amputation, designated as the BIODOME (Biomechanical Interface for Optimized Delivery of MEMS Orchestrated 
Mammalian Epimorphosis). 
 
Following mid-second phalanx digit amputation on t he right hind foot of adult female 
C57/BL6 mice, a BIODOME device was surgically attached and fastened via Locktite glue at the 
tip of the amputated digit (Figure 42). The BIODOME device was filled with the same bioactive 
ECM homing signals that were used without a BIODOME to recruit a multipotential cell cluster 
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(MCC) at the site of amputation. In order to determine whether a more long term, continuous 
treatment of the amputated digit with bioactive ECM peptides would result in a greater 
accumulation, the peptides were left in the BIODOME for 2 da ys post-amputation. E-collars 
were placed around the neck of each mouse to prevent chewing and the BIODOMES were left 
on for 2 days and then removed with acetone to dissolve the glue. Mice were then euthanized at 
day 14 post-amputation (12 days post-removal of placed BIODOME) and toes were submitted 
for histology.  
 
Figure 42. Placement of a BIODOME device. 
 
At 14 days post-amputation (12 days post-BIODOME removal), gross examination of the 
amputated digits showed that treatment with bioactive ECM peptides in the BIODOME resulted 
in larger, more bulbous structure at the site of amputation as compared to treatment with 
phosphate buffered saline (PBS) (Figure 43). Microscopic, histologic examination showed that, 
indeed this bulbous accumulation consisted of a heterogeneous cellular accumulation distal to the 
site of amputation (Figure 43).  
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Figure 43. Gross examination and histologic examination of the amputated digits fitted with a BIDOME 
and treated with bioactive ECM homing signals (UBM) or phosphate buffered saline (PBS). 
 
In order to further characterize the cellular accumulation at the site of amputation, the 
cells were microdissected from the site of amputation. Previous work has showed that treatment 
with bioactive ECM peptides resulted in the accumulation of a population of cells with 
osteogenic, adipogenic, and neuroectodermal lineage differentiation potential. Preliminary work 
completed in collaboration with Dr. Susan Braunhut’s group shows that continuous treatment for 
2 days of bioactive ECM homing peptides within a BIODOME results in a similar accumulation 
of cells. At day 21 post-amputation and treatment with bioactive peptides, microdissected cells 
were isolated, filtered, and plated into a culture flask. Treatment with bioactive ECM peptides 
resulted in a more cellular accumulation. Upon microdissection, approximately 8 times as many 
cells were isolated from digits treated with bioactive ECM peptides as compared to PBS (Figure 
44). After culturing the cells for 5 days, equal numbers of cells from PBS and peptide treated 
groups were subjected to conditions of adipogenic differentiation and osteogenic differentiation. 
130 
After 3 weeks of culture in adipogenic or osteogenic differentiation, cells isolated from peptide 
treated digits were capable of osteogenic differentiation, whereas PBS treated digits showed no 
differentiation potential (Figure 45). 
 
 
Figure 44. Treatment with an ECM bioactive peptide resulted in a greater cellular accumulation at the site 
of amputation, as shown by isolating and culturing the cells (31,111 cells in the peptide treated group vs 4,444 cells 
in the PBS treated group). 
 
 
Figure 45. Treatment with an ECM bioactive peptide resulted in a cellular accumulation capable of 
osteogenic differentiation, whereas PBS treatment as a control yielded cells with no differentiation potential. 
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5.6.2 The importance of injury in ECM-mediated progenitor cell recruitment: a role for 
macrophage derived HMGB1 
To investigate the effect that ECM degradation products may have upon macrophages as well as 
the subsequent effect of the macrophage conditioned medium upon migration of human 
perivascular stem cells in vitro. Following the culture of THP-1 cells in the presence of various 
concentrations of ECM degradation products, the resulting conditioned medium was harvested 
for Boyden chamber migration assays (Figure 46). 
  
 
Figure 46. Schematic diagram showing the experimental outline for studies with THP-1 cells. 
 
Preliminary data suggested that, as compared to the same ECM supplemented medium, 
THP-1 cell conditioned medium causes a dose-dependent increase in perivascular stem cell 
migration in vitro. Notably, supplementation of culture medium with the same concentration of 
ECM degradation products did not result in the same level of migration, suggesting that either 
the THP-1 cells release a soluble factor or they act upon the ECM degradation products to create 
a more pro-chemotactic product (Figure 47). 
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Figure 47. Migration of human perivascular stem cells showed that the perivascular stem cells migrated 
towards THP-1 cell conditioned medium in a dose dependent fashion. Culturing of the THP-1 cells in the presence 
of ECM degradation products potentiated the chemotactic potential of the resulting conditioned medium. Error bars 
represent Mean + SEM (n=4). 
  
Further work showed that there was a dose dependent increase in HMGB1 in the 
conditioned media supplemented with ECM degradation products (Figure 48). Additionally, 
blockade of the HMGB1 molecule in the conditioned medium (Figure 49) or a potential receptor 
target of HMGB1 on human perivascular stem cells resulted in a decrease in migration (Figure 
50).  RT-qPCR showed that ECM degradation products increase HMGB1 expression in THP-1 
cells (Figure 50). 
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Figure 48. Conditioned medias were assessed for HMGB1 content by ELISA. THP-1 conditioned medium 
that contained ECM degradation products showed a greater concentration of HMGB1, but ECM degradation 
products in the absence of THP-1 cells did not have a greater amount of HMGB1. This suggests that the HMGB1 
was cell derived.  
 
Figure 49. Addition of an HMGB1 antibody to the conditioned medium abrogated the chemotactic 
potential of the conditioned medium for human perivascular stem cells. 
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Figure 50.  (Above) Blockade of the RAGE receptor on human perivascular stem cells via antibody 
partially limited the migration of human perivascular stem cells in vitro. (Below) RT-qPCR for HMGB1 expression 
following THP-1 cell culture showed that ECM degradation products cause an increase in THP-1 cell mRNA 
expression for HMGB1. 
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5.6.3 Development of a murine model of volumetric muscle injury 
The findings of the present thesis showed that the peptides created from ex vivo pepsin mediated 
degradation of ECM scaffolds results in the site directed accumulation of progenitor cells that 
not only express markers of mesodermal progenitor cells, but are also capable of 
neuroectodermal and mesodermal differentiation in vitro when isolated. Based on these findings, 
it was postulated that one mechanism by which ECM scaffolds promote constructive remodeling 
of soft tissues is via site directed recruitment of progenitor cells to a site of injury by cryptic 
peptides released following in vivo degradation of the implanted ECM scaffold. However, there 
were notable limitations to the work discussed in the present thesis. The model of digit 
amputation injury utilized was a non-regnerating model of injury, but treatment with ECM 
degradation products did not actually result in constructive remodeling of the digit itself. 
Additionally, in previous preclinical and clinical studies that have observed constructive 
remodeling at a site of injury have always utilized intact ECM scaffolds as opposed to the 
degradation products. 
 To address these limitations, it is important to develop a non-regenerating model of injury 
in which ECM scaffolds do promote constructive remodeling of the injured tissue. Previous 
studies have shown in multiple injury models in various organs that replacement of injured 
muscle of any kind with a degradable ECM scaffold eventually results in constructive 
remodeling of the injured tissue (Badylak, Lantz et al. 1989; Badylak, Meurling et al. 2000; 
Badylak, Kokini et al. 2002; Kochupura, Azeloglu et al. 2005; Turner, Yates et al. 2010; 
Badylak, Hoppo et al. 2011). Thus, a volumetric skeletal muscle injury be an ideal model in 
which to directly investigate the role of ECM degradation upon subsequent mechanisms thought 
to contribute to constructive remodeling of the site of injury. 
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 In order to parallel the work completed in the present thesis, adult 6-8 week old C57/BL6 
mice were subjected to a 3mm long, full width defect to the fascia lata muscle the left hindleg 
(Figure 51). Nonresorbable 7-0 Prolene sutures were used to delineate the deep borders of the 
wound (Figure 52). An ECM sheet was fastened to either side of the fasica lata muscle so as to 
create a pocket within the site of muscle injury (Figure 53). The defect was filled with a hydrated 
three dimensional powdered construct composed of ECM, and allowed to remodel for 14 days. 
At 14 pos t days post-surgery and ECM implantation, the site of muscle injury still showed 
evidence of the ECM construct occupying the defect site (Figure 54). Histologic examination of 
the site of ECM implantation at days 7 a nd 14 post-surgery showed a dense mononuclear 
response at the site of ECM implantation (Figure 55, Figure 56).  
 
 
Figure 51. A 3 mm long, full width defect was created in the fascia lata muscle of the left hindleg of adult 
C57/BL6 mice. 
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Figure 52. Non-resorbable 7-0 Prolene sutures were laid at the bottom of the defect to delineate the deep 
border of the wound site. 
 
Figure 53. An ECM scaffold composed of porcine urinary bladder was sutured to the lateral edge of the 
proximal and distal ends of the injured fascia lata muscle. A pocket was created at the site of injury that can be filled 
with any construct of interest. 
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Figure 54. Following creation of the defect and filling of the defect with a construct composed of 
powdered porcine urinary bladder extracellular matrix, the site of implantation has begun to remodel at day 14 post-
implantation. 
   
 
Figure 55. Histologic examination of Trichrome stained sections of muscle injury showed a dense 
mononuclear infiltrate at the site of ECM implantation at 7 days post-surgery. Dashed lines indicate the site of ECM 
implantation, and the rectangle indicates the location of the high magnification image.  
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Figure 56. Histologic examination of Trichrome stained sections of muscle injury showed a dense 
mononuclear infiltrate at the site of ECM implantation at 14 days post-surgery. Dashed lines indicate the site of 
ECM implantation, and the rectangle indicates the location of the high magnification image. 
5.7 OVERALL CONCLUSIONS 
Overall, the findings of the present thesis: [1] showed that ex vivo generated ECM degradation 
products were chemotactic for progenitor cells in vitro and promoted the site directed 
recruitment of progenitor cells in vivo, [2] identified a single cryptic peptide from the mixture of 
ECM degradation products with similar in vitro and in vivo properties for progenitor cells, and 
[3]  showed that the single cryptic peptide also had the potential to alter progenitor cell 
differentiation in vitro and in vivo, specifically along an osteogenic lineage.  
The findings of the thesis have laid the foundations for future studies to directly address 
the interaction between ECM degradation, progenitor cell recruitment, immune cell polarization, 
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and integrin signaling in mediating site-appropriate and functional tissue deposition at a site of 
ECM implantation.  
 
141 
APPENDIX A 
PARTIAL LIST OF COMMERCIALLY AVAILABLE ECM SCAFFOLDS 
. 
Product Company Tissue Source Format Application 
AlloDerm Lifecell Human skin Cross-linked Soft tissue 
repair 
AlloPatch® Musculoskeletal 
Transplant 
Foundation 
Human fascia 
lata 
Cross-linked Orthpedic 
applications 
Axis™ Mentor Human dermis Natural Pelvic organ 
prolapsed 
CollaMend® Bard Porcine dermis Cross-linked Soft tissue 
repair 
CuffPatch™ Arthrotek Porcine small 
intestinal 
submucosa 
(SIS) 
Cross-linked Reinforcement 
of soft tissues 
DurADAPT™ Pegasus 
Biologicals 
Horse 
pericardium 
Cross-linked Dura repair  
Dura-Guard® Synovis Surgical Bovine 
pericardium 
  Spinal and 
cranial repair 
Durasis® Cook SIS Porcine small 
intestinal 
submucosa 
(SIS) 
Natural Repair dura 
matter  
Durepair® TEI Biosciences Fetal bovine 
skin 
Natural Repair of 
cranial or 
spinal dura 
FasLata® Bard Cadaveric 
fascia lata 
Natural Soft tissue 
repair 
Graft Jacket® Wright Medical 
Tech 
Human skin Cross-linked Foot ulcers 
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Oasis® Healthpoint Porcine small 
intestinal 
submucosa 
(SIS) 
Natural Partial & full 
thickness 
wounds; 
superficial and 
second degree 
burns 
NeoForm Mentor 
Worldwide LLC 
Human dermis   Tendon, breast 
OrthADAPT™ Pegasus 
Biologicals 
Horse 
pericardium 
Cross-linked Reinforcement, 
repair and 
reconstruction 
of soft tissue in 
orthopedics 
Pelvicol® Bard Porcine dermis Cross-linked Soft tissue 
repair 
Peri-Guard® Synovis Surgical Bovine 
pericardium 
  Pericardial and 
soft tissue 
repair 
Permacol™ Tissue Science 
Laboratories 
Porcine skin Cross-linked Soft 
connective 
tissue repair 
PriMatrix™ TEI Biosciences Fetal bovine 
skin 
Natural Wound 
management 
Restore™ DePuy Porcine small 
intestinal 
submucosa 
(SIS) 
Natural Reinforcement 
of soft tissues 
Stratasis® Cook SIS Porcine small 
intestinal 
submucosa 
(SIS) 
Natural Treatment of 
urinary 
incontinence 
SurgiMend™ TEI Biosciences Fetal bovine 
skin 
Natural Surgical repair 
of damaged or 
ruptured soft 
tissue 
membranes 
Surgisis® Cook SIS Porcine small 
intestinal 
submucosa 
(SIS) 
Natural Soft tissue 
repair and 
reinforcement 
Suspend™ Mentor Human fascia 
lata 
Natural Urethral sling 
TissueMend® TEI Biosciences Fetal bovine 
skin 
Natural Surgical repair 
and 
reinforcement 
of soft tissue in 
rotator cuff 
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Vascu-Guard® Synovis Surgical Bovine 
pericardium 
  Reconstruction 
of blood 
vessels in 
neck, legs, and 
arms 
Veritas® Synovis Surgical Bovine 
pericardium 
  Soft tissue 
repair  
Xelma™ Molnlycke ECM protein, 
PGA, water 
  Venous leg 
ulcers 
Xenform™ TEI Biosciences Fetal bovine 
skin 
Natural Abdominal and 
pelvic soft 
tissue 
applications 
Zimmer® Tissue Science 
Laboratories 
Procine dermis Cross-linked Orthopedic 
applications 
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APPENDIX B 
MATLAB SCRIPT FOR ISOLATING NUCLEI AND COLLAGEN FROM 
TRICHROME IMAGES 
% [pixels,percentage] = filterImage(filename, showImage, color1, color2) 
% 
% GAG quantification in an Alcean Blue stained slide. This program 
% essentially takes advantage of the fact that GAGs stain light blue in an 
% Alcean Blue stain. By converting images from RGB (i.e. TIF format) to an 
% HSV (hue/saturation/intensity) image. The hue consists of 256 different 
% ranging from 0 to 255, and MATLAB uses a scale of 0 to 1 to distinguish 
% between different hues. Because intensities of colors and lighting can 
% differe from image to to image (due to variability in slides and  
% microscope image capturing conditions, etc etc), the color cutoffs 
% (color1 and color 2) should be optimized for each set of images.  
% 
% This program is only intended for TIF files!  
% 
% Inputs:    filename = full pathway of the TIF file (EX: 'C:\..\test.tif') 
% 
%            showImage = boolean character;  
%                    1 => shows filtered image containing elastin 
%                    0 => does not show any image 
% 
%            color1/color2 - the range of colors to extract; always 0<x<255 
%                    color1 < color2 always; On a scale of 0 to 255, each  
%                    hue has a unique number associated with it; For the  
%                    Alcean Blue stain looking for GAGs, it seems that 110  
%                    to about 170 seems to be a fairly good range for  
%                    getting the GAG staining (i.e. color1=110, color2=170) 
% 
% 
% Outputs:     pixels = total number of pixels that are elastin positive 
%              percentage = percentage of total image area that is elastin 
%                           positive 
% 
% 
% Vineet Agrawal; January 5, 2009 
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function [filtImage,pixels,percentage] = filtImage(filename, showImage, 
color1, color2) 
  
rgbImage = imread(filename);    % loads TIF file into RGB format 
hsvImage = rgb2hsv(rgbImage);     % converts RGB format to an intensity file 
gImage = hsvImage(:,:,1); 
  
% Filtered image, starts of all white 
fImage = ones(size(gImage))-1;  
% Total number of positive pixels 
pixels = 0;                                
  
% Goes through intensity image and filters away high intensities (whiter) 
% and keeps lower intensities (blacker) pixels. The sensitivity of the 
% filtration is dependent upon threshold. 
% 
% color1 = 31, color2 = 51 for yellow 
% color1 = 62, color2 = 102 for green 
for a = 1:size(gImage,1) 
    for b = 1:size(gImage,2) 
        if gImage(a,b) >= color1/255 && gImage(a,b) <= color2/255 
            if gImage(a,b) >= 31/255 && gImage(a,b) <= 61/255  
            fImage(a,b) = 1; 
            pixels = pixels+1; 
            hsvImage(a,b,3) = 1; 
            end 
        end 
    end 
end 
  
%fImage = imfill(gImage,'holes'); 
fImage2 = bwmorph(fImage,'clean'); 
fImage2 = bwmorph(fImage2,'fill'); 
fImage3 = bwmorph(fImage2,'shrink',Inf); 
%fImage3 = imoverlay(fImage,fImage2,[0.3 1 0.3]); 
figure; imagesc(fImage2); colormap(gray); 
figure; imagesc(fImage3); colormap(gray); 
length(find(fImage3 == 1)) 
%fImage2 = bwperim(fImage); 
%figure; imagesc(fImage2); colormap(gray); 
figure; imagesc(imoverlay(fImage2,fImage3,[1 0 0])); 
%figure; imagesc(fImage3); 
  
  
% if showImage does not equal zero, the filtered image is shown 
if showImage 
    figure; subplot(2,1,1); imagesc(fImage); colormap(gray); 
    subplot(2,1,2); imagesc(hsv2rgb(hsvImage)); 
end 
  
% Divides by total number of pixels in image to get percentage of area that 
% is positive. 
percentage = pixels/(size(gImage,1)*size(gImage,2)); 
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APPENDIX C 
LIST OF CONFERENCE PROCEEDINGS AND MANUSCRIPTS 
The following is a list of refereed conference proceeding and manuscripts, either accepted or in 
preparation, that have materialized during my tenure as a graduate student in the Badylak 
laboratory. 
C.1 LIST OF REFEREED MANUSCRIPTS 
Agrawal V, Kelly J, Tottey S, Daly K, Johnson SA, Siu BF, Reing JE, Badylak SF. An Isolated 
Cryptic Peptide Influences Osteogenesis and Bone Remodeling in an Adult Mammalian Model 
of Digit Amputation. Tissue Engineering Part A 2011. PMID: 21740273. 
 
Agrawal V, Tottey S, Johnson SA, Freund JM, Siu BF, Badylak SF. Recruitment of progenitor 
cells by an ECM cryptic peptide in a mouse model of digit amputation. Tissue Engineering Part 
A 2011. PMID: 21563860. 
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Agrawal V, Johnson SA, Reing J, Zhang L, Tottey S, Wang G, Hirschi KK, Braunhut S, Gudas 
LJ, Badylak SF. An epimorphic regeneration approach to tissue replacement in adult mammals. 
Proceedings of the National Academy of Sciences 2010. 107( 8): 3351-5. PMID: 19966310 
(Cover Image). PMCID: PMC2840465. 
 
Agrawal V, Brown BN, Beattie AJ, Gilbert TW, Badylak SF. Evidence of Innervation following 
Extracellular Matrix Scaffold Mediated Remodeling of Muscular Tissues. Journal of Tissue 
Engineering and Regenerative Medicine 2009. 3(8): 590-600. PMID: 19701935. 
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Extracellular Matrix as a Biologic Scaffold Material for Acute Vocal Fold Repair. Laryngoscope 
2009, 119(9): 1856-63. PMID: 19572393. 
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Meeting 2011, Chicago, IL, April 2011. 
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